prednisone has been researched along with Lymphoma in 838 studies
Prednisone: A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.
prednisone : A synthetic glucocorticoid drug that is particularly effective as an immunosuppressant, and affects virtually all of the immune system. Prednisone is a prodrug that is converted by the liver into prednisolone (a beta-hydroxy group instead of the oxo group at position 11), which is the active drug and also a steroid.
Lymphoma: A general term for various neoplastic diseases of the lymphoid tissue.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Forty-four dogs with multicentric lymphoma were treated using a cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) induction protocol or treated using a cyclophosphamide, mitoxantrone, vincristine, and prednisolone (CMOP) induction protocol." | 9.22 | Comparison of efficacy and toxicity of doxorubicin and mitoxantrone in combination chemotherapy for canine lymphoma. ( Lee, JJ; Liao, AT; Wang, SL, 2016) |
| "OBJECTIVE To determine the effect of prednisone omission from a multidrug chemotherapy protocol on outcome in dogs with peripheral nodal lymphomas." | 9.22 | A randomized controlled trial of the effect of prednisone omission from a multidrug chemotherapy protocol on treatment outcome in dogs with peripheral nodal lymphomas. ( Childress, MO; Ramos-Vara, JA; Ruple, A, 2016) |
| "Patients with stage III-IV indolent lymphoma with responding or stable disease after cyclophosphamide, vincristine, and prednisone (CVP) chemotherapy were stratified by initial tumor burden, residual disease after CVP (minimal or gross), and histology, and randomly assigned to observation (OBS) or MR 375 mg/m(2) once per week for 4 weeks every 6 months for 2 years." | 9.14 | Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 Study. ( Colocci, N; Frankel, S; Gascoyne, RD; Gordon, LI; Habermann, TM; Hochster, H; Horning, SJ; Ryan, T; Weller, E; Zhang, L, 2009) |
| "To assess the efficacy and safety of the combination of non-pegylated liposome-encapsulated doxorubicin (Myocet(R)) with cyclophosphamide, vincristine, prednisone and rituximab (R-COMP) in patients with aggressive non-Hodgkin's B-cell lymphomas." | 9.12 | Liposome-encapsulated doxorubicin in combination with cyclophosphamide, vincristine, prednisone and rituximab in patients with lymphoma and concurrent cardiac diseases or pre-treated with anthracyclines. ( Alterini, R; Bernardi, F; Bosi, A; Carrai, V; Mappa, S; Nassi, L; Rigacci, L, 2007) |
| "We evaluated the efficacy and safety of ondansetron hydrochloride (OND) on nausea and vomiting during repeated courses of CHOP or ACOMP-B therapy in patients with malignant lymphoma." | 9.10 | [Clinical usefulness of ondansetron hydrochloride for nausea and vomiting during repeated courses of chemotherapy for malignant lymphoma--impact of prognosis announcement on anti-emetic effect and evaluation of patient perception of chemotherapy-associate ( Fujimaki, K; Fukawa, H; Harano, H; Hashimoto, Y; Hattori, M; Kanamori, H; Kodama, F; Koharasawa, H; Mohri, H; Motomura, S; Sakai, R; Takemura, S; Tanabe, J; Tomita, N, 2002) |
| " We have studied the role of a benzodiazepine (alprazolam: A) in addition to granisetron for controlling emesis in patients treated with moderately emetogenic chemotherapy for malignant lymphomas according to an anxiety scale (Covi score)." | 9.09 | Granisetron plus or minus alprazolam for emesis prevention in chemotherapy of lymphomas: a randomized multicenter trial. Granisetron Trialists Group. ( Bauduer, F; Coiffier, B; Desablens, B, 1999) |
| "From December 1995 to July 1997, six patients with primary malignant lymphoma in the central nervous system were treated with 2 to 5 cycles of the M-CHOP regimen (methotrexate 3 g/m2 on day 1, cyclophosphamide 750 mg/m2 on day 1, doxorubicin 40 mg/m2 on day 1, vincristine 1." | 9.08 | [Primary malignant lymphoma in the central nervous system treated with high dose methotrexate (MTX)-CHOP (M-CHOP)]. ( Furuta, T; Maeda, Y; Matsumoto, K; Ohmoto, T; Ono, Y; Tamiya, T, 1998) |
| "To evaluate the response to oral Etoposide when combined with mesna, ifosfamide, and mitoxantrone in patients with relapsed and/or refractory lymphoma." | 9.07 | A phase II trial of oral etoposide with mitoxantrone and ifosfamide/mesna consolidated with intravenous etoposide, methylprednisolone, high-dose arabinoside, and cisplatin as salvage therapy for relapsing and/or refractory lymphomas. ( Cabanillas, F; Hagemeister, FB; Hill, D; McLaughlin, P; Moore, DF; Rodriguez, MA; Romaguera, JE; Sarris, AH; Swan, F; Younes, A, 1994) |
| "Eighty-two adult patients with advanced B-lymphoma, treated between 1981 and 1983 with VEPA (vincristine, cyclophosphamide, prednisolone and doxorubicin) or VEPA-M (VEPA plus methotrexate) in a prospective randomized fashion, were evaluated for pretreatment characteristics." | 9.06 | Major prognostic factors of adult patients with advanced B-cell lymphoma treated with vincristine, cyclophosphamide, prednisone and doxorubicin (VEPA) or VEPA plus methotrexate (VEPA-M). ( Kikuchi, M; Konda, S; Minato, K; Ogawa, M; Ota, K; Shimoyama, M; Takatsuki, K; Tominaga, S; Tsugane, S; Yunoki, K, 1988) |
| "In order to compare the efficacy and toxicity of mitoxantrone and adriamycin in non-Hodgkin's lymphoma, a randomized trial has been conducted by a cooperative study group since June 1984." | 9.06 | [A comparative study of mitoxantrone and adriamycin in patients with non-Hodgkin's lymphoma: a preliminary result]. ( Kimura, I; Masaoka, T; Namba, K; Ohnoshi, T; Sampi, K, 1986) |
| "In a nationwide multicenter study, single-agent treatment with prednimustine (PM) was compared with combination chemotherapy with CVP (cyclophosphamide, vincristine, and prednisolone) in patients with stage III-IV non-Hodgkin's lymphoma (NHL) with favorable histology (Rappaport groups nodular lymphocytic poorly differentiated, nodular mixed, and diffuse lymphocytic poorly and well-differentiated)." | 9.06 | Prednimustine v cyclophosphamide-vincristine-prednisolone in the treatment of non-Hodgkin's lymphoma with favorable histopathology: results of a national cancer care program in Sweden. ( Cavallin-Ståhl, E; Möller, TR, 1986) |
| "17 patients with diffuse non-Hodgkin's lymphoma with unfavorable histologies were treated with cyclophosphamide, hydroxyldaunorubicin (doxorubicin), vincristine (Oncovin), prednisone and bleomycin (CHOP-Bleo)." | 9.05 | Long-term results of patients with advanced diffuse, non-Hodgkin's lymphoma treated with cyclophosphamide, doxorubicin, vincristine, prednisone and bleomycin (CHOP-Bleo). ( Case, DC, 1983) |
| "Between January 1973 and January 1979, 131 patients with malignant non-Hodgkin's lymphomas (107 lymphocytic lymphomas, 24 histiocytic lymphomas) were treated with cyclophosphamide-vincristin-prednisone (CVP) either alone or combined with Adriamycin (CVP-A)." | 9.05 | Combination chemotherapy with cyclophosphamide, vincristine, prednisone and the contribution of adriamycin in the treatment of adult non-Hodgkin's lymphomas a report of 131 cases. ( Duhamel, G; Gorin, NC; Najman, A; Parlier, Y; Stachowiak, J, 1982) |
| "24 patients with non-Hodgkin's lymphomas of low-grade malignancy (stage III and IV) were treated either with a single drug (prednimustine) or with combination chemotherapy (cyclophosphamide, vincristine and prednisone)." | 9.05 | Value of prednimustine in treating non Hodgkin's lymphomas of favourable histological type. ( Háber, J; Klener, P, 1985) |
| "Between 1977 and 1983 the Southwest Oncology Group (SWOG) evaluated chemotherapy alone (cyclophosphamide, doxorubicin, vincristine, prednisone; CHOP) or chemoimmunotherapy (CHOP-levamisole or CHOP-levamisole-BCG) in a randomized prospective clinical trial involving 715 eligible patients with all types of malignant lymphoma (ML)." | 9.05 | Chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisone alone or with levamisole or with levamisole plus BCG for malignant lymphoma: a Southwest Oncology Group Study. ( Balcerzak, SP; Costanzi, JJ; Dabich, L; Eyre, HJ; Fabian, CJ; Grozea, PN; Jones, SE; Miller, TP; Morrison, FS; Van Slyck, EJ, 1985) |
| "Two hundred and ninety-eight evaluable patients with non-Hodgkin's lymphoma were stratified according to histology, treated with either BCNU, cyclophosphamide, Oncovin (vincristine), and prednisone (BCOP) or cyclophosphamide, Oncovin (vincristine), and prednisone (COP), and evaluated at 3 months." | 9.04 | BCNU with and without cyclophosphamide, vincristine, and prednisone (COP) and cycle-active therapy in non-Hodgkin's lymphoma. ( Bartolucci, AA; Dorfman, RF; Durant, JR; Gams, RA, 1977) |
| "30 dogs with multicentric lymphoma and neutrophilia (including 16 treated with a cyclophosphamide, doxorubicin, vincristine, and prednisone [CHOP]-based protocol) and 37 historical control dogs without neutrophilia treated with a CHOP-based protocol." | 8.02 | Evaluation of neutrophilia as a prognostic factor in dogs with multicentric lymphoma treated with a cyclophosphamide, doxorubicin, vincristine, and prednisone-based chemotherapy protocol. ( Pellin, M; Veluvolu, S; Vos, N, 2021) |
| "Prednisone resistance develops rapidly and essentially universally when dogs with lymphoma are treated with corticosteroids." | 7.96 | Development of prednisone resistance in naïve canine lymphoma: Longitudinal evaluation of NR3C1α, ABCB1, and 11β-HSD mRNA expression. ( Burke, NS; Fidel, JL; Hanot, CC; Mealey, KL; Sellon, RK; White, LA, 2020) |
| "The aims of this study were to evaluate the safety of mustargen, vincristine, procarbazine and prednisone (MOPP) chemotherapy in the treatment of relapsed or refractory feline lymphoma, and to determine the overall response rate and median remission time with this protocol." | 7.96 | Efficacy and toxicity of mustargen, vincristine, procarbazine and prednisone (MOPP) for the treatment of relapsed or resistant lymphoma in cats. ( Brown, DC; Krick, EL; MaloneyHuss, MA; Mauldin, GE; Veluvolu, SM, 2020) |
| "Eighty-eight dogs with relapsed lymphoma were treated with the MOMP (mechlorethamine, vincristine, melphalan and prednisone) protocol on a 28-day treatment cycle." | 7.81 | Mechlorethamine, vincristine, melphalan and prednisone (MOMP) for the treatment of relapsed lymphoma in dogs. ( Back, AR; Lee, J; Phillips, JC; Schleis, SE; Smith, AN; Smrkovski, OA, 2015) |
| "To evaluate the clinical response rate, progression-free survival time, overall survival time, and possible prognostic factors associated with a cyclophosphamide-, vincristine-, and prednisone (COP)-based chemotherapy protocol in cats with lymphoma." | 7.79 | Lymphoma in cats treated with a weekly cyclophosphamide-, vincristine-, and prednisone-based protocol: 114 cases (1998-2008). ( Gregor, TP; Jackson, K; Krick, EL; Waite, AH, 2013) |
| "To evaluate factors associated with second remission in dogs with lymphoma retreated with a cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) protocol after relapse following initial treatment with a first-line 6-month CHOP protocol." | 7.77 | Evaluation of factors associated with second remission in dogs with lymphoma undergoing retreatment with a cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy protocol: 95 cases (2000-2007). ( Chretin, JD; Erb, HN; Flory, AB; Garrett, LD; Locke, JE; Northrup, NC; Phillips, BS; Rassnick, KM; Selting, KA, 2011) |
| "To evaluate the toxicity and efficacy of a modification of a previously evaluated combination of lomustine, vincristine, procarbazine, and prednisone (LOPP) as a rescue protocol for refractory lymphoma in dogs." | 7.77 | Evaluation of the University of Florida lomustine, vincristine, procarbazine, and prednisone chemotherapy protocol for the treatment of relapsed lymphoma in dogs: 33 cases (2003-2009). ( Barabas, K; Clemente, M; Fahey, CE; Kow, K; Lurie, D; Lyles, S; Milner, RJ; Parfitt, S, 2011) |
| "Forty-one dogs with resistant lymphoma were treated with a modified MOPP (mechlorethamine, vincristine, procarbazine and prednisone) protocol (MPP [mechlorethamine, procarbazine and prednisone] administered on a 21-day cycle, shortened from the 28-day MOPP cycle)." | 7.75 | Mechlorethamine, procarbazine and prednisone for the treatment of resistant lymphoma in dogs. ( Childress, MO; Gieger, TL; Hume, KR; Keys, DA; Kosarek, CE; LeRoy, BE; Northrup, NC; Saba, CF; Wall, TM, 2009) |
| "To assess response rate, median duration of response, adverse effects, and prognostic factors associated with concurrent administration of lomustine and prednisone as a first-line treatment for dogs with multicentric lymphoma." | 7.74 | Lomustine and prednisone as a first-line treatment for dogs with multicentric lymphoma: 17 cases (2004-2005). ( Bannink, EO; Kaneene, JB; Mullins, MN; Obradovich, JE; Sauerbrey, ML; Van Dorp, TE, 2007) |
| " The risk is significantly evident in patients with aggressive lymphoma, which is highly responsive to standard chemotherapy with cyclophosphamide, hydroxydaunomycin, vincristine, and prednisone (CHOP) achieving a complete response rate of 60-80% and 5-year survival rate of 30-50% with only 1% of treatment-related mortality." | 7.72 | Preemptive use of interferon or lamivudine for hepatitis B reactivation in patients with aggressive lymphoma receiving chemotherapy. ( Chen, TY; Huang, WT; Leaw, SJ; Su, WC; Tsao, CJ; Yen, CJ, 2004) |
| "In the current study, the authors analyzed prognostic factors in patients with aggressive lymphoma treated with a chemotherapy regimen comprised of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) with or without radiotherapy." | 7.71 | Bulky disease is an adverse prognostic factor in patients treated with chemotherapy comprised of cyclophosphamide, doxorubicin, vincristine, and prednisone with or without radiotherapy for aggressive lymphoma. ( Cabanillas, F; Cox, JD; Ha, CS; Hess, MA; Pro, B; Rodriguez, MA; Wilder, RB, 2001) |
| "The activity of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) in the treatment of primary central nervous system lymphoma (PCNSL) prior to radiotherapy was studied in six patients." | 7.69 | Cyclophosphamide, doxorubicin, vincristine, and prednisone for primary central nervous system lymphoma: short-duration response and multifocal intracerebral recurrence preceding radiotherapy. ( Boyko, OB; Brizel, DM; Brown, MT; Burger, PC; Gockerman, JP; Halperin, EC; Lachance, DH; Schold, SC, 1994) |
| "To determine response rate and remission as well as survival times for dogs with multicentric lymphoma treated first with doxorubicin alone or in combination with asparaginase and then with cyclophosphamide, vincristine sulfate, and prednisone (CVP) and to identify prevalence of toxicoses associated with this protocol and factors associated with prognosis." | 7.69 | Doxorubicin alone or in combination with asparaginase, followed by cyclophosphamide, vincristine, and prednisone for treatment of multicentric lymphoma in dogs: 121 cases (1987-1995). ( Getzy, DM; Mallinckrodt, CH; Ogilvie, GK; Valerius, KD, 1997) |
| "A radioreceptor assay for serum 1,25-dihydroxyvitamin D (calcitriol) was used to screen patients with hypercalcemia of malignancy." | 7.67 | Hypercalcemia associated with increased serum calcitriol levels in three patients with lymphoma. ( Breslau, NA; Frenkel, EP; McGuire, JL; Pak, CY; Zerwekh, JE, 1984) |
| "Twenty-one patients with intermediate- and high-grade lymphomas were treated with modified cyclophosphamide, vincristine, methotrexate, leucovorin, and cytarabine (COMLA)." | 7.67 | Modified cyclophosphamide, vincristine, methotrexate, leucovorin, and cytarabine (COMLA) in intermediate- and high-grade lymphoma: an effective short-course regimen. ( Baer, MR; Flexner, JM; Greer, JP; Hainsworth, JD; Stein, RS; Wolff, SN, 1986) |
| "This is a case report of an aggressive multifocal non-Hodgkin's lymphoma in a cadaver kidney recipient arising in the early phase of her immunosuppressive maintenance therapy program with cyclosporin A and prednisone." | 7.67 | Multifocal aggressive lymphoma of the gastrointestinal tract in a renal transplant patient treated with cyclosporin A and prednisone. ( Castro, CJ; Klimo, P; Worth, A, 1985) |
| "High-dose methotrexate (HDMTX) with citrovorum factor (CF) was used to treat non-Hodgkin's lymphomas either as a single agent in those patients who had previously failed to respond to conventional chemotherapy or in previously untreated patients in combination with bleomycin, Adriamycin, cytoxan, and vincristine." | 7.66 | Methotrexate as a single agent and in combination chemotherapy for the treatment of non-Hodgkin's lymphoma of unfavorable histology. ( Canellos, GP; Frei, E; Moloney, WC; Rosenthal, DS; Skarin, AT, 1981) |
| "Peplomycin containing combination chemotherapy with cyclophosphamide, hydroxy-daunomycin, oncovin and prednisone (CHOP-P) was performed in one patient with ATL and 8 patients with advanced diffuse lymphoma." | 7.66 | [Combination chemotherapy using peplomycin for the treatment of non-Hodgkin's lymphoma including adult T cell leukemia]. ( Ichimaru, M; Kamihira, S; Kinoshita, K; Nakano, M; Sakitani, M, 1983) |
| "The combination of cyclophosphamide, adriamycin, vincristine, and prednisone (CHOP) alternating with total body irradiation (TBI) has been shown earlier to be effective therapy in patients with malignant lymphoma who have received prior chemotherapy and/or radiation therapy." | 7.66 | The combined modality therapy of diffuse histology non-Hodgkin's lymphoma with cyclophosphamide, adriamycin, vincristine, prednisone (CHOP) and total body irradiation. ( Antunez, A; Dixon, D; Fabian, CJ; Kraus, TA; Weick, JK, 1983) |
| "In a pilot study of cyclical chemotherapy in patients with poor-prognosis non-Hodgkin's lymphoma (NHL), high-dose methotrexate (MTX) 1 g/m2 with folinic acid rescue was given as initial treatment and then between cycles of a single-arm CHOP combination administered every 4 weeks." | 7.66 | A pilot study of cyclical chemotherapy with high-dose methotrexate and CHOP (MTX-CHOP) in poor-prognosis non-Hodgkin's lymphoma (NHL). ( Barnard, DL; Cartwright, SC; Child, JA; Lauder, I; Simmons, AV; Stone, J; Thorogood, J, 1983) |
| "A regimen consisting of two courses of methotrexate (MTX) with leucovorin rescue followed 1 week later by cyclophosphamide, vincristine, and prednisone (MTX-COP) was studied in ten patients with disseminated diffuse non-Hodgkin's lymphoma who had had no prior chemotherapy." | 7.66 | Combinations of methotrexate (COP or CHOP) in the treatment of previously untreated and treated lymphomas. ( Gomez, GA; Han, T; Henderson, E; Moayeri, H; Naeher, C; Plager, J; Shimaoka, K; Stutzman, L, 1982) |
| "Fourty-three of 61 patients suffering from low-grade malignant non-Hodgkin's lymphomas according to the Kiel classification were subjected to an intermittent combination chemotherapy with chlorambucil and prednisone." | 7.66 | Intermittent combination chemotherapy with chlorambucil and prednisone of low-grade malignant non-Hodgkin's lymphomas according to the Kiel classification. ( Garbrecht, M; Stolzenbach, G, 1979) |
| "Disseminated infection caused by Fusarium moniliforme is described in a 32-year-old granulocytopenic man with malignant lymphoma being treated with cytotoxic drugs and corticosteroids." | 7.66 | Disseminated infection by Fusarium moniliforme during treatment for malignant lymphoma. ( Fisher, RI; Jennings, AE; Kubota, TT; Kwon-Chung, KJ; Young, NA, 1978) |
| "Seventy-three patients with advanced non-Hodgkin lymphoma were treated with bleomycin, Adriamycin, cyclophosphamide, vincristine (Oncovin) and prednisone (BACOP), administered intensively during a 7-wk induction course followed by intermittent cycles every 3 wk for a total of 28 wk." | 7.65 | Combination chemotherapy of advanced non-Hodgkin lymphoma with bleomycin, adriamycin, cyclophosphamide, vincristine, and prednisone (BACOP). ( Frei, E; Moloney, WC; Rosenthal, DS; Skarin, AT, 1977) |
| "Sixty-seven evaluable patients with mixed cellular and histiocytic lymphomas, both nodular and diffuse, were treated with a combined drug regimen of BCNU, cyclophosphamide, vincristine, and prednisone administered for six monthly courses." | 7.65 | 1,3-bis(2-chloroethyl)-1-nitrosourea(BCNU), cyclophosphamide, vincristine- and prednisone-(BCOP). A new therapeutic regimen for diffuse histiocytic lymphoma. ( Chan, YK; Dorfman, R; Durant, JR; Loeb, V, 1975) |
| "From July 1971 to July 1974, 58 patients with advanced non-Hodgkin's lymphomas were treated with cyclophosphamide, vincristine, prednisone (CVP) at Stanford Medical Center." | 7.65 | Combination chemotherapy with cyclophosphamide, vincristine, and prednisone in advanced non-Hodgkin's lymphomas. ( Portlock, CS; Rosenberg, SA, 1976) |
| "Plerixafor-treated subjects collected 7." | 6.80 | Plerixafor in combination with granulocyte-colony-stimulating factor after chemotherapy increases mobilization efficiency in patients with lymphoma or myeloma: results of a Phase II clinical trial. ( Flowers, C; Gaylor, C; Harvey, RD; Jagirdar, N; Kaufman, J; Langston, A; Lechowicz, MJ; Lipscomb, C; Lonial, S; Nooka, A; Waller, EK, 2015) |
| "Prednisone was given orally at 60 mg/m(2) per day for five consecutive days within each 28-day cycle." | 6.75 | A phase I trial of UCN-01 and prednisone in patients with refractory solid tumors and lymphomas. ( Conley, BA; Dancey, J; Doroshow, JH; Figg, WD; Gardner, ER; Gutierrez, ME; Kummar, S; Melillo, G; Murgo, AJ; Sausville, EA, 2010) |
| "Dexverapamil was escalated eight dose levels, from 240 to 1,200 mg/m2/d." | 6.68 | Controlled trial of dexverapamil, a modulator of multidrug resistance, in lymphomas refractory to EPOCH chemotherapy. ( Bates, SE; Bryant, G; Fojo, A; Herdt, J; Jaffe, ES; Regis, J; Steinberg, SM; Wilson, WH; Wittes, RE; Zhan, Z, 1995) |
| "Lubiprostone was more effective than stimulant laxatives at treating vinca alkaloid-induced intractable constipation in patients with hematological malignancies, and its use could enable safe vinca alkaloid chemotherapy." | 5.56 | Effect of lubiprostone on vinca alkaloid-induced constipation in patients with hematological malignancies: a propensity score-matched analysis. ( Fukuda, H; Hayashi, T; Imai, T; Kawada, K; Miyamura, M; Morita, Y; Ohta, T; Tanaka, K, 2020) |
| "In the group of high-grade malignant lymphomas there were 39% complete remission, 37% partial remission, and 24% without response." | 5.26 | [Results of chemotherapy with cyclophosphamide, vincristine, methotrexate and prednisone in recurring or disseminated non-Hodgkin lymphomas in the University of Kiel Radiology Clinic]. ( Liffers, R, 1981) |
| " Eighteen patients were in early stage (I or II) and 11 of them were also submitted to involved field radiotherapy (60Co), immediately before (stage I) or during (stage II) the chemotherapy, with a mean dosage of 4,500 rad." | 5.26 | Combination chemotherapy with cyclophosphamide, adriamycin, vincristine and prednisone (CHOP) for non-Hodgkin's lymphomas with unfavorable histology: preliminary results. ( Abate, G; Bruni, GS; Comella, G; Comella, P; Pergola, M; Zarrilli, D, 1980) |
| "45%, respectively, in Hodgkin's disease, and 85% vs." | 5.25 | Combined cyclophosphamide vincristine, procarbazine, and prednisone (COPP) therapy of malignant lymphoma. Evaluation of 190 patients. ( Barros, CA; Morgenfeld, MC; Palau, M; Pavlovsky, A; Pavlovsky, S; Somoza, N; Suarez, A, 1975) |
| "Forty-four dogs with multicentric lymphoma were treated using a cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) induction protocol or treated using a cyclophosphamide, mitoxantrone, vincristine, and prednisolone (CMOP) induction protocol." | 5.22 | Comparison of efficacy and toxicity of doxorubicin and mitoxantrone in combination chemotherapy for canine lymphoma. ( Lee, JJ; Liao, AT; Wang, SL, 2016) |
| "OBJECTIVE To determine the effect of prednisone omission from a multidrug chemotherapy protocol on outcome in dogs with peripheral nodal lymphomas." | 5.22 | A randomized controlled trial of the effect of prednisone omission from a multidrug chemotherapy protocol on treatment outcome in dogs with peripheral nodal lymphomas. ( Childress, MO; Ramos-Vara, JA; Ruple, A, 2016) |
| "Patients with stage III-IV indolent lymphoma with responding or stable disease after cyclophosphamide, vincristine, and prednisone (CVP) chemotherapy were stratified by initial tumor burden, residual disease after CVP (minimal or gross), and histology, and randomly assigned to observation (OBS) or MR 375 mg/m(2) once per week for 4 weeks every 6 months for 2 years." | 5.14 | Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 Study. ( Colocci, N; Frankel, S; Gascoyne, RD; Gordon, LI; Habermann, TM; Hochster, H; Horning, SJ; Ryan, T; Weller, E; Zhang, L, 2009) |
| "Chemotherapy with alemtuzumab and the combination of cyclophosphamide, adriamycin, oncovin, and prednisone (CHOP) has become experimental trial therapy for aggressive T-cell lymphoma." | 5.13 | EBV-positive immunodeficiency lymphoma after alemtuzumab-CHOP therapy for peripheral T-cell lymphoma. ( Boers, JE; Coenen, JL; Kluin-Nelemans, HC; Rosati, S; van Imhoff, GW, 2008) |
| "Eighty-four patients age < 60 years with aggressive lymphoma and elevated lactate dehydrogenase (LDH) levels were randomized to receive either 4 (Arm A) or 6 (Arm B) courses of cyclophosphamide, doxorubicin, vincristine, etoposide, and prednisone (megaCHOEP)." | 5.12 | Four versus six courses of a dose-escalated cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen plus etoposide (megaCHOEP) and autologous stem cell transplantation: early dose intensity is crucial in treating younger patients with po ( Berdel, WE; Dorken, B; Glass, B; Kloess, M; Kneba, M; Loeffler, M; Metzner, B; Pfreundschuh, M; Reiser, M; Schmitz, N; Trumper, L, 2006) |
| "Previously untreated patients older than 60 years with localized stage I or II histologically aggressive lymphoma and no adverse prognostic factors of the International Prognostic Index were randomly assigned to receive either four cycles of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) plus involved-field radiotherapy (299 patients) or chemotherapy alone with four cycles of CHOP (277 patients)." | 5.12 | CHOP alone compared with CHOP plus radiotherapy for localized aggressive lymphoma in elderly patients: a study by the Groupe d'Etude des Lymphomes de l'Adulte. ( Bonnet, C; Fermé, C; Fillet, G; Ganem, G; Gisselbrecht, C; Martin, C; Molina, TJ; Mounier, N; Quesnel, B; Reyes, F; Thiéblemont, C; Tilly, H, 2007) |
| "To assess the efficacy and safety of the combination of non-pegylated liposome-encapsulated doxorubicin (Myocet(R)) with cyclophosphamide, vincristine, prednisone and rituximab (R-COMP) in patients with aggressive non-Hodgkin's B-cell lymphomas." | 5.12 | Liposome-encapsulated doxorubicin in combination with cyclophosphamide, vincristine, prednisone and rituximab in patients with lymphoma and concurrent cardiac diseases or pre-treated with anthracyclines. ( Alterini, R; Bernardi, F; Bosi, A; Carrai, V; Mappa, S; Nassi, L; Rigacci, L, 2007) |
| "This study was designed to test the hypothesis that administration of granulocyte colony-stimulating factor (G-CSF; filgrastim) during induction chemotherapy with CHOP (cyclophosphamide, vincristine, doxorubicin, prednisone) or CNOP (doxorubicin replaced with mitoxantrone) in elderly patients with aggressive non-Hodgkin lymphoma (NHL) improves time to treatment failure (TTF), complete remission (CR) rate, and overall survival (OS)." | 5.10 | CHOP is superior to CNOP in elderly patients with aggressive lymphoma while outcome is unaffected by filgrastim treatment: results of a Nordic Lymphoma Group randomized trial. ( Anderson, H; Björkholm, M; Cavallin-Stahl, E; Hagberg, H; Holte, H; Kvaløy, S; Myhre, J; Osby, E; Pertovaara, H; Teerenhovi, L, 2003) |
| "We evaluated the efficacy and safety of ondansetron hydrochloride (OND) on nausea and vomiting during repeated courses of CHOP or ACOMP-B therapy in patients with malignant lymphoma." | 5.10 | [Clinical usefulness of ondansetron hydrochloride for nausea and vomiting during repeated courses of chemotherapy for malignant lymphoma--impact of prognosis announcement on anti-emetic effect and evaluation of patient perception of chemotherapy-associate ( Fujimaki, K; Fukawa, H; Harano, H; Hashimoto, Y; Hattori, M; Kanamori, H; Kodama, F; Koharasawa, H; Mohri, H; Motomura, S; Sakai, R; Takemura, S; Tanabe, J; Tomita, N, 2002) |
| " We have studied the role of a benzodiazepine (alprazolam: A) in addition to granisetron for controlling emesis in patients treated with moderately emetogenic chemotherapy for malignant lymphomas according to an anxiety scale (Covi score)." | 5.09 | Granisetron plus or minus alprazolam for emesis prevention in chemotherapy of lymphomas: a randomized multicenter trial. Granisetron Trialists Group. ( Bauduer, F; Coiffier, B; Desablens, B, 1999) |
| "To compare a short intensified regimen followed by sequential consolidation therapy (doxorubicin, cyclophosphamide, vindesine, bleomycin, and prednisone [ACVBP]) to the standard regimen of methotrexate, bleomycin, cyclophosphamide, and etoposide (m-BACOD) in patients with low-risk aggressive lymphoma." | 5.09 | Randomized comparison of ACVBP and m-BACOD in the treatment of patients with low-risk aggressive lymphoma: the LNH87-1 study. Groupe d'Etudes des Lymphomes de l'Adulte. ( Biron, P; Bordessoule, D; Bosly, A; Brière, J; Coiffier, B; Dupriez, B; Herbrecht, R; Lederlin, P; Mounier, N; Nouvel, C; Sebban, C; Tilly, H, 2000) |
| "From December 1995 to July 1997, six patients with primary malignant lymphoma in the central nervous system were treated with 2 to 5 cycles of the M-CHOP regimen (methotrexate 3 g/m2 on day 1, cyclophosphamide 750 mg/m2 on day 1, doxorubicin 40 mg/m2 on day 1, vincristine 1." | 5.08 | [Primary malignant lymphoma in the central nervous system treated with high dose methotrexate (MTX)-CHOP (M-CHOP)]. ( Furuta, T; Maeda, Y; Matsumoto, K; Ohmoto, T; Ono, Y; Tamiya, T, 1998) |
| "To evaluate the response to oral Etoposide when combined with mesna, ifosfamide, and mitoxantrone in patients with relapsed and/or refractory lymphoma." | 5.07 | A phase II trial of oral etoposide with mitoxantrone and ifosfamide/mesna consolidated with intravenous etoposide, methylprednisolone, high-dose arabinoside, and cisplatin as salvage therapy for relapsing and/or refractory lymphomas. ( Cabanillas, F; Hagemeister, FB; Hill, D; McLaughlin, P; Moore, DF; Rodriguez, MA; Romaguera, JE; Sarris, AH; Swan, F; Younes, A, 1994) |
| "In order to assess long-term outcome of patients with localized (stage I or II) diffuse large-cell lymphoma treated with initial combination chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) with or without involved-field radiotherapy following chemotherapy, we combined data from two prospective trials in Tucson (64 patients) and Vancouver (78 patients)." | 5.06 | Long-term follow-up and analysis for prognostic factors for patients with limited-stage diffuse large-cell lymphoma treated with initial chemotherapy with or without adjuvant radiotherapy. ( Connors, JM; Jones, SE; Miller, TP, 1989) |
| "Eighty-two adult patients with advanced B-lymphoma, treated between 1981 and 1983 with VEPA (vincristine, cyclophosphamide, prednisolone and doxorubicin) or VEPA-M (VEPA plus methotrexate) in a prospective randomized fashion, were evaluated for pretreatment characteristics." | 5.06 | Major prognostic factors of adult patients with advanced B-cell lymphoma treated with vincristine, cyclophosphamide, prednisone and doxorubicin (VEPA) or VEPA plus methotrexate (VEPA-M). ( Kikuchi, M; Konda, S; Minato, K; Ogawa, M; Ota, K; Shimoyama, M; Takatsuki, K; Tominaga, S; Tsugane, S; Yunoki, K, 1988) |
| "In order to compare the efficacy and toxicity of mitoxantrone and adriamycin in non-Hodgkin's lymphoma, a randomized trial has been conducted by a cooperative study group since June 1984." | 5.06 | [A comparative study of mitoxantrone and adriamycin in patients with non-Hodgkin's lymphoma: a preliminary result]. ( Kimura, I; Masaoka, T; Namba, K; Ohnoshi, T; Sampi, K, 1986) |
| "In a nationwide multicenter study, single-agent treatment with prednimustine (PM) was compared with combination chemotherapy with CVP (cyclophosphamide, vincristine, and prednisolone) in patients with stage III-IV non-Hodgkin's lymphoma (NHL) with favorable histology (Rappaport groups nodular lymphocytic poorly differentiated, nodular mixed, and diffuse lymphocytic poorly and well-differentiated)." | 5.06 | Prednimustine v cyclophosphamide-vincristine-prednisolone in the treatment of non-Hodgkin's lymphoma with favorable histopathology: results of a national cancer care program in Sweden. ( Cavallin-Ståhl, E; Möller, TR, 1986) |
| "17 patients with diffuse non-Hodgkin's lymphoma with unfavorable histologies were treated with cyclophosphamide, hydroxyldaunorubicin (doxorubicin), vincristine (Oncovin), prednisone and bleomycin (CHOP-Bleo)." | 5.05 | Long-term results of patients with advanced diffuse, non-Hodgkin's lymphoma treated with cyclophosphamide, doxorubicin, vincristine, prednisone and bleomycin (CHOP-Bleo). ( Case, DC, 1983) |
| "In a randomized multicenter trial, 209 recipients of cadaveric renal transplants were treated either with cyclosporine and prednisone or with standard therapy that included azathioprine and prednisone." | 5.05 | A randomized clinical trial of cyclosporine in cadaveric renal transplantation. ( , 1983) |
| "Investigators of the Children's Cancer Study Group entered 73 children with previously untreated localized non-Hodgkin's lymphoma on a prospective randomized trial of systemic treatment with either a four-drug program (cyclophosphamide, vincristine, methotrexate, prednisone [COMP]) or a 10-drug (LSA2-L2 modified) program of 18 months duration." | 5.05 | The treatment of localized non-Hodgkin's lymphoma in children: a report from the Children's Cancer Study Group. ( Anderson, JR; Chilcote, RR; Coccia, PF; Exelby, PR; Jenkin, RD; Kersey, JH; Kushner, JH; Meadows, AT; Siegel, SE; Sposto, R, 1984) |
| "In a randomized, prospective trial from 1974-1978, 73 patients with non-Hodgkin's lymphomas in clinical Stage I or II were treated with extended field radiotherapy alone (RT) or RT plus adjuvant chemotherapy with vincristine, streptonigrin, cyclophosphamide and prednisone (RT + CT)." | 5.05 | A randomized study of radiotherapy versus radiotherapy plus chemotherapy in stage I-II non-Hodgkin's lymphomas. ( Ersbøll, J; Hansen, HS; Hansen, MM; Nissen, NI; Pedersen-Bjergaard, J; Rygård, J; Walbom-Jørgensen, S, 1983) |
| "One hundred and twenty-three patients with advanced measureable malignant lymphomas resistant to conventional chemotherapy were entered in a prospectively randomized trial of two teniposide (VM-26)-based combination chemotherapy regimens: V-PLAT (VM-26, cisplatin, and prednisone) and V-HEX (VM-26, hexamethylmelamine, and prednisone)." | 5.05 | Comparative trial of two teniposide-based combination chemotherapy regimens for the treatment of advanced malignant lymphomas. ( Anderson, J; Bennett, JM; Berard, CW; Brodovsky, HS; Glick, JH; Merrill, JM; Neiman, RS; O'Connell, MJ, 1982) |
| "This report describes two comparisons of combination chemotherapy (COP) with chlorambucil in the management of Stages III, IV Grade 1 non-Hodgkin's lymphoma." | 5.05 | Chemotherapy in the management of stage III/IV grade 1 non-Hodgkin's lymphomas (Report no 17). ( Hayhoe, FG, 1981) |
| "Fifty-two patients with stage III or IV nodular mixed lymphocytic-histiocytic lymphoma (NM) were entered on a prospective randomized trial comparing cyclophosphamide-prednisone (CP) to either COPP (cyclophosphamide, vincristine, procarbazine, prednisone) or BCVP (BCNU, cyclophosphamide, vincristine, prednisone)." | 5.05 | Nodular mixed lymphoma: results of a randomized trial failing to confirm prolonged disease-free survival with COPP chemotherapy. ( Barnes, JM; Bennett, JM; Berard, CW; Ezdinli, EZ; Glick, JH; Orlow, EL, 1981) |
| "Between January 1973 and January 1979, 131 patients with malignant non-Hodgkin's lymphomas (107 lymphocytic lymphomas, 24 histiocytic lymphomas) were treated with cyclophosphamide-vincristin-prednisone (CVP) either alone or combined with Adriamycin (CVP-A)." | 5.05 | Combination chemotherapy with cyclophosphamide, vincristine, prednisone and the contribution of adriamycin in the treatment of adult non-Hodgkin's lymphomas a report of 131 cases. ( Duhamel, G; Gorin, NC; Najman, A; Parlier, Y; Stachowiak, J, 1982) |
| "24 patients with non-Hodgkin's lymphomas of low-grade malignancy (stage III and IV) were treated either with a single drug (prednimustine) or with combination chemotherapy (cyclophosphamide, vincristine and prednisone)." | 5.05 | Value of prednimustine in treating non Hodgkin's lymphomas of favourable histological type. ( Háber, J; Klener, P, 1985) |
| "The Swedish Lymphoma Study Group has compared the results of treatment with a CHOP regimen (cyclophosphamide, adriamycin, vincristine and prednisone) with those of treatment with a MEV regimen (methotrexate, cyclophosphamide and vincristine) in patients suffering from generalized non-Hodgkin's lymphoma (NHL) of unfavourable histopathology in a prospective randomized trial." | 5.05 | CHOP vs MEV for the treatment of non-Hodgkin's lymphoma of unfavourable histopathology: a randomized clinical trial. ( Björkholm, M; Glimelius, B; Hagberg, H; Killander, A; Lindemalm, C; Mellstedt, H, 1985) |
| "A total of 296 evaluable patients with unfavorable categories of malignant lymphoma were randomly assigned treatment with cyclophosphamide, vincristine, and prednisone plus BCNU (BCOP) or doxorubicin (CHOP)." | 5.05 | Phase III study of BCOP v CHOP in unfavorable categories of malignant lymphoma: a Southeastern Cancer Study Group trial. ( Bartolucci, AA; Dandy, M; Gams, RA; Omura, G; Rainey, M; Silberman, H, 1985) |
| "Between 1977 and 1983 the Southwest Oncology Group (SWOG) evaluated chemotherapy alone (cyclophosphamide, doxorubicin, vincristine, prednisone; CHOP) or chemoimmunotherapy (CHOP-levamisole or CHOP-levamisole-BCG) in a randomized prospective clinical trial involving 715 eligible patients with all types of malignant lymphoma (ML)." | 5.05 | Chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisone alone or with levamisole or with levamisole plus BCG for malignant lymphoma: a Southwest Oncology Group Study. ( Balcerzak, SP; Costanzi, JJ; Dabich, L; Eyre, HJ; Fabian, CJ; Grozea, PN; Jones, SE; Miller, TP; Morrison, FS; Van Slyck, EJ, 1985) |
| "Two triple-drug combinations (cyclophosphamide, vincristine, and prednisone [CVP] and adriamycin, bleomycin, and prednisone [ABP]) were randomly tested in 57 consecutive patients with pathologic stage IV non-Hodgkin's lymphoma." | 5.04 | Non-cross-resistant combinations in stage IV non-Hodgkin's lymphomas. ( Bonadonna, G; Monfardini, S; Villa, E, 1977) |
| "As a part of an ongoing prospective controlled trial, the Southwest Oncology Group compared the results of treatment of advanced non-Hodgkin's lymphoma with two CHOP regimens (cyclophosphamide, adriamycin, vincristine and prednisone with either low-dose bleomycin or BCG by scarification) to a COP regimen (cyclophosphamide, vincristine and prednisone) with low-dose bleomycin (COP-Bleo)." | 5.04 | Superiority of adriamycin-containing combination chemotherapy in the treatment of diffuse lymphoma: a Southwest Oncology Group study. ( Butler, JJ; Byrne, GE; Coltman, CA; Fisher, R; Grozea, PN; Haskins, CL; Haut, A; Jones, SE; Metz, EN; Moon, TE; Morrison, FS; Stephens, RL, 1979) |
| "Two hundred and ninety-eight evaluable patients with non-Hodgkin's lymphoma were stratified according to histology, treated with either BCNU, cyclophosphamide, Oncovin (vincristine), and prednisone (BCOP) or cyclophosphamide, Oncovin (vincristine), and prednisone (COP), and evaluated at 3 months." | 5.04 | BCNU with and without cyclophosphamide, vincristine, and prednisone (COP) and cycle-active therapy in non-Hodgkin's lymphoma. ( Bartolucci, AA; Dorfman, RF; Durant, JR; Gams, RA, 1977) |
| " protocol consisting of: vincristine-prednisone plus surgery and/or radiotherapy as induction treatment, craniocervical radiotherapy and intrathecal methotrexate as CNS preventive treatment and anti-leukemia (6-mercaptopurine, methotrexate and vincristine-prednisone pulses) or anti-lymphoma (COPP) treatment as maintenance, in a randomized trial." | 5.04 | Non-Hodgkin's lymphoma in children: an analysis of 122 cases from Argentina. ( Cebrian-Bonesana, A; Kvicala, R; Lein, JM; Ojeda, FG; Pavlovsky, S; Penchansky, L; Pependieck, C; Roca-Garcia, C; Sackmann-Muriel, S; Schvartzman, E, 1978) |
| " The risk of treatment-induced acute leukemias as well as sterility can be avoided or greatly decreased with drug combinations not including procarbazine HCI and alkylating agents." | 4.77 | Chemotherapy of malignant lymphomas. ( Bonadonna, G, 1985) |
| "Patients with aggressive B-cell lymphoma and MYC rearrangement at fluorescence in situ hybridization exhibit poor outcome after R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone)." | 4.12 | Safety and efficacy of a dose-dense short-term therapy in patients with MYC-translocated aggressive lymphoma. ( Allione, B; Angelillo, P; Cattaneo, C; Erbella, F; Facchetti, F; Ferreri, AJM; Flospergher, E; Foppoli, M; Lleshi, A; Pagani, C; Pecciarini, L; Ponzoni, M; Re, A; Rossi, G; Sassone, M; Spina, M; Steffanoni, S; Verga, L, 2022) |
| "30 dogs with multicentric lymphoma and neutrophilia (including 16 treated with a cyclophosphamide, doxorubicin, vincristine, and prednisone [CHOP]-based protocol) and 37 historical control dogs without neutrophilia treated with a CHOP-based protocol." | 4.02 | Evaluation of neutrophilia as a prognostic factor in dogs with multicentric lymphoma treated with a cyclophosphamide, doxorubicin, vincristine, and prednisone-based chemotherapy protocol. ( Pellin, M; Veluvolu, S; Vos, N, 2021) |
| "Prednisone resistance develops rapidly and essentially universally when dogs with lymphoma are treated with corticosteroids." | 3.96 | Development of prednisone resistance in naïve canine lymphoma: Longitudinal evaluation of NR3C1α, ABCB1, and 11β-HSD mRNA expression. ( Burke, NS; Fidel, JL; Hanot, CC; Mealey, KL; Sellon, RK; White, LA, 2020) |
| "The aims of this study were to evaluate the safety of mustargen, vincristine, procarbazine and prednisone (MOPP) chemotherapy in the treatment of relapsed or refractory feline lymphoma, and to determine the overall response rate and median remission time with this protocol." | 3.96 | Efficacy and toxicity of mustargen, vincristine, procarbazine and prednisone (MOPP) for the treatment of relapsed or resistant lymphoma in cats. ( Brown, DC; Krick, EL; MaloneyHuss, MA; Mauldin, GE; Veluvolu, SM, 2020) |
| "To compare the progression-free survival of dogs with high-grade T-cell lymphoma treated with either a cyclophosphamide, doxorubicin, vincristine and prednisone-based or a modified mechlorethamine, vincristine, prednisone and procarbazine chemotherapy protocol." | 3.91 | Comparison of combination l-asparaginase plus CHOP or modified MOPP treatment protocols in dogs with multi-centric T-cell or hypercalcaemic lymphoma. ( Angelo, G; Cronin, K; Keys, D, 2019) |
| " Using a national database, we identified patients with lymphoma/leukemia with ≥1 etoposide, vincristine, doxorubicin, cyclophosphamide, and prednisone (EPOCH) chemotherapy claim and evaluated chemotherapy initiation delay (ID), >1 day from admission." | 3.85 | Factors and Costs Associated With Delay in Treatment Initiation and Prolonged Length of Stay With Inpatient EPOCH Chemotherapy in Patients With Hematologic Malignancies. ( Accordino, MK; Hershman, DL; Hillyer, GC; Neugut, AI; Vasan, S; Wright, JD, 2017) |
| " Here, we hypothesize that including a selective human CAR activator with the CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) regimen can improve the efficacy without exacerbating off-target toxicity of this regimen in non-Hodgkin lymphoma treatment." | 3.83 | Activation of the Constitutive Androstane Receptor Increases the Therapeutic Index of CHOP in Lymphoma Treatment. ( Baer, MR; Hassan, HE; Hedrich, WD; Heyward, S; Wang, H; Xiao, J; Zhang, J; Zhang, Y, 2016) |
| "Eighty-eight dogs with relapsed lymphoma were treated with the MOMP (mechlorethamine, vincristine, melphalan and prednisone) protocol on a 28-day treatment cycle." | 3.81 | Mechlorethamine, vincristine, melphalan and prednisone (MOMP) for the treatment of relapsed lymphoma in dogs. ( Back, AR; Lee, J; Phillips, JC; Schleis, SE; Smith, AN; Smrkovski, OA, 2015) |
| "To analyze the efficacy of cyclophosphamideplus, epirubicin, vincristine, prednisone plus etoposide and/or bleomycin, with or without rituximab (R±BEACOP) regimen in patient with poor-prognosis lymphoma." | 3.81 | [Efficacy of R±BEACOP regimen in patients with poor-prognosis lymphoma]. ( Dong, F; Ke, X; Pang, Y; Wang, J, 2015) |
| " In order to evaluate if a similar dysfunction is induced in small animals undergoing chemotherapy, we assessed the complete blood count, leukocytic, plasma and fecal canine parvovirus (CPV) viral load, and anti-CPV protective antibody titers, in dogs with lymphoma treated with CHOP (cyclophosphamide, doxorubicin, vincristine and prednisolone) protocol, before and during chemotherapy." | 3.80 | Influence of chemotherapy for lymphoma in canine parvovirus DNA distribution and specific humoral immunity. ( Braz, BS; Duarte, A; Elias, MA; Henriques, J; Lourenço, AM; Nunes, T; Tavares, L; Vicente, G, 2014) |
| "To evaluate the clinical response rate, progression-free survival time, overall survival time, and possible prognostic factors associated with a cyclophosphamide-, vincristine-, and prednisone (COP)-based chemotherapy protocol in cats with lymphoma." | 3.79 | Lymphoma in cats treated with a weekly cyclophosphamide-, vincristine-, and prednisone-based protocol: 114 cases (1998-2008). ( Gregor, TP; Jackson, K; Krick, EL; Waite, AH, 2013) |
| "To determine if the oral PEP-C regimen, consisting of prednisone 20 mgm, etoposide 50 mgm, procarbazine 50 mgm, and cyclophosphamide 50 mgm given in either a daily, alternate day, or fractionated basis, is effective in a variety of lymphomas." | 3.78 | Metronomic therapy for refractory/relapsed lymphoma: the PEP-C low-dose oral combination chemotherapy regimen. ( Coleman, M; Elstrom, RL; Leonard, JP; Martin, P; Ruan, G, 2012) |
| "To evaluate factors associated with second remission in dogs with lymphoma retreated with a cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) protocol after relapse following initial treatment with a first-line 6-month CHOP protocol." | 3.77 | Evaluation of factors associated with second remission in dogs with lymphoma undergoing retreatment with a cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy protocol: 95 cases (2000-2007). ( Chretin, JD; Erb, HN; Flory, AB; Garrett, LD; Locke, JE; Northrup, NC; Phillips, BS; Rassnick, KM; Selting, KA, 2011) |
| "To evaluate the toxicity and efficacy of a modification of a previously evaluated combination of lomustine, vincristine, procarbazine, and prednisone (LOPP) as a rescue protocol for refractory lymphoma in dogs." | 3.77 | Evaluation of the University of Florida lomustine, vincristine, procarbazine, and prednisone chemotherapy protocol for the treatment of relapsed lymphoma in dogs: 33 cases (2003-2009). ( Barabas, K; Clemente, M; Fahey, CE; Kow, K; Lurie, D; Lyles, S; Milner, RJ; Parfitt, S, 2011) |
| "Forty-one dogs with resistant lymphoma were treated with a modified MOPP (mechlorethamine, vincristine, procarbazine and prednisone) protocol (MPP [mechlorethamine, procarbazine and prednisone] administered on a 21-day cycle, shortened from the 28-day MOPP cycle)." | 3.75 | Mechlorethamine, procarbazine and prednisone for the treatment of resistant lymphoma in dogs. ( Childress, MO; Gieger, TL; Hume, KR; Keys, DA; Kosarek, CE; LeRoy, BE; Northrup, NC; Saba, CF; Wall, TM, 2009) |
| " For acute myelogenous leukemia, cytarabine with anthracycline agent is believed to be the standard treatment in first remission induction therapy." | 3.74 | [The standard treatments for patients with hematological malignancies in Japan]. ( Ishizawa, K, 2007) |
| "To assess response rate, median duration of response, adverse effects, and prognostic factors associated with concurrent administration of lomustine and prednisone as a first-line treatment for dogs with multicentric lymphoma." | 3.74 | Lomustine and prednisone as a first-line treatment for dogs with multicentric lymphoma: 17 cases (2004-2005). ( Bannink, EO; Kaneene, JB; Mullins, MN; Obradovich, JE; Sauerbrey, ML; Van Dorp, TE, 2007) |
| "The treatment of diffuse large B-cell lymphoma with chemotherapy was retrospectively evaluated in 348 patients who had received at least three cycles of CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone)-like, ACVBP (doxorubicin, cyclophosphamide, vindesine, bleomycin, and prednisone)-like or CHVmP-BV (cyclophosphamide, hydroxorubicin, Vm-26, prednisone, vincristine and bleomycin) treatment in Belgium between 1995 and 2000." | 3.74 | Achievement of optimal average relative dose intensity and correlation with survival in diffuse large B-cell lymphoma patients treated with CHOP. ( Berneman, Z; Bosly, A; Bron, D; Dauwe, M; De Bock, R; Ferrant, A; Kaufman, L; Van Hoof, A; Verhoef, G, 2008) |
| "In the histiocytic lymphomas, BCNU added to CVP increases the percentage of CRs but it does so at the expense of considerable toxicity." | 3.74 | Chemotherapy of non-Hodgkin's lymphomas: Eastern Cooperative Oncology Group experience. ( Bennett, JM; Carbone, PP; Ezdinli, E; Johnson, GJ; Lenhard, RE; Pocock, SJ, 1977) |
| "From 1999 to 2002, 20 patients with aggressive non-Hodgkin lymphoma, among 28 who failed autologous peripheral blood progenitor cell transplantation, were rescued with cyclophosphamide, hydroxydaunomycin, Oncovin (vincristine), and prednisone (CHOP)/rituximab (RTX) and granulocyte-macrophage colony-stimulating factor (GM-CSF)." | 3.73 | A new schedule of CHOP/rituximab plus granulocyte-macrophage colony-stimulating factor is an effective rescue for patients with aggressive lymphoma failing autologous stem cell transplantation. ( Candela, M; Capelli, D; Gini, G; Leoni, P; Lucesole, M; Montanari, M; Olivieri, A; Poloni, A; Scortechini, I; Troiani, E, 2005) |
| " The immunosuppressive drugs prednisone and cyclosporin A (CsA) are routinely used during HSCT to prevent or treat graft-versus-host disease (GVHD) or to inhibit antibody-mediated inflammation." | 3.72 | Do the immunosuppressive drugs used as treatment for graft-versus-host disease directly inhibit lymphoid tumor cell growth? ( D'Costa, S; Hurwitz, JL; Slobod, KS, 2003) |
| " The risk is significantly evident in patients with aggressive lymphoma, which is highly responsive to standard chemotherapy with cyclophosphamide, hydroxydaunomycin, vincristine, and prednisone (CHOP) achieving a complete response rate of 60-80% and 5-year survival rate of 30-50% with only 1% of treatment-related mortality." | 3.72 | Preemptive use of interferon or lamivudine for hepatitis B reactivation in patients with aggressive lymphoma receiving chemotherapy. ( Chen, TY; Huang, WT; Leaw, SJ; Su, WC; Tsao, CJ; Yen, CJ, 2004) |
| "In the current study, the authors analyzed prognostic factors in patients with aggressive lymphoma treated with a chemotherapy regimen comprised of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) with or without radiotherapy." | 3.71 | Bulky disease is an adverse prognostic factor in patients treated with chemotherapy comprised of cyclophosphamide, doxorubicin, vincristine, and prednisone with or without radiotherapy for aggressive lymphoma. ( Cabanillas, F; Cox, JD; Ha, CS; Hess, MA; Pro, B; Rodriguez, MA; Wilder, RB, 2001) |
| "To determine clinical and pathologic findings in cats with alimentary malignant lymphoma and results of treatment with a combination of prednisone, L-asparaginase, vincristine, cyclophosphamide, doxorubicin, and methotrexate." | 3.70 | Results of chemotherapy for cats with alimentary malignant lymphoma: 21 cases (1993-1997) ( Kraegel, SA; Lucroy, MD; Madewell, BR; Zwahlen, CH, 1998) |
| "The activity of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) in the treatment of primary central nervous system lymphoma (PCNSL) prior to radiotherapy was studied in six patients." | 3.69 | Cyclophosphamide, doxorubicin, vincristine, and prednisone for primary central nervous system lymphoma: short-duration response and multifocal intracerebral recurrence preceding radiotherapy. ( Boyko, OB; Brizel, DM; Brown, MT; Burger, PC; Gockerman, JP; Halperin, EC; Lachance, DH; Schold, SC, 1994) |
| "To determine response rate and remission as well as survival times for dogs with multicentric lymphoma treated first with doxorubicin alone or in combination with asparaginase and then with cyclophosphamide, vincristine sulfate, and prednisone (CVP) and to identify prevalence of toxicoses associated with this protocol and factors associated with prognosis." | 3.69 | Doxorubicin alone or in combination with asparaginase, followed by cyclophosphamide, vincristine, and prednisone for treatment of multicentric lymphoma in dogs: 121 cases (1987-1995). ( Getzy, DM; Mallinckrodt, CH; Ogilvie, GK; Valerius, KD, 1997) |
| "Combined modality therapy consisting of CHOP-Bleo (cyclophosphamide, Adriamycin [doxorubicin], vincristine (Oncovin), prednisone, and bleomycin) and limited-field radiotherapy was given to 47 patients with Stage III and IIIE diffuse large cell lymphomas." | 3.67 | Combined modality therapy in Stage III and Stage IIIE diffuse large cell lymphomas. ( Fuller, LM; Hagemeister, FB; Manning, JT; Oh, KK; Shullenberger, CC; Sullivan, JA; Velasquez, W, 1984) |
| " Congestive heart failure resulting in death occurred in one case given 315mg /m2 of adriamycin and then 90 mg/m2 of mitoxantrone." | 3.67 | [Adriamycin-based combination chemotherapy in the treatment of advanced malignant lymphoma. A progress report]. ( Hattori, M; Honda, T; Sampi, K, 1984) |
| "One-hundred and ninety-four adult patients with histologically proven stage III and IV non-Hodgkin's lymphomas, treated with CVP (cyclophosphamide, vincristine and prednisone) alternated with ABP (adriamycin, bleomycin and prednisone), were analyzed to test the validity of the clinicoprognostic correlation offered by the working formulation in comparison with the Rappaport and Kiel classifications." | 3.67 | A clinicopathologic study in advanced non-Hodgkin's lymphomas treated with sequential non-cross-resistant regimens: comparison of the working formulation with the Rappaport and Kiel classifications. ( Bajetta, E; Buzzoni, R; Canetta, R; Giardini, R; Monfardini, S; Rilke, F; Valagussa, P; Viviani, S, 1984) |
| "A radioreceptor assay for serum 1,25-dihydroxyvitamin D (calcitriol) was used to screen patients with hypercalcemia of malignancy." | 3.67 | Hypercalcemia associated with increased serum calcitriol levels in three patients with lymphoma. ( Breslau, NA; Frenkel, EP; McGuire, JL; Pak, CY; Zerwekh, JE, 1984) |
| "58 consecutively referred, previously untreated patients with nodular lymphomas (stages III and IV) were treated with two different combination chemotherapy regimens-(cyclophosphamide, vincristine and prednisone (COP), and BCNU , cyclophosphamide, vincristine, melphalan and prednisone (M-2) - to compare remission induction and duration as well as survival." | 3.67 | Comparison of M-2 protocol with COP in patients with nodular lymphoma. ( Case, DC, 1984) |
| "Fifty-one patients with diffuse large-cell lymphoma (DLCL) were treated with a six-drug combination chemotherapy regimen including cyclophosphamide, doxorubicin, procarbazine, bleomycin, vincristine, and prednisone." | 3.67 | Chemotherapy for diffuse large-cell lymphoma--rapidly responding patients have more durable remissions. ( Armitage, JO; Dowling, M; Howe, D; Hutchins, M; Johnson, PS; Mailliard, J; Moravec, DF; Okerbloom, J; Sorensen, S; Weisenburger, DD, 1986) |
| "Long-term follow-up results of two studies using cyclophosphamide, doxorubicin, vincristine, and prednisone plus bleomycin (CHOP-Bleo) for the treatment of diffuse large-cell lymphoma are presented." | 3.67 | A 10-year update of CHOP-Bleo in the treatment of diffuse large-cell lymphoma. ( Bodey, GP; Cabanillas, F; Freireich, EJ; Lee, R, 1986) |
| "COPBLAM III, a polychemotherapy regimen consisting of cyclophosphamide, infusional vincristine, prednisone, infusional bleomycin, doxorubicin, and procarbazine, was administered to 51 patients with diffuse large-cell lymphoma." | 3.67 | COPBLAM III: infusional combination chemotherapy for diffuse large-cell lymphoma. ( Bernhardt, B; Boyd, DB; Coleman, M; Files, JC; Gaynor, M; Kopel, SK; McDermott, D; Papish, SW; Schwartz, S; Topilow, A, 1988) |
| "A patient with malignant lymphoma repeatedly developed transient rosacea-like dermatitis several days after each interruption of continuous oral prednisone intake." | 3.67 | Steroid-withdrawal rosacea-like dermatitis. ( Tagami, H; Tomita, Y, 1989) |
| "Twenty-one patients with intermediate- and high-grade lymphomas were treated with modified cyclophosphamide, vincristine, methotrexate, leucovorin, and cytarabine (COMLA)." | 3.67 | Modified cyclophosphamide, vincristine, methotrexate, leucovorin, and cytarabine (COMLA) in intermediate- and high-grade lymphoma: an effective short-course regimen. ( Baer, MR; Flexner, JM; Greer, JP; Hainsworth, JD; Stein, RS; Wolff, SN, 1986) |
| "Thirty-three patients with diffuse non-Hodgkin's lymphoma (stages I and II) received intermediate doses of oral methotrexate followed by leucovorin calcium every four weeks, on days 1 and 8, followed on day 15 by intravenous cyclophosphamide and vincristine sulfate." | 3.67 | Primary chemotherapy for localized non-Hodgkin's lymphomas with diffuse histologic characteristics. Preliminary report of a prospective study. ( Barcos, M; Gomez, GA; Han, T; Henderson, ES; Krishnamsetty, RM; Nava, H; Ozer, H; Reddy, S, 1986) |
| "Between June 1979 and June 1984 18 adult patients with small noncleaved cell lymphoma (SNCL) (diffuse undifferentiated lymphoma, Burkitt's and non-Burkitt's types of the Rappaport classification) were treated with high-dose cyclophosphamide, doxorubicin, vincristine, prednisone, midcycle high-dose methotrexate, and intrathecal methotrexate." | 3.67 | Combined modality therapy for adults with small noncleaved cell lymphoma (Burkitt's and non-Burkitt's types). ( Bernstein, JI; Coleman, CN; Dorfman, RF; Rosenberg, SA; Strickler, JG, 1986) |
| "This is a case report of an aggressive multifocal non-Hodgkin's lymphoma in a cadaver kidney recipient arising in the early phase of her immunosuppressive maintenance therapy program with cyclosporin A and prednisone." | 3.67 | Multifocal aggressive lymphoma of the gastrointestinal tract in a renal transplant patient treated with cyclosporin A and prednisone. ( Castro, CJ; Klimo, P; Worth, A, 1985) |
| "High-dose methotrexate (HDMTX) with citrovorum factor (CF) was used to treat non-Hodgkin's lymphomas either as a single agent in those patients who had previously failed to respond to conventional chemotherapy or in previously untreated patients in combination with bleomycin, Adriamycin, cytoxan, and vincristine." | 3.66 | Methotrexate as a single agent and in combination chemotherapy for the treatment of non-Hodgkin's lymphoma of unfavorable histology. ( Canellos, GP; Frei, E; Moloney, WC; Rosenthal, DS; Skarin, AT, 1981) |
| "Peplomycin containing combination chemotherapy with cyclophosphamide, hydroxy-daunomycin, oncovin and prednisone (CHOP-P) was performed in one patient with ATL and 8 patients with advanced diffuse lymphoma." | 3.66 | [Combination chemotherapy using peplomycin for the treatment of non-Hodgkin's lymphoma including adult T cell leukemia]. ( Ichimaru, M; Kamihira, S; Kinoshita, K; Nakano, M; Sakitani, M, 1983) |
| "Subacute polyneuropathy that responded to prednisone was the initial symptom in two patients, one of whom was later found to have histiocytic lymphoma and the other, chronic lymphocytic leukemia." | 3.66 | Lymphoma and leukemia manifested by steroid-responsive polyneuropathy. ( Farrell, DF; Knauss, TA; Sumi, SM, 1983) |
| "Ninety-five patients with advanced non-Hodgkin's lymphoma were treated with four courses of cyclophosphamide, adriamycin, vincristine and prednisone, with or without procarbazine [CHOP(P)] chemotherapy; either 150 rad total body irradiation (for "extensive" disease) or 3,500 rad local radiation therapy (for "limited" disease); and a final four courses of CHOP(P) chemotherapy." | 3.66 | Combined modality therapy of advanced non-Hodgkin's lymphoma: an analysis of remission duration and survival in 95 patients. ( Appelbaum, FR; Bagley, CM; Dahlberg, S; Farewell, VT; Kadin, ME; Neiman, PE; Rudolph, RH; Sullivan, KM; Thomas, ED, 1983) |
| "Twenty-seven previously untreated patients with favorable prognosis non-Hodgkin's lymphoma were treated with a combination of total body irradiation followed by cyclophosphamide - vincristine - prednisone (CVP)." | 3.66 | Multimodality therapy of favorable prognosis non-Hodgkin's lymphoma. ( Corder, MP; Leimert, JT; Lovett, JM; Tewfik, HH, 1983) |
| "The combination of cyclophosphamide, adriamycin, vincristine, and prednisone (CHOP) alternating with total body irradiation (TBI) has been shown earlier to be effective therapy in patients with malignant lymphoma who have received prior chemotherapy and/or radiation therapy." | 3.66 | The combined modality therapy of diffuse histology non-Hodgkin's lymphoma with cyclophosphamide, adriamycin, vincristine, prednisone (CHOP) and total body irradiation. ( Antunez, A; Dixon, D; Fabian, CJ; Kraus, TA; Weick, JK, 1983) |
| "Forty-five patients with localized non-Hodgkin's lymphoma of unfavorable histologic type (41 patients had diffuse histiocytic, 2 had nodular mixed, and 2 had minimally nodular histiocytic lymphoma) were treated with initial chemotherapy (28 patients), including cyclophosphamide, adriamycin, vincristine, and prednisone (CHOP), or with initial CHOP followed by involved field radiotherapy (17 patients)." | 3.66 | Initial chemotherapy for clinically localized lymphomas of unfavorable histology. ( Jones, SE; Miller, TP, 1983) |
| "In a pilot study of cyclical chemotherapy in patients with poor-prognosis non-Hodgkin's lymphoma (NHL), high-dose methotrexate (MTX) 1 g/m2 with folinic acid rescue was given as initial treatment and then between cycles of a single-arm CHOP combination administered every 4 weeks." | 3.66 | A pilot study of cyclical chemotherapy with high-dose methotrexate and CHOP (MTX-CHOP) in poor-prognosis non-Hodgkin's lymphoma (NHL). ( Barnard, DL; Cartwright, SC; Child, JA; Lauder, I; Simmons, AV; Stone, J; Thorogood, J, 1983) |
| "A regimen consisting of two courses of methotrexate (MTX) with leucovorin rescue followed 1 week later by cyclophosphamide, vincristine, and prednisone (MTX-COP) was studied in ten patients with disseminated diffuse non-Hodgkin's lymphoma who had had no prior chemotherapy." | 3.66 | Combinations of methotrexate (COP or CHOP) in the treatment of previously untreated and treated lymphomas. ( Gomez, GA; Han, T; Henderson, E; Moayeri, H; Naeher, C; Plager, J; Shimaoka, K; Stutzman, L, 1982) |
| "Twelve of 13 adult patients with acute lymphocytic leukemia, acute undifferentiated leukemia, or convoluted T-cell lymphoma (T-cell ALL) who were treated with Adriamycin, vincristine, and prednisone achieved a complete remission." | 3.66 | Effective multidrug, multimodality consolidation therapy of adult acute lymphocytic leukemia: a preliminary report. ( Collins, RD; Flexner, JM; Stein, RS, 1982) |
| "Two hundred and fifty-two patients with advanced stages of favorable non-Hodgkin's lymphoma (NHL) subtypes (nodular histiocytic (NH), and diffuse well-differentiated lymphocytic (DLWD)) were analyzed for response and survival to moderate (cyclophosphamide-prednisone (CP)) vs." | 3.66 | Moderate versus intensive chemotherapy of prognostically favorable non-Hodgkin's lymphoma: a progress report. ( Berard, C; Costello, WG; Ezdinli, EZ; Hartsock, RJ; Silverstein, MN; Sokal, JE, 1980) |
| "Nineteen patients with advanced non-Hodgkin's lymphoma resistant to previous chemotherapy were treated with combination chemotherapy consisting of lomustine (CCNU), cytarabine, and prednisone." | 3.66 | Salvage chemotherapy for non-Hodgkin's lymphoma. ( Khoo, RK; Ng, PR; Todd, D, 1982) |
| "Three patients with Hodgkin disease, eight with non-Hodgkin lymphoma, and one with chronic lymphocytic leukemia refractory to conventional combination chemotherapy were treated for remission induction with a new kinetically designed four-drug combination consisting of bleomycin, vincristine, adriamycin, and prednisone and given the acronym "BOAP." | 3.66 | A kinetically designed chemotherapeutic regimen for advanced refractory lymphoma patients. ( Braine, HG; Coltman, CA; Kerr, RO; Rossof, AH, 1978) |
| "A woman, aged 58, who had undergone prolonged treatment with corticosteroids for generalized necrotizing vasculitis, and had received azathioprine (Imurel) for 18 months, 4 years after discontinuing the latter treatment, developed peripheral neuropathy and a rapidly progressing cerebral disorder suggesting a basal meningeal process." | 3.66 | Primary malignant lymphoma of the CNS and polyneuropathy in a patient with necrotizing vasculitis treated with immunosuppression. ( Jellinger, K; Kothbauer, P; Sunder-Plassmann, E; Weiss, R, 1979) |
| "The results of a chemotherapy regimen utilizing adriamycin in combination with vincristine, prednisone plus or minus cyclophosphamide (CHOP-HOP) for the treatment of non-Hodgkin lymphoma are compared to those of a non-adriamycin containing combination (COP)." | 3.66 | Improvement in complete response rate, duration of response and survival with adriamycin combination chemotherapy for non-Hodgkin lymphoma: a prognostic factor comparison of two regimens. ( Cabanillas, F; Freireich, EJ; Rodriguez, V, 1978) |
| "Fourty-three of 61 patients suffering from low-grade malignant non-Hodgkin's lymphomas according to the Kiel classification were subjected to an intermittent combination chemotherapy with chlorambucil and prednisone." | 3.66 | Intermittent combination chemotherapy with chlorambucil and prednisone of low-grade malignant non-Hodgkin's lymphomas according to the Kiel classification. ( Garbrecht, M; Stolzenbach, G, 1979) |
| "A case of localized lymphomatous polyposis of the rectum successfully treated with a combination of cyclophosphamide, vincristine and prednisone (COP regimen) is reported and the literature is briefly reviewed." | 3.66 | Regression of lymphomatous polyposis of the rectum after COP-treatment. ( Branehög, I; Hultén, L; Ridell, B; Weinfeld, A, 1979) |
| " The present study was conducted to determine the characteristics related to response and survival in patients with stage III and IV non-Hodgkin's lymphoma who were treated with combinations of cyclophosphamide, vincristine sulfate, and prednisone." | 3.66 | Factors predicting for response and survival in adults with advanced non-Hodgkin's lymphoma. ( Burke, JS; Butler, JJ; Cabanillas, F; Moon, TE; Rodriguez, V; Smith, TL, 1978) |
| "Disseminated infection caused by Fusarium moniliforme is described in a 32-year-old granulocytopenic man with malignant lymphoma being treated with cytotoxic drugs and corticosteroids." | 3.66 | Disseminated infection by Fusarium moniliforme during treatment for malignant lymphoma. ( Fisher, RI; Jennings, AE; Kubota, TT; Kwon-Chung, KJ; Young, NA, 1978) |
| " In 1976 she developed a mixed cryoglobulinemia and an immune complex mediated vasculitis manifested by purpura and neuropathy which improved on prednisone and chlorambucil therapy." | 3.66 | Behçet's disease associated with a lymphoproliferative disorder, mixed cryoglobulinemia, and an immune complex mediated vasculitis. ( Houston, KA; McDuffie, FC; O'duffy, JD, 1978) |
| "Forty-seven adults with advanced malignant lymphoma (the majority in stage IV) were treated with a combination of cyclophosphamide, hydroxyldaunorubicin (Adriamycin), vincristine (Oncovin), prednisone, and bleomycin (CHOP-Bleo)." | 3.65 | Combination chemotherapy ("CHOP-Bleo") in advanced (non-Hodgkin) malignant lymphoma. ( Bodey, GP; Burgess, MA; Cabanillas, F; Freireich, EJ; McKelvey, EM; Rodriguez, V; Valdivieso, M, 1977) |
| "Seventy-three patients with advanced non-Hodgkin lymphoma were treated with bleomycin, Adriamycin, cyclophosphamide, vincristine (Oncovin) and prednisone (BACOP), administered intensively during a 7-wk induction course followed by intermittent cycles every 3 wk for a total of 28 wk." | 3.65 | Combination chemotherapy of advanced non-Hodgkin lymphoma with bleomycin, adriamycin, cyclophosphamide, vincristine, and prednisone (BACOP). ( Frei, E; Moloney, WC; Rosenthal, DS; Skarin, AT, 1977) |
| "Combination chemotherapy with CHOP (cyclophosphamide, Adriamycin, vincristine, and prednisone) and HOP (Adrimycin, vincristine, and prednisone, was used as treatment for patients with pathologically staged, advanced non-Hodgkin's lymphoma." | 3.65 | Hydroxyldaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma. ( Coltman, C; Gamble, JF; Gottlieb, JA; Grozea, PN; Gutterman, J; Haut, A; Jones, SE; Lane, M; McKelvey, EM; Moon, TE; Stephens, R; Talley, RW; Wilson, HE, 1976) |
| "Four patients with malignant lymphoma who were treated with multiple courses of combination chemotherapy, consisting of cyclophosphamide, Oncovin, procarbazine, and prednisone (COPP), developed avascular necrosis of the femoral head(s)." | 3.65 | Avascular necrosis of the femoral head with combination therapy. ( Desser, RK; Miller, JB; Roth, DG; Sweet, DL; Ultmann, JE, 1976) |
| "Cytarabine is an effective agent in the treatment of acute leukemia." | 3.65 | Drugs five years later: cytarabine. ( Kremer, WB, 1975) |
| "Sixty-seven evaluable patients with mixed cellular and histiocytic lymphomas, both nodular and diffuse, were treated with a combined drug regimen of BCNU, cyclophosphamide, vincristine, and prednisone administered for six monthly courses." | 3.65 | 1,3-bis(2-chloroethyl)-1-nitrosourea(BCNU), cyclophosphamide, vincristine- and prednisone-(BCOP). A new therapeutic regimen for diffuse histiocytic lymphoma. ( Chan, YK; Dorfman, R; Durant, JR; Loeb, V, 1975) |
| "Four adult patients with malignant lymphoma were treated with combination chemotherapy including an alkylating agent, vincristine, procarbazine (in all but one case), and intermittent high-dose prednisone." | 3.65 | Osteonecrosis of the femoral head in patients with lymphoma treated with intermittent combination chemotherapy (including corticosteroids). ( DeVita, VT; Ihde, DC, 1975) |
| " Seventeen patients with Hodgkin's disease and 15 with non-Hodgkin's lymphoma were subjected to nontherapeutic splenectomy as part of the staging procedure prior to their initial treatment with MOPP (nitrogen mustard, vincristine, procarbazine, and prednisone) or CVP (cyclophosphamide, vincristine, and prednisone) chemotherapy, respectively." | 3.65 | Effect of splenectomy on tolerance to combination chemotherapy in patients with lymphoma. ( Canellos, GP; DeVita, VT; Ihde, DC; Young, RC, 1976) |
| "From July 1971 to July 1974, 58 patients with advanced non-Hodgkin's lymphomas were treated with cyclophosphamide, vincristine, prednisone (CVP) at Stanford Medical Center." | 3.65 | Combination chemotherapy with cyclophosphamide, vincristine, and prednisone in advanced non-Hodgkin's lymphomas. ( Portlock, CS; Rosenberg, SA, 1976) |
| "2%) were subject to dosing adjustments." | 3.01 | The physical exam's role in determining dose-limiting toxicity prior to immunochemotherapy administration in lymphoma. ( Brown, AB; Carty, SA; Kaminski, MS; Phillips, TJ; Runge, JS; Wilcox, RA, 2023) |
| "Plerixafor-treated subjects collected 7." | 2.80 | Plerixafor in combination with granulocyte-colony-stimulating factor after chemotherapy increases mobilization efficiency in patients with lymphoma or myeloma: results of a Phase II clinical trial. ( Flowers, C; Gaylor, C; Harvey, RD; Jagirdar, N; Kaufman, J; Langston, A; Lechowicz, MJ; Lipscomb, C; Lonial, S; Nooka, A; Waller, EK, 2015) |
| "Prednisone was given orally at 60 mg/m(2) per day for five consecutive days within each 28-day cycle." | 2.75 | A phase I trial of UCN-01 and prednisone in patients with refractory solid tumors and lymphomas. ( Conley, BA; Dancey, J; Doroshow, JH; Figg, WD; Gardner, ER; Gutierrez, ME; Kummar, S; Melillo, G; Murgo, AJ; Sausville, EA, 2010) |
| "Dexverapamil is a competitive inhibitor of the P-glycoprotein (Pgp) efflux pump, a potent mechanism of multidrug resistance (mdr-1) in vitro." | 2.68 | Phase I and pharmacokinetic study of the multidrug resistance modulator dexverapamil with EPOCH chemotherapy. ( Balis, FM; Bates, SE; Bryant, G; Chabner, BA; Jamis-Dow, C; Klecker, RW; Kohler, DR; Steinberg, SM; Wilson, WH; Wittes, RE, 1995) |
| "Dexverapamil was escalated eight dose levels, from 240 to 1,200 mg/m2/d." | 2.68 | Controlled trial of dexverapamil, a modulator of multidrug resistance, in lymphomas refractory to EPOCH chemotherapy. ( Bates, SE; Bryant, G; Fojo, A; Herdt, J; Jaffe, ES; Regis, J; Steinberg, SM; Wilson, WH; Wittes, RE; Zhan, Z, 1995) |
| "Serious infection during neutropenia was the most common complication." | 2.67 | Unexpectedly high toxicity of MACOP-B in young patients with low grade lymphoma. ( Arranz, R; Cámara, R; Fernández-Rañada, JM; Figuera, A; Pérez, G; Steegmann, JL; Tomás, JF; Vazquez, L, 1991) |
| "58% of the non-Hodgkin's lymphomas occurred in patients with marked immunodeficiency, 85% were high grade malignancies and 47% had primary extranodal disease." | 2.67 | [Malignant lymphoma associated with HIV infection]. ( Becker, K; Clemens, MR; Fischer, T; Helm, EB; Knauf, W; Mitrou, PS; Pohl, C; Schrappe-Bächer, M; Serke, M; Westerhausen, M, 1991) |
| " A comparison of drug dosage in the group receiving TPN and the group receiving standard nutrition is a measure of drug tolerance in these patients." | 2.65 | A prospective randomized study of adjuvant parenteral nutrition in the treatment of diffuse lymphoma: effect on drug tolerance. ( Brennan, MF; Fisher, RI; Popp, MB; Simon, RM, 1981) |
| " Toxicity was acceptable with minor adjustments in dosage and timing of the myelosuppressive agents." | 2.65 | A new therapy schedule for pediatric non-Hodgkin lymphoma toxicity with preliminary results. ( Anderson, J; Chilcote, R; Coccia, P; Exelby, P; Hammond, D; Jenkin, RD; Kushner, J; Leikin, S; Meadows, AT; Siegel, S; Wilson, JF, 1980) |
| "In our experience hirsutism and viral infections are marked." | 2.65 | Sixteen months experience with cyclosporin-A in human kidney transplantation. ( Baillod, RA; Farrington, K; Fernando, ON; Moorhead, JF; Sweny, P; Varghese, Z; Younis, F, 1981) |
| " The frequency of infection was significantly lower among the patients on the PEPA program, and dosage escalation of the chemotherapeutic agents was accomplished more often among these patients." | 2.65 | Protected environment-prophylactic antibiotic program for malignant lymphoma. Randomized trial during chemotherapy to induce remission. ( Bodey, GP; Cabanillas, F; Freireich, EJ; Rodriguez, V, 1979) |
| "The response rate and survival in diffuse histiocytic lymphoma have improved since the first study." | 2.64 | Chemotherapy of non-Hodgkin's lymphoma: 10 years' experience in the Southwest Oncology Group. ( Coltman, CA; Jones, SE; Luce, JK; McKelvey, EM; Moon, TE, 1977) |
| "The aim of this study was to evaluate the clinical efficacy of Aidi injection combined with CHOP chemotherapy regimen in the treatment of malignant lymphoma." | 2.53 | Aidi injection combined with CHOP chemotherapy regimen in the treatment of malignant lymphoma: A meta-analysis based on randomized controlled trials. ( Fang, B; Jiang, J; Jiang, Y; Jin, W; Lan, Y; Liu, M; Liu, Y; Ma, G; Qu, Z; Wang, X; Zeng, Y, 2016) |
| "EBV-associated lymphomas are well characterized in patients with known defects in cellular immunity as occurs post-transplantation or HIV/AIDS but are increasingly recognized in patients without overt immunodeficiencies." | 2.48 | EBV-associated lymphomas in adults. ( Roschewski, M; Wilson, WH, 2012) |
| "Lymphoma is the most common hematologic neoplasm of dogs." | 2.45 | Lymphoma: which chemotherapy protocol and why? ( Chun, R, 2009) |
| "Primary colorectal lymphoma is an infrequent disease of unknown origin and with a growing incidence." | 2.44 | Primary colorectal lymphomas: review of the literature. ( Annoni, M; Bianchi, V; Boni, L; Castano, P; Dionigi, G; Dionigi, R; Rovera, F; Villa, F, 2007) |
| "Paraneoplastic pemphigus has been established as a newly recognized but distinctive syndrome." | 2.40 | Paraneoplastic pemphigus. ( Anhalt, GJ, 1997) |
| "Malignant lymphoma is classified into the following five major categories: aggressive lymphoma, indolent B-lymphoma, Hodgkin's disease, T-lymphoblastic lymphoma and adult T-cell leukemia-lymphoma (ATL)." | 2.39 | [Recent progress in the chemotherapy of malignant lymphoma]. ( Tobinai, K, 1995) |
| "Chemotherapy of malignant lymphomas has accomplished a significant progress during the two decades." | 2.38 | [Current status of chemotherapy in the treatment of malignant lymphomas]. ( Hayashi, K; Kimura, I; Mizuta, J; Murashima, M; Ohnoshi, T; Tada, A; Tagawa, S; Ueno, K, 1989) |
| "Most patients with early-stage Hodgkin's disease can now be cured by one of several therapeutic approaches." | 2.37 | Early-stage Hodgkin's disease: current approaches to treatment. ( MacKenzie, R; Rusthoven, JJ, 1985) |
| "Localized nodal lymphoma is uncommon, but important to identify since it is potentially curable by irradiation." | 2.36 | The place of radiation therapy in the treatment of non-Hodgkin's lymphomas. ( Canellos, GP; Chaffey, JT; Hellman, S; Moloney, WC; Rosenthal, DS; Skarin, AT, 1977) |
| "Patients with malignant lymphoma, diffuse type, have an unfavorable prognosis when compared to those patients with modular patterns." | 2.36 | Chemotherapy of non-Hodgkin lymphoma: the diffuse types. ( Sweet, DL; Ultmann, JE, 1978) |
| "Adult T-cell leukemia lymphoma (ATLL) is an aggressive mature T-cell neoplasm caused by human T-cell lymphotropic virus type 1 (HTLV-1) infection." | 1.91 | Poor Outcome of Adult T-Cell Leukemia/Lymphoma with Current Available Therapy: An Experience of Two Centers. ( Boisclair, S; Brahim, A; Bridgellal, S; Castillo-Tokumori, F; Dong, N; Pullukkara, JJ; Saeed, H; Sandoval-Sus, J; Sokol, L; Walker, D; Zhang, L, 2023) |
| "Lymphoma is the most common feline hematopoietic malignancy." | 1.62 | Incidence and treatment of feline renal lymphoma: 27 cases. ( Hohenhaus, AE; Lamb, KE; Williams, AG, 2021) |
| "The risk of malignant lymphomas is markedly increased in HIV-infected persons even in the era of effective combination antiretroviral therapy." | 1.62 | [Diagnosis and treatment of HIV-associated lymphoma: Update 202]. ( Hentrich, M, 2021) |
| "Lubiprostone was more effective than stimulant laxatives at treating vinca alkaloid-induced intractable constipation in patients with hematological malignancies, and its use could enable safe vinca alkaloid chemotherapy." | 1.56 | Effect of lubiprostone on vinca alkaloid-induced constipation in patients with hematological malignancies: a propensity score-matched analysis. ( Fukuda, H; Hayashi, T; Imai, T; Kawada, K; Miyamura, M; Morita, Y; Ohta, T; Tanaka, K, 2020) |
| "Lymphoma is the most common type of canine hematological malignancy where the multicentric (cMCL) form accounts for 75% of all cases." | 1.56 | Liquid biopsy based on small extracellular vesicles predicts chemotherapy response of canine multicentric lymphomas. ( Argyle, DJ; Ávila, ACFCM; Costa, MT; de Nardi, AB; Fukumasu, H; Garnica, TK; Lesbon, JCC; Matiz, ORS; Nishiya, AT; Ribeiro, RCS; Rochetti, AL; Silveira, JC; Strefezzi, RF; Zoppa, A, 2020) |
| "While both are rare, lupus erythematosus panniculitis of the orbit is even more exceptional; this patient's indolent, chronic relapsing course distinguished itself from the typical aggression of orbital T-cell lymphoma." | 1.48 | Orbital T-cell lymphoma versus lupus panniculitits: a T-cell-mediated spectrum of orbital lymphoproliferative disease. ( Huggins, AB; Kim, C; Rabinowitz, MP, 2018) |
| "Here, we report three cases of malignant lymphoma with spontaneous splenic rupture." | 1.48 | Three cases of spontaneous splenic rupture in malignant lymphoma. ( Amaki, J; Ando, K; Hiraiwa, S; Ichiki, A; Kajiwara, H; Kawai, H; Nakamura, N; Sekiguchi, T, 2018) |
| "The recommendation to treat canine lymphoma with a discontinuous protocol is based on small case numbers and mostly historic controls." | 1.46 | Comparison of a CHOP-LAsp-based protocol with and without maintenance for canine multicentric lymphoma. ( Ernst, T; Kessler, M; Lautscham, EM; Neiger, R; Willimzig, L, 2017) |
| "We report a case of primary adrenal malignant lymphoma with inferior vena cava thrombus which was successfully treated by surgical resection and chemotherapy." | 1.43 | [A Case of Primary Adrenal Malignant Lymphoma with Inferior Vena Cava Thrombus]. ( Fujita, T; Hirano, S; Iwamura, M; Kaneko, S; Koguchi, D; Matsumoto, K; Nagi, S; Ooyama, T; Tabata, K, 2016) |
| "The treatment with prednisone resulted in a rapid resolution of clinical symptoms." | 1.42 | Polymyalgia rheumatica in a patient with splenic marginal zone lymphoma - a case report. ( Gawroński, K; Kisiel, B; Rzepecki, P; Tłustochowicz, W, 2015) |
| "We present the case of a patient with malignant lymphoma resulting from chronic pyothorax after artificial pneumothorax for pulmonary tuberculosis." | 1.40 | Pyothorax-associated lymphoma: complete remission achieved by chemotherapy alone. ( Iwazaki, M; Kuwahira, I; Masuda, R; Nakagawa, T; Nakamura, N; Nakano, K; Nakano, T, 2014) |
| "Primary bone lymphoma is a rare disease, representing less than 5% of all extra-nodal non-Hodgkin lymphomas." | 1.39 | Primary bone lymphoma: a retrospective analysis of 22 patients treated in a single tertiary center. ( Bakiri, M; Briasoulis, A; Harhalakis, N; Karmiris, T; Matikas, A; Oikonomopoulou, D; Tzannou, I, 2013) |
| "Orbital lymphoma is a very rare type of primary Non-Hodgkin lymphoma." | 1.37 | Treatment of a patient with adnexal lymphoma with Rituximab. ( Bilgir, F; Bilgir, O; Calan, M; Oztekin, O; Sari, F; Yuksel, A, 2011) |
| "Primary breast lymphoma is a rare disease entity." | 1.37 | [Primary lymphoma of breast: a clinicopathologic and prognostic study of 40 cases]. ( Fu, L; Fu, XL; Jin, ZJ; Lang, RG; Liu, FF; Lü, AJ; Wang, XF; Wang, Y; Yang, H, 2011) |
| "Primary thyroid lymphoma is an uncommon neoplasm frequently associated with lymphocytic thyroiditis (LT)." | 1.37 | Fluorodeoxyglucose positron emission tomography in primary thyroid lymphoma with coexisting lymphocytic thyroiditis. ( Arabi, M; Dvorak, R; Gross, MD; Kujawski, L; Smith, LB, 2011) |
| "Considerations were Devic's disease versus metastases." | 1.36 | Breast lymphoma in Sjögren's syndrome complicated by acute monocular blindness. ( Molina, RM; Navarra, SV; Soldevilla, HF, 2010) |
| "Secondary and primary cardiac tumors are rare, and primary cardiac lymphoma are exceptional." | 1.36 | [Pericardial tamponade and third-degree atrioventricular block revealing a primary cardiac lymphoma]. ( Ballout, J; Helou, S; Houchaymi, Z, 2010) |
| "Actinomycin D was administered at a median dosage of 0." | 1.35 | Actinomycin D as rescue therapy in dogs with relapsed or resistant lymphoma: 49 cases (1999--2006). ( Bannink, EO; Hauptman, JG; Mullins, MN; Obradovich, JE; Sauerbrey, ML, 2008) |
| "This type of breast cancer should be added to a differential diagnosis when a solitary tumor is found in the breast on mammography." | 1.35 | Primary malignant lymphoma of the breast. ( Mizukami, Y; Okumura, H; Takayama, T; Takemura, A; Taniya, T, 2009) |
| "Recent advancement in the therapy of malignant lymphoma enables optional treatment strategies such as radioimmunotherapy with 90Y-labeled anti-CD20 monoclonal antibody or oral fludalabine for indolent non-Hodgkin's lymphoma and high-dose chemotherapy with autologous stem cell transplantation for aggressive non-Hodgkin's lymphoma." | 1.35 | [Application of 18F-FDG PET for the assessment of early response to the treatment and prognosis of patients]. ( Endo, K; Higuchi, T; Kuji, I; Matsuda, H; Murakami, K; Nakajima, K; Oriuchi, N; Tsukamoto, N, 2009) |
| "To examine the association of OP with hematologic malignancies and to assess the clinical course of affected patients." | 1.34 | Organizing pneumonia in patients with hematologic malignancies: a steroid-responsive lesion. ( Daniels, CE; Markovic, SN; Myers, JL; Ryu, JH; Utz, JP, 2007) |
| " Antibiotic peak concentration in blood decreased by 55%, doxorubicin circulated several times longer, and the area under the concentration-time curve increased 5 times if compared with standard doxorubicin administration." | 1.34 | Doxorubicin pharmacokinetics in lymphoma patients treated with doxorubicin-loaded eythrocytes. ( Ataullakhanov, FI; Galkina, NM; Kulikova, EV; Medvedev, PV; Pivnik, AV; Skorokhod, O; Vitvitsky, VM; Zybunova, EE, 2007) |
| "We present two cases of malignant lymphoma that developed a high fever that eventually reached an extremely high 38." | 1.33 | [Two cases of malignant lymphoma with high fever and C-reactive protein (CRP) elevation after treatment with granulocyte colony-stimulating factor (G-CSF)]. ( Horiike, S; Kanbayashi, Y; Matsumoto, Y; Mukoyama, N; Nishida, K; Nomura, K; Shimizu, D; Taniwaki, M, 2006) |
| "Chemotherapy used to treat lymphoma can cause severe neutropenia." | 1.33 | Severe neutropenia in CHOP occurs most frequently in cycle 1: a predictive model. ( Delgado, DJ; Fridman, M; Liberman, RF; Rabinowitz, AP; Tronic, BS; Weiner, NJ, 2006) |
| "Transvenous intracardiac tumor biopsy under fluoroscopic or transesophageal echocardiographic guidance, is a minimally invasive technique which makes definite diagnosis possible." | 1.32 | [Primary cardiac lymphoma: diagnosis by transjugular biopsy]. ( Carbonell Porras, A; Flox Camacho, A; Hernández Hernández, F; Salguero Bodes, R; Sánchez Pérez, I; Tascón Pérez, J, 2003) |
| "This case presents a primary malignant lymphoma of the clivus, histologically confirmed after intra-operative MRI-guided transnasal-transsphenoidal biopsy." | 1.32 | Clivus lymphoma. ( Jung, CS; Seifert, V; Zimmermann, M, 2004) |
| "Lymphoma is a malign disease of the lymphoid system." | 1.32 | Cyclooxygenase-2 (Cox-2) expression in lymphomas. ( Erdoğan, S; Ergin, M; Hakverdi, S; Hazar, B; Seyrek, E; Tuncer, I, 2004) |
| "Pancreatic lymphoma is a rare neoplasm." | 1.31 | Is there a role for surgical resection in the treatment of early-stage pancreatic lymphoma? ( Abrams, RA; Cameron, JL; Colemann, J; Koniaris, LG; Lillemoe, KD; Nakeeb, A; Pitt, H; Yeo, CJ, 2000) |
| "Primary malignant lymphoma of bone (PLB) is an uncommon tumour." | 1.31 | Primary lymphoma of bones. ( Altay, M; Bayrakci, K; Erekul, S; Ogüt, H; Saglik, Y; Samur, M; Yildiz, Y, 2001) |
| "In contrast, serum IL-12 levels in malignant lymphoma patients did not change significantly." | 1.31 | Comparison of interleukin-12 with lung cancer and malignant lymphoma undergoing autologous peripheral blood stem cell transplantation. ( Fukuhara, S; Kanazawa, S; Kuwana, M; Nomura, S; Yamaguchi, K; Yoshimura, C, 2002) |
| "Patients treated for Hodgkin's disease and non-Hodgkin lymphomas were followed for 5 years after start of therapy." | 1.30 | Five-year follow-up of saliva in patients treated for lymphomas. ( Keinànen, S; Laine, P; Lindqvist, C; Meurman, JH; Pyrhönen, S; Teerenhovi, L, 1997) |
| "All three were diagnosed as having malignant lymphoma by histological examination, and treated with chemotherapy and steroids." | 1.30 | Spontaneous gastrointestinal perforation in patients with lymphoma receiving chemotherapy and steroids. Report of three cases. ( Egami, K; Furukawa, K; Kiyama, T; Matsukura, N; Onda, M; Tokunaga, A; Wada, M; Yamashita, K; Yoshiyuki, T, 1999) |
| "Primary malignant lymphoma localized in the uterine cervix is a rare condition for which radiation therapy, surgery, or chemotherapy either alone or in combination have been the mainstay of treatment." | 1.29 | Primary malignant lymphoma of the uterine cervix shows favorable response to neoadjuvant chemotherapy. ( Chang, CH; Chou, CY; Huang, KE; Kuo, HC; Liu, MT; Tzeng, CC, 1994) |
| "Structural chromosomal abnormalities were present in 7." | 1.29 | Analysis of chromosomal abnormalities in human sperm after chemotherapy by karyotyping and fluorescence in situ hybridization (FISH). ( Leonard, NJ; Martin, RH; Rademaker, AW, 1995) |
| "We report here the case of a high grade malignant lymphoma which was characterized by an immunophenotype typical for CD3-negative NK-cells (CD2+, CD3-, CD16+, CD56(+), CD57-)." | 1.29 | High grade malignant lymphoma with clinical characteristics and immunophenotype of natural killer cells. ( Fehr, J; Rüegg, R; Schleiffenbaum, B; Zimmermann, D, 1995) |
| "Lymphomas were localized mainly in the jejunum and mesenteric nodes." | 1.29 | Primary small-intestinal lymphomas in Taiwan: immunoproliferative small-intestinal disease and nonimmunoproliferative small-intestinal disease. ( Dunn, P; Kuo, TT; Liaw, SJ; Shih, LY, 1994) |
| "Whenever thyroid lymphoma is suspected, we recommend an ultrasound scan of the thyroid gland and fine needle aspiration biopsy as initial diagnostic procedures." | 1.29 | Clinical aspects of primary thyroid lymphoma: diagnosis and treatment based on our experience of 119 cases. ( Ikeda, H; Katayama, S; Kuma, K; Matsuzuka, F; Miyauchi, A; Narabayashi, I; Sugawara, M, 1993) |
| " After our early experience with group 1, we attempted to use a lower cyclosporine dosage in group 2." | 1.29 | Heart transplantation for chronic Chagas' heart disease. ( Amato-Neto, V; Bacal, F; Bellotti, G; Bocchi, EA; Fiorelli, A; Higuchi, ML; Jatene, AD; Mocelin, AO; Pileggi, F; Stolf, NA; Uip, D, 1996) |
| "Its occurrence in malignant lymphoma has not been reported heretofore." | 1.28 | Pneumothorax following cytotoxic chemotherapy in malignant lymphoma. ( Chang, SC; Hsu, JR; Perng, RP, 1990) |
| "In a random HIV-seropositive population, malignant lymphomas were diagnosed in 31 patients, of whom 24 (77%) had non-Hodgkin lymphoma (NHL) and 7 (23%) Hodgkin lymphoma (HL)." | 1.28 | Malignant lymphomas in HIV-seropositive patients. Frequency, features, and prognosis. Report on 31 cases. ( Cervos-Navarro, J; Dienemann, D; Jautzke, G; Langford, A; Pohle, HD; Ruf, B; Schürmann, D; Stein, H, 1991) |
| "Pathologically the diagnosis was malignant lymphoma, diffuse, large cell type and clinical stage was stage IV." | 1.28 | [Priapism with malignant lymphoma: a case report]. ( Asakura, H; Masuda, T; Nakazono, M; Tazaki, H; Yamamoto, T, 1989) |
| "In 1984, the complete remission of malignant lymphoma was observed after MOPP, COPP and VAPP chemotherapies." | 1.28 | [Secondary leukemia (AML) with TcR beta rearrangement]. ( Akiyoshi, T; Hisano, S; Ishibashi, M; Kawara, T; Kikuchi, M; Kimura, N; Kyoshoin, K; Morioka, E; Okumura, M, 1989) |
| "Fifty-six patients with malignant lymphoma of aggressive histologic type (51 large cell, three diffuse undifferentiated, and two nodular mixed) were treated with three non-cross-resistant combination chemotherapy regimens that were introduced sequentially according to the response to therapy." | 1.27 | Sequential chemotherapy and late intensification for malignant lymphomas of aggressive histologic type. ( Bodey, GP; Burgess, MA; Cabanillas, F; Freireich, EJ, 1983) |
| "Of 10 patients with non-Hodgkin's lymphoma 2 achieved complete remission and 5 a partial response." | 1.27 | Treatment of refractory lymphoproliferative diseases with daily, low-dose vincristine, continuous infusion of bleomycin, and high-dose prednisone. ( Gomez, GA; Han, T; Henderson, ES; Ozer, H, 1984) |
| "In two patients Hodgkin's lymphoma was discovered and in a third histiocytic lymphoma." | 1.27 | Hodgkin's and non-Hodgkin's lymphomas masquerading as "idiopathic" liver granulomas. ( Aderka, D; Avidor, I; Kraus, M; Pinkhas, J; Sidi, Y; Weinberger, A, 1984) |
| "A patient with lymphomatoid granulomatosis and focal transformation to lymphoma limited to the central nervous system presented with severe central neurogenic hyperventilation." | 1.27 | Lymphomatoid granulomatosis presenting as central neurogenic hyperventilation. ( Passamonte, PM; Sunderrajan, EV, 1984) |
| "Thirty-four subsequent second malignant neoplasms were observed in 33 patients among those treated for Hodgkin's disease." | 1.27 | Second malignant neoplasms complicating Hodgkin's disease: the National Cancer Institute experience. ( DeVita, VT; Glatstein, E; Kelley, PA; Kinsella, TJ; Makuch, RW; Tester, WJ; Waller, B, 1984) |
| "The primary treatment in low-grade malignant lymphomas was a combination of chlorambucil and prednisone: in case of progression or therapeutic failure more aggressive schedules (COP, C-MOPP, HOP, CHOP, BACOP) were used." | 1.27 | [Results of cytostatic polychemotherapy in non-Hodgkin lymphomas]. ( Bliem, J; Denz, H; Hehenwarter, W; Huber, H; Kratzer, H; Michlmayr, G; Nitsche, D; Tschurtschenthaler, G, 1983) |
| "Interstitial pulmonary fibrosis is described in a 26-year-old woman with malignant lymphoma after prolonged intake of cyclophosphamide." | 1.27 | Pulmonary fibrosis after prolonged treatment with low-dose cyclophosphamide. A case report. ( Abdel Karim, FW; Allam, C; Ayash, RE; Salem, PA, 1983) |
| "A strategy for treatment of malignant lymphoma requires fundamentally a field of multidisciplinary treatment including mainly radiotherapy and chemotherapy in a collaboration with surgical procedure and immunotherapeutic maneuver." | 1.27 | [Malignant lymphoma]. ( Kita, K; Shirakawa, S; Tanaka, I, 1985) |
| "Ninety-seven patients with aggressive malignant lymphoma (ML) were treated with an intensive and sequential chemotherapy (protocol LNH-80)." | 1.27 | Intensive and sequential combination chemotherapy for aggressive malignant lymphomas (protocol LNH-80). ( Archimbaud, E; Berger, F; Bryon, PA; Coiffier, B; Extra, JM; Ffrench, M; Fiere, D; Gentilhomme, O; Guyotat, D; Magaud, JP, 1986) |
| "The prognosis of malignant lymphomas has been transformed since the introduction of this drug in the chemotherapeutic protocols: the level of complete remission increased from 25% with CVP protocols to 50% with CHOP-types protocols, and to more than 70% with intensive chemotherapy protocols (m-BACOD, LNH-80)." | 1.27 | [Contribution of anthracyclines in treatment of lymphoproliferative disorders]. ( Coiffier, B, 1987) |
| "This lymphoma was diagnosed as diffuse, medium cell and B cell type." | 1.27 | [A case of B cell malignant lymphoma with in the liver and brain metastasis in Hashimoto's disease]. ( Asano, G; Fukuda, Y; Kuki, K; Maeda, S; Masugi, Y; Oosono, E; Shimizu, K; Shoji, T; Yamada, N; Yoshikawa, A, 1987) |
| "Signet-ring cell lymphomas are rare especially as primary gastric tumours; alpha chain disease of the stomach is also unusual." | 1.27 | Gastric signet-ring cell lymphoma with alpha heavy chains. ( Tungekar, MF, 1986) |
| "It suggests that this rare and highly malignant lymphoma should be considered in the differential diagnosis of interstitial lung disease, and shows the value of open lung biopsy in unexplained interstitial lung disease." | 1.27 | Angiotropic large cell lymphoma presenting as interstitial lung disease. ( Blaisse, M; Gerritzen, FM; Spaander, PJ; Tan, TB, 1988) |
| "The neurofibroma was congenital and extensively involved the soft tissue and bone of the face and neck." | 1.27 | Malignant lymphoma arising in a large congenital neurofibroma of the head and neck. Report of a case. ( Foucar, E; Gooding, RA; Palmer, CH; Radi, MJ, 1988) |
| "At present, the recommendable treatment of T2 lymphoma is to apply the best regimens obtained from B cell lymphoma study." | 1.27 | [Pathological features and treatment of T lymphoma]. ( Ota, K; Oyama, A, 1986) |
| "T-cell lymphomas were found to have significantly poorer prognosis than B-cell lymphomas." | 1.27 | Difference in prognosis between T- and B-cell lymphomas: clinical study at Shikoku Cancer Center Hospital. ( Kimura, Y; Koike, S; Morita, M; Moriwaki, S; Ogushi, I; Okabe, K; Sato, G; Takashima, S; Toki, H; Yumoto, Y, 1986) |
| "However, a rare primary malignant lymphoma of the trachea developed and presented with steroid refractory, upper airways obstruction." | 1.27 | Sjögren's syndrome: severe upper airways obstruction due to primary malignant tracheal lymphoma developing during successful treatment of lymphocytic interstitial pneumonitis. ( Barland, P; Becker, N; Kamholz, S; Rakoff, S; Rosen, N; Sher, A, 1987) |
| "A patient seen at presentation for Hodgkin's disease (HD) at stage IV B was successfully treated with MOPP." | 1.27 | Gastric non-Hodgkin's lymphoma after successful treatment of Hodgkin's disease. ( Eridani, S; Singh, AK, 1986) |
| "Primary brain lymphomas are usually treated with surgery in combination with radiotherapy, whereas only a few cases have been treated with chemotherapy." | 1.27 | Primary brain malignant non-Hodgkin lymphoma: report of a case treated with chemotherapy in combination with radiotherapy. ( Büchi, G; Ferrari, G; Geda, C; Grosso, E; Termine, G, 1986) |
| "In addition, acute renal failure developed in both patients, and myolysis in one." | 1.27 | Purpura fulminans in pneumococcal sepsis. ( Berneman, ZN; Bieger, R; Bridts, C; Buyssens, N; Hautekeete, ML; Peetermans, ME; Stevens, WJ, 1986) |
| "Thirty-four patients with Hodgkin's disease and non-Hodgkin's lymphoma underwent therapeutic splenectomies to improve hematologic tolerance for chemotherapy." | 1.27 | The potential benefits of therapeutic splenectomy for patients with Hodgkin's disease and non-Hodgkin's lymphomas. ( Cox, RS; Hoppe, RT; Jacobs, C; Rosenberg, SA; Schreiber, DP, 1985) |
| "35 cases of non-Hodgkin malignant lymphomas of head and neck, stages I and II." | 1.27 | [Non-Hodgkin lymphomas of the head and neck, stages I and II. Apropos 35 cases]. ( Beral, HM; Bertrand, JC; Chantelar, JV; Ghenim, C; Guerin, RA; Guilbert, F; Nizri, D; Szpirglas, H; Touboul, E; Zribi, A, 1985) |
| "Diagnosis and therapy of malignant lymphoma of the skin were reviewed." | 1.27 | [Malignant lymphoma of the skin]. ( Miyamoto, H; Nakajima, H, 1985) |
| "Among low-grade malignant lymphomas (LGML) centroblastic-centrocytic follicular and diffuse or diffuse and "CLL" subtypes were mostly associated with blood involvement (31% and 55%, respectively)." | 1.27 | Non-Hodgkin's lymphomas in leukaemic phase: incidence, prognosis and therapeutic implications. ( Bandini, G; Cantore, M; Fiacchini, M; Gherlinzoni, F; Lauria, F; Mazza, P; Pileri, S; Poletti, G; Tura, S, 1985) |
| "A 62-year-old woman who developed systemic lupus erythematosus 6 years following chemotherapy for malignant lymphoma is reported." | 1.27 | Systemic lupus erythematosus six years following chemotherapy for malignant lymphoma. ( Berliner, S; Galili, N; Mor, C; Pinkhas, J; Sidi, Y; Weinberger, A, 1985) |
| "Because nonrandom acquired clonal chromosome abnormalities are a consistent feature of malignancies, our data suggest that AILD may be a malignant disease despite its original description as a benign proliferative process." | 1.26 | Nonrandom chromosome abnormalities in angioimmunoblastic lymphadenopathy. ( Haren, JM; Kaneko, Y; Larson, RA; Rowley, JD; Variakojis, D, 1982) |
| "The eight patients who reported pretreatment nausea had more extensive disease than the other patients and had received twice as much chemotherapy." | 1.26 | Pretreatment nausea in cancer chemotherapy: a conditioned response? ( Carli, T; Curtis, GC; Kleinman, PD; Nesse, RM, 1980) |
| " Since the absorption rate is not clinically relevant in patients on long-term glycoside therapy, our results indicate that digitoxin is preferable to digoxin in such patients." | 1.26 | Cytostatic drugs are without significant effect on digitoxin plasma level and renal excretion. ( Kuhlmann, J; Rietbrock, N; Wilke, J, 1982) |
| " The neurological toxicity was little and led to reduction of the dosage in only two adults with preexisting neuropathy." | 1.26 | A phase II study of vindesine in patients with hematological malignancies. ( Bosly, A; Cornu, G; Delannoy, A; Ferránt, A; Hulhoven, R; Michaux, JL; Sokal, G, 1980) |
| "In the group of high-grade malignant lymphomas there were 39% complete remission, 37% partial remission, and 24% without response." | 1.26 | [Results of chemotherapy with cyclophosphamide, vincristine, methotrexate and prednisone in recurring or disseminated non-Hodgkin lymphomas in the University of Kiel Radiology Clinic]. ( Liffers, R, 1981) |
| " All patients were given a 50 IU intravenous test dose followed in 30 min by the full dosage (10,000 IU/m2), if no reaction occurred to the test dose." | 1.26 | Anaphylactoid reactions to Escherichia coli and Erwinia asparaginase in children with leukemia and lymphoma. ( Barker, LF; Crom, WR; Dahl, GV; Denison, M; Evans, WE; Mauer, AM; Murphy, SB; Rivera, G; Tsiatis, A, 1982) |
| "The visceral carcinomas (2 breast cancers, 1 carcinoma respectively of the pancreas, the rectum, the liver, the kidneys, the renal pelvis, and the urinary bladder, and one seminoma) were treated by generally accepted surgical principles as far as treatment of the patients was possible." | 1.26 | [Malignant tumors in bearers of kidney grafts in immunosuppressive therapy]. ( Binswanger, U; Briner, J; Largiadèr, F; Uhlschmid, G; Vollenweider, A, 1982) |
| "Fifteen patients with lymphomatoid granulomatosis were studied prospectively over a 10-year period." | 1.26 | Lymphomatoid Granulomatosis. Prospective clinical and therapeutic experience over 10 years. ( Costa, J; Fauci, AS; Haynes, BF; Katz, P; Wolff, SM, 1982) |
| " Eighteen patients were in early stage (I or II) and 11 of them were also submitted to involved field radiotherapy (60Co), immediately before (stage I) or during (stage II) the chemotherapy, with a mean dosage of 4,500 rad." | 1.26 | Combination chemotherapy with cyclophosphamide, adriamycin, vincristine and prednisone (CHOP) for non-Hodgkin's lymphomas with unfavorable histology: preliminary results. ( Abate, G; Bruni, GS; Comella, G; Comella, P; Pergola, M; Zarrilli, D, 1980) |
| "Records of 133 infections occurring in 73 of 125 patients with late-stage non-Hodgkin's lymphoma on intensive chemotherapy programs for a median of 23 months were reviewed." | 1.26 | Infections during intensive chemotherapy for non-Hodgkin's lymphoma. ( Bishop, JF; Diggs, CH; Schimpff, SC; Wiernik, PH, 1981) |
| "The simultaneous cure of both the intestinal lymphangiectasia and lymphoma with combination chemotherapy suggests new relationships between these conditions as well as new possibilities for the treatment of acquired forms of intestinal lymphangiectasis associated with overwhelming gastrointestinal protein loss." | 1.26 | Resolution of longstanding protein-losing enteropathy in a patient with intestinal lymphangiectasia after treatment for malignant lymphoma. ( Bartter, FC; Broder, S; Callihan, TR; DeVita, VT; Jaffe, ES; Strober, W; Waldmann, TA, 1981) |
| "15 patients with malignant lymphomas (stage III B or IV) who had become resistant to previous combination chemotherapy were treated with DTIC." | 1.26 | Imidazole carboxamide (DTIC) in the treatment of advanced lymphomas. Efficacy of DTIC in cases which fail to respond to conventional chemotherupetic combinations. ( Donner, L; Klener, P, 1977) |
| "Low-grade malignant lymphomas are treated best with conventional doses of an alkylating agent." | 1.26 | [Chemotherapy in non-Hodgkin's lymphomas (author's transl)]. ( Schmidt, CG, 1977) |
| "The first patient had acute myelogenous leukemia and developed a recurrence with morphologic features of acute myelogenous leukemia." | 1.26 | Myelogenous leukemia evolving during the course of lymphoid malignancy in children. ( Corrigan, JJ; Hays, T; Hutter, JJ; Lanzkowsky, P; Rosen, RC; Shende, A, 1979) |
| "In both, Hodgkin's disease and non-Hodgkin's lymphomas, induction of remission, relaps-free survival and prognostic significance of initial clinical stage were evaluated, in relation to the therapeutic modality." | 1.26 | Chemotherapy of advanced malignant lymphomas comparative evaluation of results with single agent and combination therapy. ( Donner, L; Klener, P; Roth, Z, 1976) |
| "Early diagnosis of pancreatitis is frequently not possible, as symptoms are vague, physical findings may be minimal, and laboratory studies are frequently inconclusive until the injury is severe." | 1.26 | Early detection of chemotherapy-related pancreatic enlargement in children using abdominal sonography: a preliminary report. ( Culbert, SJ; Okamura, J; Samuels, BI; Sullivan, MP, 1976) |
| "Autopsy revealed a malignant lymphoma of mixed histiocytic-lymphocytic type involving mainly the mesenteric lymph nodes, but also affecting the jejunal mucosa, liver, spleen and extraabdominal lymph nodes." | 1.25 | Abdominal lymphoma with alpha-heavy chain disease. ( Golouh, R; Plesnicar, S; Sumi-Kriznik, T, 1975) |
| "45%, respectively, in Hodgkin's disease, and 85% vs." | 1.25 | Combined cyclophosphamide vincristine, procarbazine, and prednisone (COPP) therapy of malignant lymphoma. Evaluation of 190 patients. ( Barros, CA; Morgenfeld, MC; Palau, M; Pavlovsky, A; Pavlovsky, S; Somoza, N; Suarez, A, 1975) |
| "Patients with diffuse histiocytic lymphoma who achieved a complete remission after 6 months of treatment without maintenance have remained disease-free, whereas those with nodular poorly differentiated lymphocytic and diffuse well differentiated lymphocytic lymphomata demonstrate a pattern of continuous late recurrence." | 1.25 | Results of combination chemotherapy of non-Hodgkin's lymphoma. ( Berard, C; Canellos, GP; Chabner, BA; DeVita, VT; Schein, PS; Young, RD, 1975) |
| "The non-Hodgkin's lymphomas are a group of diseases and syndromes." | 1.25 | The treatment of non-Hodgkin's lymphoma. ( Chaffey, JT; Hellman, S; Moloney, WC; Rosenthal, DS, 1975) |
| "No evidence of malignant lymphoma was seen in any of these autopsies." | 1.25 | Angio-immunoblastic lymphadenopathy. Diagnosis and clinical course. ( Frizzera, G; Moran, EM; Rappaport, H, 1975) |
| "Nineteen cases of malignant lymphomata were selected for study from a group of about 1500 collected cases of malignant lymphomata because they showed histological evidence of non-infectious epithelioid-cell granulomata in one or more tissues." | 1.25 | Sarcoid reactions and sarcoidosis in Hodgkin's disease and other malignant lymphomata. ( Brincker, H, 1972) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 498 (59.43) | 18.7374 |
| 1990's | 90 (10.74) | 18.2507 |
| 2000's | 118 (14.08) | 29.6817 |
| 2010's | 106 (12.65) | 24.3611 |
| 2020's | 26 (3.10) | 2.80 |
| Authors | Studies |
|---|---|
| Runge, JS | 1 |
| Brown, AB | 1 |
| Phillips, TJ | 1 |
| Kaminski, MS | 1 |
| Carty, SA | 1 |
| Wilcox, RA | 1 |
| Schep, D | 1 |
| Van Koughnett, JA | 1 |
| Velker, V | 1 |
| Correa, RJM | 1 |
| Ferreri, AJM | 1 |
| Angelillo, P | 1 |
| Erbella, F | 1 |
| Cattaneo, C | 1 |
| Verga, L | 1 |
| Lleshi, A | 1 |
| Allione, B | 1 |
| Ponzoni, M | 1 |
| Facchetti, F | 1 |
| Pagani, C | 1 |
| Foppoli, M | 1 |
| Pecciarini, L | 1 |
| Sassone, M | 1 |
| Steffanoni, S | 1 |
| Flospergher, E | 1 |
| Rossi, G | 1 |
| Spina, M | 2 |
| Re, A | 1 |
| Rapiti, N | 1 |
| Abdelatif, N | 1 |
| Rapiti, A | 1 |
| Moosa, MY | 1 |
| Goto, S | 1 |
| Iwasaki, R | 1 |
| Sakai, H | 1 |
| Mori, T | 1 |
| Rodriguez-Piza, I | 1 |
| Borrego, JF | 1 |
| Treggiari, E | 1 |
| Verganti, S | 1 |
| Priestnall, SL | 1 |
| Lara-Garcia, A | 1 |
| Cooper, A | 1 |
| Kline, J | 1 |
| Zimmerman, K | 1 |
| Walsh, KA | 1 |
| Ferrari, JT | 1 |
| Keuler, NS | 1 |
| Atherton, MJ | 1 |
| Lenz, JA | 1 |
| Saeed, H | 1 |
| Sandoval-Sus, J | 1 |
| Castillo-Tokumori, F | 1 |
| Dong, N | 2 |
| Pullukkara, JJ | 1 |
| Boisclair, S | 1 |
| Brahim, A | 1 |
| Walker, D | 1 |
| Bridgellal, S | 1 |
| Zhang, L | 2 |
| Sokol, L | 1 |
| Hanot, CC | 1 |
| Mealey, KL | 1 |
| Fidel, JL | 1 |
| Burke, NS | 1 |
| White, LA | 1 |
| Sellon, RK | 1 |
| Al-Quteimat, OM | 1 |
| Jurczak, W | 2 |
| Długosz-Danecka, M | 1 |
| Szmit, S | 2 |
| Lee, WS | 1 |
| Lee, JJ | 4 |
| Liao, AT | 4 |
| Kao, CL | 1 |
| Wang, SL | 4 |
| Kawada, K | 1 |
| Ohta, T | 1 |
| Fukuda, H | 1 |
| Hayashi, T | 1 |
| Tanaka, K | 2 |
| Imai, T | 1 |
| Morita, Y | 1 |
| Miyamura, M | 1 |
| Matsuda, S | 1 |
| Suzuki, R | 1 |
| Takahashi, T | 2 |
| Suehiro, Y | 1 |
| Tomita, N | 2 |
| Izutsu, K | 1 |
| Fukuhara, N | 1 |
| Imaizumi, Y | 1 |
| Shimada, K | 1 |
| Nakazato, T | 1 |
| Yoshida, I | 1 |
| Miyazaki, K | 1 |
| Yamaguchi, M | 1 |
| Suzumiya, J | 1 |
| Garnica, TK | 1 |
| Lesbon, JCC | 1 |
| Ávila, ACFCM | 1 |
| Rochetti, AL | 1 |
| Matiz, ORS | 1 |
| Ribeiro, RCS | 1 |
| Zoppa, A | 1 |
| Nishiya, AT | 1 |
| Costa, MT | 1 |
| de Nardi, AB | 1 |
| Argyle, DJ | 1 |
| Strefezzi, RF | 1 |
| Silveira, JC | 1 |
| Fukumasu, H | 1 |
| Kurian, R | 1 |
| Hedrich, W | 1 |
| Mackowiak, B | 1 |
| Li, L | 1 |
| Wang, H | 2 |
| El Khoury, M | 1 |
| Maietta, A | 1 |
| Tran, A | 1 |
| Trop, I | 1 |
| Lalonde, L | 1 |
| Mesurolle, B | 1 |
| Williams, AG | 1 |
| Hohenhaus, AE | 1 |
| Lamb, KE | 1 |
| Cordoba, R | 1 |
| Luminari, S | 2 |
| Eyre, TA | 2 |
| Illuminati, G | 1 |
| Nardi, P | 1 |
| Fratini, C | 1 |
| Pasqua, R | 1 |
| Giordano, C | 1 |
| Girolami, M | 1 |
| Carboni, F | 1 |
| Tani, A | 1 |
| Saegusa, Y | 1 |
| Ogawa, K | 1 |
| Tomiyasu, H | 1 |
| Takeuchi, Y | 1 |
| Harada, K | 1 |
| Kobayashi, T | 1 |
| Setoguchi, A | 1 |
| Nakamichi, J | 1 |
| Mizuno, T | 1 |
| Irie, M | 1 |
| Tokita, M | 1 |
| Fujita, K | 2 |
| Suenaga, M | 1 |
| Motegi, T | 1 |
| Ohmi, A | 1 |
| Goto-Koshino, Y | 1 |
| Ohno, K | 1 |
| Tsujimoto, H | 1 |
| Hentrich, M | 1 |
| Troedson, K | 1 |
| Ignatenko, N | 1 |
| Fejos, C | 1 |
| Zablotski, Y | 1 |
| Hirschberger, J | 1 |
| Veluvolu, S | 1 |
| Pellin, M | 2 |
| Vos, N | 2 |
| Tokiya, R | 1 |
| Yoden, E | 1 |
| Konishi, K | 1 |
| Kamitani, N | 1 |
| Hiratsuka, J | 1 |
| Koresawa, R | 1 |
| Hirose, T | 1 |
| Sano, F | 1 |
| Tokunaga, H | 1 |
| Kondo, T | 1 |
| Wada, H | 1 |
| Sugihara, T | 1 |
| Baptista, MJ | 1 |
| Tapia, G | 1 |
| Hernández-Rivas, JÁ | 1 |
| Martínez-Trillos, A | 1 |
| Mate, JL | 1 |
| Navarro, JT | 1 |
| Liu, W | 1 |
| Li, J | 2 |
| Huang, WY | 1 |
| Liu, H | 1 |
| Li, ZJ | 1 |
| Lv, R | 1 |
| Deng, SH | 1 |
| Fu, MW | 1 |
| Sui, WW | 1 |
| Wang, TY | 1 |
| Qiu, LG | 1 |
| Zou, DH | 1 |
| Moore, EL | 1 |
| Vernau, W | 1 |
| Rebhun, RB | 1 |
| Skorupski, KA | 1 |
| Burton, JH | 2 |
| Kimura, Y | 4 |
| Takeuchi, M | 2 |
| Matsue, K | 1 |
| Huggins, AB | 1 |
| Kim, C | 1 |
| Rabinowitz, MP | 1 |
| Salvarani, C | 1 |
| Brown, RD | 1 |
| Christianson, TJH | 1 |
| Huston, J | 1 |
| Ansell, SM | 2 |
| Giannini, C | 1 |
| Hunder, GG | 1 |
| Takaishi, K | 1 |
| Muto, T | 1 |
| Mimura, N | 1 |
| Takiguchi, J | 1 |
| Nagao, Y | 1 |
| Oshima-Hasegawa, N | 1 |
| Tsukamoto, S | 1 |
| Takeda, Y | 1 |
| Mitsukawa, S | 1 |
| Ohwada, C | 1 |
| Ota, S | 1 |
| Iseki, T | 1 |
| Nakaseko, C | 1 |
| Sakaida, E | 1 |
| LaRue, MK | 1 |
| Taylor, AR | 1 |
| Back, AR | 2 |
| Lindley, SE | 1 |
| Boudreaux, BL | 1 |
| Almond, GT | 1 |
| Shores, A | 1 |
| Brawner, WR | 1 |
| Smith, AN | 2 |
| Saito, T | 1 |
| Okamura, A | 1 |
| Inoue, J | 1 |
| Makiura, D | 1 |
| Doi, H | 1 |
| Yakushijin, K | 1 |
| Matsuoka, H | 1 |
| Sakai, Y | 1 |
| Ono, R | 1 |
| Amaki, J | 1 |
| Sekiguchi, T | 1 |
| Hiraiwa, S | 1 |
| Kajiwara, H | 1 |
| Kawai, H | 1 |
| Ichiki, A | 1 |
| Nakamura, N | 2 |
| Ando, K | 1 |
| Drew, L | 1 |
| Angelo, G | 1 |
| Cronin, K | 1 |
| Keys, D | 1 |
| MaloneyHuss, MA | 1 |
| Mauldin, GE | 3 |
| Brown, DC | 1 |
| Veluvolu, SM | 1 |
| Krick, EL | 2 |
| Jordan, B | 1 |
| Zierz, S | 1 |
| Weber, T | 1 |
| Jordan, K | 1 |
| Bugeja, M | 1 |
| Micallef, S | 1 |
| Vail, DM | 1 |
| Roncon, L | 1 |
| Marco, Z | 1 |
| Aggio, S | 1 |
| Rigatelli, G | 1 |
| Rinuncini, M | 1 |
| Arifin, AJ | 1 |
| Lam, S | 1 |
| MacNeil, SD | 1 |
| Nakagawa, T | 1 |
| Nakano, T | 1 |
| Masuda, R | 1 |
| Iwazaki, M | 1 |
| Kuwahira, I | 1 |
| Nakano, K | 1 |
| Waite, AH | 2 |
| Jackson, K | 1 |
| Gregor, TP | 1 |
| Klingebiel, T | 1 |
| Schrappe, M | 1 |
| Binesh, F | 1 |
| Vahedian, H | 1 |
| Akhavan, A | 1 |
| Hakiminia, M | 1 |
| Schleis, SE | 1 |
| Smrkovski, OA | 1 |
| Lee, J | 1 |
| Phillips, JC | 1 |
| Sobociński, M | 1 |
| Machaczka, M | 1 |
| Drozd-Sokołowska, J | 1 |
| Joks, M | 1 |
| Dzietczenia, J | 1 |
| Wróbel, T | 1 |
| Kumiega, B | 1 |
| Zaucha, JM | 1 |
| Knopińska-Posłuszny, W | 1 |
| Spychałowicz, W | 1 |
| Prochwicz, A | 1 |
| Drohomirecka, A | 1 |
| Skotnicki, AB | 1 |
| Matikas, A | 1 |
| Briasoulis, A | 1 |
| Tzannou, I | 1 |
| Oikonomopoulou, D | 1 |
| Bakiri, M | 1 |
| Karmiris, T | 1 |
| Harhalakis, N | 1 |
| Lee, JA | 1 |
| Jeong, WK | 1 |
| Min, JH | 1 |
| Kim, J | 1 |
| Sonbol, MB | 1 |
| Rana, V | 1 |
| Kenderian, SS | 1 |
| Finnes, H | 1 |
| Witzig, TE | 1 |
| Zhao, Q | 1 |
| Liu, HP | 1 |
| Gu, YJ | 1 |
| Cong, WM | 1 |
| Lee, SY | 1 |
| Kurita, N | 1 |
| Yokoyama, Y | 1 |
| Seki, M | 1 |
| Hasegawa, Y | 1 |
| Okoshi, Y | 1 |
| Chiba, S | 1 |
| Fabrizio, F | 1 |
| Calam, AE | 1 |
| Dobson, JM | 1 |
| Middleton, SA | 1 |
| Murphy, S | 1 |
| Taylor, SS | 1 |
| Schwartz, A | 1 |
| Stell, AJ | 1 |
| Groebner, M | 1 |
| Südhoff, T | 1 |
| Doering, M | 1 |
| Kirmayer, M | 1 |
| Nitsch, T | 1 |
| Prügl, L | 1 |
| Römer, W | 1 |
| Wolf, H | 1 |
| Tacke, J | 1 |
| Massoudy, P | 1 |
| Nüsse, T | 1 |
| Elsner, D | 1 |
| Mihaljevic, B | 1 |
| Vukovic, V | 1 |
| Smiljanic, M | 1 |
| Milic, N | 1 |
| Todorovic, M | 1 |
| Bila, J | 1 |
| Andjelic, B | 1 |
| Djurasinovic, V | 1 |
| Jelicic, J | 1 |
| Antic, D | 1 |
| Fan, H | 1 |
| Lu, X | 1 |
| Wang, X | 3 |
| Liu, Y | 3 |
| Guo, B | 1 |
| Zhang, Y | 3 |
| Zhang, W | 1 |
| Nie, J | 1 |
| Feng, K | 1 |
| Chen, M | 1 |
| Wang, Y | 2 |
| Shi, F | 1 |
| Fu, X | 1 |
| Zhu, H | 1 |
| Han, W | 1 |
| Tsuji, K | 1 |
| Kishi, S | 1 |
| Tsuchida, T | 1 |
| Yamauchi, T | 1 |
| Ikegaya, S | 1 |
| Urasaki, Y | 1 |
| Fujiwara, Y | 1 |
| Ueda, T | 1 |
| Okazawa, H | 1 |
| Kimura, H | 1 |
| Kauffmann, RM | 1 |
| Grayson, BL | 1 |
| Mosse, CA | 1 |
| Geiger, TM | 1 |
| Statoua, M | 1 |
| Mokrim, M | 1 |
| El Ghanmi, J | 1 |
| Karmouni, T | 1 |
| El Khadir, K | 1 |
| Koutani, A | 1 |
| Attya, AI | 1 |
| Errihani, H | 1 |
| Elias, MA | 1 |
| Duarte, A | 1 |
| Nunes, T | 1 |
| Lourenço, AM | 1 |
| Braz, BS | 1 |
| Vicente, G | 1 |
| Henriques, J | 1 |
| Tavares, L | 1 |
| Thomas, JD | 1 |
| Duggal, S | 1 |
| Bosler, D | 1 |
| Johnston, D | 1 |
| Kisiel, B | 1 |
| Gawroński, K | 1 |
| Rzepecki, P | 1 |
| Tłustochowicz, W | 1 |
| Zietman, AL | 1 |
| Meissner, J | 1 |
| Tichy, D | 1 |
| Katzke, V | 1 |
| Kühn, T | 1 |
| Dietrich, S | 1 |
| Schmitt, T | 1 |
| Ziepert, M | 1 |
| Kuhnt, E | 1 |
| Rixecker, T | 1 |
| Zorn, M | 1 |
| Witzens-Harig, M | 1 |
| Pfreundschuh, M | 4 |
| Ho, AD | 1 |
| Jagirdar, N | 1 |
| Harvey, RD | 1 |
| Nooka, A | 1 |
| Flowers, C | 1 |
| Kaufman, J | 1 |
| Lonial, S | 1 |
| Lechowicz, MJ | 1 |
| Langston, A | 1 |
| Lipscomb, C | 1 |
| Gaylor, C | 1 |
| Waller, EK | 1 |
| Dong, F | 1 |
| Pang, Y | 1 |
| Wang, J | 3 |
| Ke, X | 1 |
| Gouldin, ED | 1 |
| Mullin, C | 1 |
| Morges, M | 1 |
| Mehler, SJ | 1 |
| de Lorimier, LP | 1 |
| Oakley, C | 1 |
| Risbon, R | 1 |
| May, L | 1 |
| Kahn, SA | 1 |
| Clifford, C | 1 |
| Wang, D | 1 |
| Zhang, Q | 1 |
| Duan, L | 1 |
| Tian, T | 1 |
| Zhang, X | 1 |
| Qiu, H | 1 |
| Hedrich, WD | 1 |
| Xiao, J | 1 |
| Heyward, S | 1 |
| Zhang, J | 1 |
| Baer, MR | 2 |
| Hassan, HE | 1 |
| Blake, MK | 1 |
| Carr, BJ | 1 |
| Avagyan, A | 1 |
| Danielyan, S | 1 |
| Voskanyan, A | 1 |
| Sargsyan, L | 1 |
| Hakobyan, L | 1 |
| Zohrabyan, D | 1 |
| Safaryan, L | 1 |
| Harutyunyan, L | 1 |
| Bardakchyan, S | 1 |
| Iskanyan, S | 1 |
| Arakelyan, S | 1 |
| Tamamyan, G | 1 |
| Pang, H | 1 |
| Jing, XG | 1 |
| Duan, D | 1 |
| Xu, L | 1 |
| Puvvada, SD | 1 |
| Stiff, PJ | 1 |
| Leblanc, M | 1 |
| Cook, JR | 1 |
| Couban, S | 1 |
| Leonard, JP | 3 |
| Kahl, B | 1 |
| Marcellus, D | 1 |
| Shea, TC | 1 |
| Winter, JN | 1 |
| Li, H | 1 |
| Rimsza, LM | 1 |
| Friedberg, JW | 2 |
| Smith, SM | 1 |
| Turno-Kręcicka, A | 1 |
| Tomczyk-Socha, M | 1 |
| Zimny, A | 1 |
| Smith, TJ | 1 |
| Hillner, BE | 1 |
| Clifford, R | 1 |
| Bloor, A | 1 |
| Boyle, L | 1 |
| Roberts, C | 1 |
| Cabes, M | 1 |
| Collins, GP | 1 |
| Devereux, S | 1 |
| Follows, G | 1 |
| Fox, CP | 1 |
| Gribben, J | 1 |
| Hillmen, P | 1 |
| Hatton, CS | 1 |
| Littlewood, TJ | 1 |
| McCarthy, H | 1 |
| Murray, J | 1 |
| Pettitt, AR | 1 |
| Soilleux, E | 1 |
| Stamatopoulos, B | 1 |
| Love, SB | 1 |
| Wotherspoon, A | 1 |
| Schuh, A | 1 |
| Chihara, D | 2 |
| Westin, JR | 2 |
| Miranda, RN | 1 |
| Cheah, CY | 1 |
| Oki, Y | 3 |
| Turturro, F | 1 |
| Romaguera, JE | 2 |
| Neelapu, SS | 1 |
| Nastoupil, LJ | 1 |
| Fayad, LE | 2 |
| Rodriguez, MA | 3 |
| Fowler, NH | 2 |
| Orlowski, RZ | 1 |
| Wang, M | 1 |
| Hagemeister, FB | 5 |
| Medeiros, LJ | 2 |
| Fanale, MA | 2 |
| Abali, H | 1 |
| Kiykim, AA | 1 |
| Engin, H | 1 |
| Güler, N | 1 |
| Tanyildiz, HG | 1 |
| Dincaslan, H | 1 |
| Yavuz, G | 1 |
| Unal, E | 1 |
| Ikinciogulları, A | 1 |
| Dogu, F | 1 |
| Tacyildiz, N | 1 |
| Cabanillas, F | 12 |
| Rivera, N | 1 |
| Pardo, WI | 1 |
| Song, HN | 1 |
| Kim, SJ | 1 |
| Ko, YH | 1 |
| Kim, WS | 1 |
| Hirano, S | 1 |
| Fujita, T | 1 |
| Ooyama, T | 1 |
| Nagi, S | 1 |
| Kaneko, S | 1 |
| Koguchi, D | 1 |
| Tabata, K | 1 |
| Matsumoto, K | 3 |
| Iwamura, M | 1 |
| Jin, W | 1 |
| Fang, B | 1 |
| Jiang, J | 1 |
| Liu, M | 1 |
| Lan, Y | 1 |
| Qu, Z | 1 |
| Ma, G | 1 |
| Jiang, Y | 1 |
| Zeng, Y | 1 |
| Childress, MO | 2 |
| Ramos-Vara, JA | 1 |
| Ruple, A | 1 |
| Hohloch, K | 1 |
| Lautscham, EM | 1 |
| Kessler, M | 1 |
| Ernst, T | 1 |
| Willimzig, L | 1 |
| Neiger, R | 1 |
| Accordino, MK | 1 |
| Wright, JD | 1 |
| Vasan, S | 1 |
| Neugut, AI | 1 |
| Hillyer, GC | 1 |
| Hershman, DL | 1 |
| Ahmad, I | 1 |
| Chufal, KS | 1 |
| Goyal, N | 1 |
| Bhatt, CP | 1 |
| James, TC | 1 |
| Shaikh, H | 2 |
| Escuadro, L | 1 |
| Villano, JL | 1 |
| Avilés, A | 3 |
| Ingegnoli, F | 1 |
| Sciascera, A | 1 |
| Galbiati, V | 1 |
| Corbelli, V | 1 |
| D'Ingianna, E | 1 |
| Fantini, F | 1 |
| Bannink, EO | 2 |
| Sauerbrey, ML | 2 |
| Mullins, MN | 2 |
| Hauptman, JG | 1 |
| Obradovich, JE | 2 |
| Thoennissen, NH | 1 |
| Keyvani, K | 1 |
| Voelker, HU | 1 |
| Bremer, J | 1 |
| Krug, U | 1 |
| Müller-Tidow, C | 1 |
| Koch, P | 2 |
| Müller-Hermelink, HK | 1 |
| Berdel, WE | 4 |
| Nasiri, S | 1 |
| Mahmoodzadeh, H | 1 |
| Sharifi, M | 1 |
| Kneba, M | 2 |
| Schrader, C | 1 |
| Köhne, H | 1 |
| Northrup, NC | 2 |
| Gieger, TL | 1 |
| Kosarek, CE | 1 |
| Saba, CF | 1 |
| LeRoy, BE | 1 |
| Wall, TM | 1 |
| Hume, KR | 1 |
| Keys, DA | 1 |
| Gupta, S | 1 |
| Syed, F | 1 |
| Murthy, RK | 1 |
| Brar, VS | 1 |
| Chalam, KV | 1 |
| Hochster, H | 1 |
| Weller, E | 1 |
| Gascoyne, RD | 2 |
| Habermann, TM | 1 |
| Gordon, LI | 1 |
| Ryan, T | 1 |
| Colocci, N | 1 |
| Frankel, S | 1 |
| Horning, SJ | 1 |
| Takemura, A | 1 |
| Mizukami, Y | 1 |
| Takayama, T | 1 |
| Taniya, T | 1 |
| Okumura, H | 1 |
| López, V | 1 |
| Martí, N | 1 |
| Ferrández, A | 1 |
| Martin, JM | 1 |
| Jordá, E | 1 |
| Oriuchi, N | 1 |
| Higuchi, T | 1 |
| Endo, K | 1 |
| Tsukamoto, N | 1 |
| Matsuda, H | 1 |
| Kuji, I | 1 |
| Murakami, K | 1 |
| Nakajima, K | 1 |
| Uchiyama, M | 1 |
| Tamai, Y | 1 |
| Ikeda, T | 1 |
| Chun, R | 1 |
| Kummar, S | 1 |
| Gutierrez, ME | 1 |
| Gardner, ER | 1 |
| Figg, WD | 1 |
| Melillo, G | 1 |
| Dancey, J | 1 |
| Sausville, EA | 1 |
| Conley, BA | 1 |
| Murgo, AJ | 1 |
| Doroshow, JH | 1 |
| Mannina, D | 1 |
| Dondi, A | 1 |
| Polimeno, G | 1 |
| Baldini, L | 1 |
| Stelitano, C | 1 |
| Merli, F | 1 |
| Dell'Olio, M | 1 |
| Gobbi, PG | 1 |
| Giglio, G | 1 |
| Barbolini, E | 1 |
| Brugiatelli, M | 1 |
| Federico, M | 1 |
| Zhu, J | 1 |
| Song, YQ | 1 |
| Ried, M | 1 |
| Rupprecht, L | 1 |
| Hirt, S | 1 |
| Zausig, Y | 1 |
| Grube, M | 1 |
| Resch, M | 1 |
| Hilker, M | 1 |
| Hofstädter, F | 1 |
| Schmid, C | 1 |
| Daters, AT | 1 |
| Mauldin, GN | 1 |
| Brodsky, EM | 1 |
| Post, GS | 1 |
| Kagoya, Y | 1 |
| Yoshimoto, T | 1 |
| Ichikawa, M | 1 |
| Hangaishi, A | 1 |
| Fukayama, M | 1 |
| Kurokawa, M | 1 |
| Morishige, M | 1 |
| Abe, T | 1 |
| Kamida, T | 1 |
| Hikawa, T | 1 |
| Fujiki, M | 1 |
| Kobayashi, H | 2 |
| Okazaki, T | 1 |
| Kimura, N | 2 |
| Kumamoto, T | 1 |
| Yamada, A | 1 |
| Kawano, Y | 1 |
| Soldevilla, HF | 1 |
| Molina, RM | 1 |
| Navarra, SV | 1 |
| Houchaymi, Z | 1 |
| Helou, S | 1 |
| Ballout, J | 1 |
| Chen, X | 1 |
| Sun, Z | 1 |
| Xia, J | 1 |
| Lori, JC | 1 |
| Stein, TJ | 1 |
| Thamm, DH | 2 |
| Sorenmo, K | 1 |
| Overley, B | 1 |
| Krick, E | 1 |
| Ferrara, T | 1 |
| LaBlanc, A | 1 |
| Shofer, F | 1 |
| Rassnick, KM | 3 |
| Bailey, DB | 1 |
| Malone, EK | 1 |
| Intile, JL | 1 |
| Kiselow, MA | 1 |
| Flory, AB | 2 |
| Barlow, LL | 1 |
| Balkman, CE | 1 |
| Barnard, SM | 1 |
| Greystoke, A | 1 |
| O'Connor, JP | 1 |
| Linton, K | 1 |
| Taylor, MB | 1 |
| Cummings, J | 1 |
| Ward, T | 1 |
| Maders, F | 1 |
| Hughes, A | 1 |
| Ranson, M | 1 |
| Illidge, TM | 1 |
| Radford, J | 1 |
| Dive, C | 1 |
| Zwick, C | 2 |
| Hartmann, F | 1 |
| Zeynalova, S | 1 |
| Pöschel, V | 1 |
| Nickenig, C | 1 |
| Reiser, M | 2 |
| Lengfelder, E | 1 |
| Peter, N | 1 |
| Schlimok, G | 1 |
| Schubert, J | 1 |
| Schmitz, N | 2 |
| Loeffler, M | 2 |
| Erb, HN | 1 |
| Garrett, LD | 1 |
| Selting, KA | 1 |
| Phillips, BS | 1 |
| Locke, JE | 1 |
| Chretin, JD | 1 |
| Bilgir, O | 1 |
| Bilgir, F | 1 |
| Calan, M | 1 |
| Yuksel, A | 1 |
| Sari, F | 1 |
| Oztekin, O | 1 |
| Yang, H | 1 |
| Lang, RG | 1 |
| Liu, FF | 1 |
| Wang, XF | 1 |
| Jin, ZJ | 1 |
| Lü, AJ | 1 |
| Fu, XL | 1 |
| Fu, L | 1 |
| Ferreri, AJ | 1 |
| Sánchez-Nieto, B | 1 |
| Goset, KC | 1 |
| Caviedes, I | 1 |
| Delgado, IO | 1 |
| Córdova, A | 1 |
| Fahey, CE | 1 |
| Milner, RJ | 1 |
| Barabas, K | 1 |
| Lurie, D | 1 |
| Kow, K | 1 |
| Parfitt, S | 1 |
| Lyles, S | 1 |
| Clemente, M | 1 |
| Rezania, K | 1 |
| Soliven, B | 1 |
| Baron, J | 1 |
| Lin, H | 1 |
| Penumalli, V | 1 |
| van Besien, K | 1 |
| Arabi, M | 1 |
| Dvorak, R | 1 |
| Smith, LB | 1 |
| Kujawski, L | 1 |
| Gross, MD | 1 |
| Cai, L | 1 |
| Stauder, MC | 1 |
| Zhang, YJ | 1 |
| Poortmans, P | 1 |
| Li, YX | 1 |
| Constantinou, N | 1 |
| Thariat, J | 1 |
| Kadish, SP | 1 |
| Nguyen, TD | 1 |
| Kirova, YM | 1 |
| Ghadjar, P | 1 |
| Weber, DC | 1 |
| Bertran, VT | 1 |
| Ozsahin, M | 1 |
| Mirimanoff, RO | 1 |
| Tsukasaki, K | 1 |
| Tobinai, K | 4 |
| Hotta, T | 1 |
| Shimoyama, M | 3 |
| Oh, J | 1 |
| Yoon, H | 1 |
| Shin, DK | 1 |
| Jang, MJ | 1 |
| Kim, GI | 1 |
| Chong, SY | 1 |
| Oh, D | 1 |
| Salit, RB | 1 |
| Fowler, DH | 1 |
| Wilson, WH | 6 |
| Dean, RM | 1 |
| Pavletic, SZ | 1 |
| Dunleavy, K | 1 |
| Hakim, F | 1 |
| Fry, TJ | 1 |
| Steinberg, SM | 3 |
| Hughes, TE | 1 |
| Odom, J | 1 |
| Bryant, K | 1 |
| Gress, RE | 1 |
| Bishop, MR | 1 |
| Osborne, CK | 1 |
| Evens, A | 1 |
| Soubeyran, P | 1 |
| Henriques de Figueiredo, B | 1 |
| Soubeyran, I | 1 |
| Mertens, C | 1 |
| Cazeau, AL | 1 |
| Roschewski, M | 1 |
| Degnan, AJ | 1 |
| Levy, LM | 2 |
| Coleman, M | 5 |
| Ruan, G | 1 |
| Elstrom, RL | 1 |
| Martin, P | 2 |
| Garrett-Mayer, E | 1 |
| Armitage, JO | 3 |
| Alves, M | 1 |
| Canoui, E | 1 |
| Deforges, L | 1 |
| Garderet, L | 1 |
| Guidet, B | 1 |
| Offenstadt, G | 1 |
| Maury, E | 1 |
| Gandhi, N | 1 |
| Soomro, IN | 1 |
| O'Connor, S | 1 |
| Sovani, V | 1 |
| Kobayashi, S | 1 |
| Sakurai, K | 1 |
| Tanikawa, M | 1 |
| Nishikawa, Y | 1 |
| Matsukawa, N | 1 |
| Okita, K | 1 |
| Fujiyoshi, Y | 1 |
| Shibamoto, Y | 2 |
| Ibnou Soufyane, N | 1 |
| Chadli, A | 1 |
| El Ghomari, H | 1 |
| Essodegui, F | 1 |
| Marouan, F | 1 |
| El Farouqi, A | 1 |
| Ababou, MR | 1 |
| Kafih, M | 1 |
| Skrabs, C | 1 |
| Müller, C | 1 |
| Agis, H | 1 |
| Mannhalter, C | 1 |
| Jäger, U | 1 |
| Metayer, C | 1 |
| Curtis, RE | 1 |
| Vose, J | 1 |
| Sobocinski, KA | 1 |
| Horowitz, MM | 1 |
| Bhatia, S | 1 |
| Fay, JW | 1 |
| Freytes, CO | 1 |
| Goldstein, SC | 1 |
| Herzig, RH | 1 |
| Keating, A | 1 |
| Miller, CB | 1 |
| Nevill, TJ | 1 |
| Pecora, AL | 1 |
| Rizzo, JD | 1 |
| Williams, SF | 1 |
| Li, CY | 1 |
| Travis, LB | 1 |
| Weisdorf, DJ | 1 |
| Gibson, AD | 1 |
| D'Orazio, A | 1 |
| Staudt, LM | 1 |
| Stein, ME | 1 |
| Epelbaum, R | 1 |
| Zaidan, J | 1 |
| Kuten, A | 1 |
| Ben-Schachar, M | 1 |
| Haim, N | 1 |
| Osby, E | 1 |
| Hagberg, H | 3 |
| Kvaløy, S | 1 |
| Teerenhovi, L | 2 |
| Anderson, H | 1 |
| Cavallin-Stahl, E | 2 |
| Holte, H | 1 |
| Myhre, J | 1 |
| Pertovaara, H | 1 |
| Björkholm, M | 3 |
| Szyper-Kravitz, M | 1 |
| Uziel, O | 1 |
| Shapiro, H | 1 |
| Radnay, J | 1 |
| Katz, T | 1 |
| Rowe, JM | 2 |
| Lishner, M | 1 |
| Lahav, M | 1 |
| Seifert, B | 1 |
| Favre, G | 1 |
| Nomiyama, K | 1 |
| Shibuya, T | 1 |
| Kataoka, C | 1 |
| Aoki, Y | 1 |
| D'Costa, S | 1 |
| Slobod, KS | 1 |
| Hurwitz, JL | 1 |
| Gillett, M | 1 |
| Haak, S | 1 |
| Davis, TS | 1 |
| Coiffier, B | 13 |
| Hadjileontis, CG | 1 |
| Kostopoulos, IS | 1 |
| Kaloutsi, VD | 1 |
| Nikolaou, AC | 1 |
| Kotoula, VA | 1 |
| Papadimitriou, CS | 1 |
| Hayashi, K | 2 |
| Joko, H | 1 |
| Koirala, TR | 1 |
| Onoda, S | 1 |
| Jin, ZS | 1 |
| Munemasa, M | 1 |
| Ohara, N | 1 |
| Oda, W | 1 |
| Tanaka, T | 1 |
| Oka, T | 1 |
| Kondo, E | 1 |
| Yoshino, T | 1 |
| Takahashi, K | 1 |
| Yamada, M | 1 |
| Akagi, T | 1 |
| NABARRO, JD | 1 |
| STEWART, JS | 1 |
| WALKER, G | 1 |
| HILL, JM | 1 |
| MARSHALL, GJ | 1 |
| FALCO, DJ | 1 |
| RANNEY, HM | 2 |
| GELLHORN, A | 2 |
| DUBOIS-FERRIERE, H | 2 |
| KYLE, RA | 1 |
| McPARLAND, CE | 1 |
| DAMESHEK, W | 1 |
| GUPTA, NN | 1 |
| MITTAL, SP | 1 |
| HARTAI, F | 1 |
| OSSIPOVSKI, B | 1 |
| BURNINGHAM, RA | 1 |
| RESTREPO, A | 1 |
| PUGH, RP | 1 |
| BROWN, EB | 1 |
| SCHLOSSMAN, SF | 1 |
| KHURI, PD | 1 |
| LESSNER, HE | 1 |
| HARRINGTON, WJ | 1 |
| IRVINE, RA | 1 |
| ROBERTSON, WB | 1 |
| BOOTSMA, BK | 1 |
| KARNOFSKY, DA | 1 |
| DEBLASIIS, M | 1 |
| DIETZSCH, HJ | 1 |
| LIBERTI, R | 1 |
| DACIE, JV | 1 |
| WATKIN, DM | 1 |
| STEINFELD, JL | 1 |
| EVANS, FJ | 1 |
| HILTON, JH | 1 |
| SBARRA, AJ | 1 |
| SHIRLEY, W | 1 |
| SELVARAJ, RJ | 1 |
| IOUCHI, E | 1 |
| ROSENBAUM, E | 1 |
| D ANGIO, GJ | 1 |
| MIUS, A | 1 |
| EVANS, AE | 1 |
| ROSEMAN, DL | 1 |
| ECONOMOU, SG | 1 |
| LUPOVITCH, A | 1 |
| KATASE, RY | 1 |
| RANDALL, HP | 1 |
| BELLAMY, MD | 1 |
| Flox Camacho, A | 1 |
| Hernández Hernández, F | 1 |
| Salguero Bodes, R | 1 |
| Sánchez Pérez, I | 1 |
| Carbonell Porras, A | 1 |
| Tascón Pérez, J | 1 |
| Cave, T | 1 |
| Billson, M | 1 |
| Todeschini, G | 1 |
| Gelio, S | 1 |
| Tecchio, C | 1 |
| Sobotkowski, J | 1 |
| Błasińska-Morawiec, M | 1 |
| Dowgier-Witczak, I | 1 |
| Lister, TA | 1 |
| Milpied, N | 1 |
| Deconinck, E | 1 |
| Gaillard, F | 1 |
| Delwail, V | 1 |
| Foussard, C | 1 |
| Berthou, C | 1 |
| Gressin, R | 1 |
| Lucas, V | 1 |
| Colombat, P | 1 |
| Harousseau, JL | 1 |
| Coupland, SE | 1 |
| Leaw, SJ | 1 |
| Yen, CJ | 1 |
| Huang, WT | 1 |
| Chen, TY | 1 |
| Su, WC | 1 |
| Tsao, CJ | 1 |
| Arcaini, L | 2 |
| Orlandi, E | 2 |
| Scotti, M | 1 |
| Brusamolino, E | 2 |
| Passamonti, F | 1 |
| Burcheri, S | 1 |
| Colombo, N | 1 |
| Vanelli, L | 1 |
| Sbalzarini, G | 1 |
| Lazzarino, M | 2 |
| Jung, CS | 1 |
| Zimmermann, M | 1 |
| Seifert, V | 1 |
| Zomas, A | 1 |
| Skandalis, A | 1 |
| Herishanu, Y | 1 |
| Bolaños-Meade, J | 1 |
| Bernardi, D | 1 |
| Giacalone, A | 1 |
| Tirelli, U | 1 |
| Hazar, B | 1 |
| Ergin, M | 1 |
| Seyrek, E | 1 |
| Erdoğan, S | 1 |
| Tuncer, I | 1 |
| Hakverdi, S | 1 |
| Marbello, L | 1 |
| Anghilieri, M | 1 |
| Nosari, A | 1 |
| Minola, E | 1 |
| Cairoli, R | 2 |
| Ricci, F | 1 |
| Morra, E | 2 |
| Norin, S | 1 |
| Kimby, E | 1 |
| Ericzon, BG | 1 |
| Christensson, B | 1 |
| Sander, B | 1 |
| Söderdahl, G | 1 |
| Hägglund, H | 1 |
| Buske, C | 1 |
| Dreyling, M | 1 |
| Unterhalt, M | 1 |
| Hiddemann, W | 1 |
| Fridrik, MA | 1 |
| Hausmaninger, H | 1 |
| Linkesch, W | 1 |
| Greil, R | 1 |
| Krieger, O | 1 |
| Baldinger, C | 1 |
| Klocker, J | 1 |
| Pont, J | 2 |
| Oberaigner, W | 1 |
| Ozdemir, F | 1 |
| Aydin, F | 1 |
| Yilmaz, M | 1 |
| Kavgaci, H | 1 |
| Bektas, O | 1 |
| Yavuz, MN | 1 |
| Yavuz, AA | 1 |
| Park, YH | 1 |
| Choi, SJ | 1 |
| Ryoo, BY | 1 |
| Kim, HT | 1 |
| Shenkier, TN | 1 |
| Voss, N | 2 |
| Chhanabhai, M | 1 |
| Fairey, R | 1 |
| Hoskins, P | 2 |
| Klasa, R | 2 |
| Morris, J | 1 |
| O'Reilly, SE | 2 |
| Pickles, T | 1 |
| Sehn, L | 1 |
| Connors, JM | 4 |
| Yamanaka, R | 3 |
| Morii, K | 3 |
| Shinbo, Y | 3 |
| Takeuchi, S | 1 |
| Tamura, T | 3 |
| Hondoh, H | 3 |
| Takahashi, H | 4 |
| Onda, K | 2 |
| Tanaka, R | 3 |
| Olivieri, A | 1 |
| Lucesole, M | 1 |
| Capelli, D | 1 |
| Gini, G | 1 |
| Montanari, M | 1 |
| Candela, M | 1 |
| Troiani, E | 1 |
| Scortechini, I | 1 |
| Poloni, A | 1 |
| Leoni, P | 1 |
| Dobrilovic, N | 1 |
| Wright, CB | 1 |
| Vester, SR | 1 |
| Patel, MA | 1 |
| Fannin, EA | 1 |
| Probst, A | 1 |
| Willich, NA | 1 |
| Reinartz, G | 1 |
| Brockmann, J | 1 |
| Liersch, R | 1 |
| del Valle, F | 1 |
| Clasen, H | 1 |
| Hirt, C | 1 |
| Breitsprecher, R | 1 |
| Schmits, R | 1 |
| Freund, M | 1 |
| Fietkau, R | 1 |
| Ketterer, P | 1 |
| Freitag, EM | 1 |
| Hinkelbein, M | 1 |
| Heinecke, A | 1 |
| Parwaresch, R | 1 |
| Tiemann, M | 1 |
| Chan, JK | 2 |
| Loizzi, V | 1 |
| Magistris, A | 1 |
| Hunter, MI | 1 |
| Rutgers, J | 1 |
| DiSaia, PJ | 1 |
| Berman, ML | 1 |
| Delgado, S | 2 |
| Nambo, MJ | 2 |
| Neri, N | 1 |
| Murillo, E | 1 |
| Cleto, S | 1 |
| Gill, SI | 1 |
| Gibbs, SD | 1 |
| Hicks, RJ | 1 |
| Seymour, JF | 1 |
| Kloess, M | 1 |
| Metzner, B | 1 |
| Dorken, B | 1 |
| Trumper, L | 1 |
| Glass, B | 1 |
| Kanbayashi, Y | 1 |
| Mukoyama, N | 1 |
| Nishida, K | 1 |
| Shimizu, D | 1 |
| Matsumoto, Y | 1 |
| Nomura, K | 1 |
| Horiike, S | 1 |
| Taniwaki, M | 1 |
| Kawai, N | 1 |
| Nishiyama, Y | 1 |
| Miyake, K | 1 |
| Tamiya, T | 3 |
| Nagao, S | 2 |
| Choo, SP | 1 |
| Lim, ST | 1 |
| Wong, EH | 1 |
| Tao, M | 1 |
| Chang, MC | 1 |
| Huang, MJ | 1 |
| Su, YW | 1 |
| Chang, YF | 1 |
| Lin, J | 1 |
| Hsieh, RK | 1 |
| Word, R | 1 |
| Urquhart, AC | 1 |
| Ejercito, VS | 1 |
| Burton, A | 1 |
| Kim, JH | 1 |
| Jang, JH | 1 |
| Koh, SB | 1 |
| Daniels, CE | 1 |
| Myers, JL | 1 |
| Utz, JP | 1 |
| Markovic, SN | 1 |
| Ryu, JH | 1 |
| Rabinowitz, AP | 1 |
| Weiner, NJ | 1 |
| Tronic, BS | 1 |
| Fridman, M | 1 |
| Liberman, RF | 1 |
| Delgado, DJ | 1 |
| Fischbach, W | 1 |
| Celsing, F | 1 |
| Johansson, E | 1 |
| Green, LD | 1 |
| Mack, L | 1 |
| Pasieka, JL | 1 |
| Ng, AK | 1 |
| Mauch, PM | 1 |
| Bonnet, C | 1 |
| Fillet, G | 2 |
| Mounier, N | 2 |
| Ganem, G | 1 |
| Molina, TJ | 1 |
| Thiéblemont, C | 2 |
| Fermé, C | 1 |
| Quesnel, B | 2 |
| Martin, C | 2 |
| Gisselbrecht, C | 2 |
| Tilly, H | 3 |
| Reyes, F | 2 |
| Mikuls, TR | 1 |
| Gleissner, B | 1 |
| Hayslip, J | 1 |
| Fenning, R | 1 |
| Kujawski, LA | 1 |
| Longo, WL | 1 |
| Williams, EC | 1 |
| Turman, NJ | 1 |
| Brandt, N | 1 |
| Mosher, DF | 1 |
| Eickhoff, JC | 1 |
| Kahl, BS | 1 |
| Ogura, M | 1 |
| Skorokhod, O | 1 |
| Kulikova, EV | 1 |
| Galkina, NM | 1 |
| Medvedev, PV | 1 |
| Zybunova, EE | 1 |
| Vitvitsky, VM | 1 |
| Pivnik, AV | 1 |
| Ataullakhanov, FI | 1 |
| Ishizawa, K | 1 |
| Van Dorp, TE | 1 |
| Kaneene, JB | 1 |
| Sano, M | 2 |
| Homma, J | 2 |
| Tsuchiya, N | 2 |
| Yajima, N | 2 |
| Peter, U | 1 |
| Honegger, H | 1 |
| Koelz, HR | 1 |
| Rigacci, L | 1 |
| Mappa, S | 1 |
| Nassi, L | 1 |
| Alterini, R | 1 |
| Carrai, V | 1 |
| Bernardi, F | 2 |
| Bosi, A | 2 |
| Bosly, A | 3 |
| Bron, D | 2 |
| Van Hoof, A | 1 |
| De Bock, R | 1 |
| Berneman, Z | 1 |
| Ferrant, A | 2 |
| Kaufman, L | 1 |
| Dauwe, M | 1 |
| Verhoef, G | 1 |
| Dionigi, G | 1 |
| Annoni, M | 1 |
| Rovera, F | 1 |
| Boni, L | 1 |
| Villa, F | 1 |
| Castano, P | 1 |
| Bianchi, V | 1 |
| Dionigi, R | 1 |
| Kunishio, K | 2 |
| Ruan, J | 1 |
| Furman, R | 1 |
| Niesvizky, R | 1 |
| Elstrom, R | 1 |
| George, P | 1 |
| Kaufman, TP | 1 |
| Ennishi, D | 1 |
| Terui, Y | 1 |
| Yokoyama, M | 1 |
| Mishima, Y | 1 |
| Takahashi, S | 1 |
| Takeuchi, K | 1 |
| Ikeda, K | 1 |
| Tanimoto, M | 1 |
| Hatake, K | 1 |
| Kakuma, T | 1 |
| Kluin-Nelemans, HC | 1 |
| Coenen, JL | 1 |
| Boers, JE | 1 |
| van Imhoff, GW | 1 |
| Rosati, S | 1 |
| Starzl, TE | 3 |
| Nalesnik, MA | 2 |
| Porter, KA | 1 |
| Ho, M | 2 |
| Iwatsuki, S | 1 |
| Griffith, BP | 1 |
| Rosenthal, JT | 1 |
| Hakala, TR | 1 |
| Shaw, BW | 1 |
| Hardesty, RL | 1 |
| Bogusławska-Jaworska, J | 2 |
| Grześkowiak-Melanowska, J | 1 |
| Kaczmarek, M | 1 |
| Kościelniak, E | 2 |
| Legutko, L | 1 |
| Sońta-Jakimczyk, D | 2 |
| Sroczyńska, M | 2 |
| Wojcik, Z | 1 |
| Klener, P | 5 |
| Donner, L | 3 |
| Portlock, CS | 5 |
| Rupniewska, ZM | 1 |
| Kurowska, M | 1 |
| Rassiga, AL | 1 |
| Canellos, GP | 7 |
| Skarin, AT | 4 |
| Rosenthal, DS | 4 |
| Moloney, WC | 5 |
| Frei, E | 7 |
| Franke, A | 1 |
| Spormann, H | 1 |
| Mey, U | 1 |
| Klastersky, J | 1 |
| Kaneko, Y | 1 |
| Larson, RA | 1 |
| Variakojis, D | 1 |
| Haren, JM | 1 |
| Rowley, JD | 1 |
| Bellesi, G | 1 |
| di Lollo, S | 1 |
| Campana, G | 1 |
| Romagnani, S | 1 |
| Rossi Ferrini, P | 1 |
| Liepman, MK | 1 |
| Wheeler, RH | 2 |
| Zuckerman, KS | 2 |
| Lobuglio, AF | 2 |
| Focan, C | 1 |
| Cryns-Lenain, E | 1 |
| Bouhy, F | 1 |
| Lapière, CM | 1 |
| Jones, SE | 13 |
| Grozea, PN | 4 |
| Metz, EN | 2 |
| Haut, A | 3 |
| Stephens, RL | 2 |
| Morrison, FS | 3 |
| Talley, R | 1 |
| Butler, JJ | 4 |
| Byrne, GE | 2 |
| Hartsock, R | 1 |
| Dixon, D | 2 |
| Salmon, SE | 1 |
| Burgess, MA | 2 |
| Bodey, GP | 6 |
| Freireich, EJ | 7 |
| Case, DC | 3 |
| Płuzańska, A | 1 |
| Krykowski, E | 1 |
| Robak, T | 1 |
| Oliskiewicz, W | 1 |
| Polkowska, E | 1 |
| Dowgier, I | 1 |
| Hyjek, E | 1 |
| Böttcher, HD | 1 |
| Pötter, R | 1 |
| Schütz, J | 1 |
| Kamihira, S | 1 |
| Sakitani, M | 1 |
| Nakano, M | 1 |
| Kinoshita, K | 1 |
| Ichimaru, M | 1 |
| Sampi, K | 5 |
| Honda, T | 4 |
| Hattori, M | 5 |
| Takayama, S | 1 |
| Bryon, PA | 2 |
| Fière, D | 2 |
| Felman, P | 2 |
| Ffrench, M | 2 |
| Rebattu, P | 1 |
| Archimbaud, E | 2 |
| Blanc, M | 1 |
| Vuvan, H | 1 |
| Guyotat, D | 2 |
| Kaku, K | 1 |
| Inoue, M | 1 |
| Fujii, S | 1 |
| Ishida, Y | 1 |
| Hiroshige, Y | 1 |
| Shinohara, K | 1 |
| Nakashima, K | 1 |
| Matsumoto, N | 1 |
| Kaneko, T | 1 |
| Velasquez, W | 1 |
| Fuller, LM | 5 |
| Oh, KK | 1 |
| Sullivan, JA | 2 |
| Manning, JT | 2 |
| Shullenberger, CC | 2 |
| Schaadt, M | 1 |
| Plaumann, L | 1 |
| Diehl, V | 1 |
| Monfardini, S | 2 |
| Rilke, F | 1 |
| Valagussa, P | 2 |
| Bajetta, E | 2 |
| Canetta, R | 1 |
| Buzzoni, R | 2 |
| Giardini, R | 1 |
| Viviani, S | 1 |
| Bartels, H | 1 |
| Schneider, B | 1 |
| Feller, AC | 1 |
| Haller, DG | 1 |
| Gomez, GA | 3 |
| Han, T | 3 |
| Ozer, H | 2 |
| Henderson, ES | 2 |
| Maor, MH | 1 |
| Maddux, B | 1 |
| Osborne, BM | 1 |
| Nelson, RS | 1 |
| Martin, RG | 2 |
| Libshitz, HI | 1 |
| Velasquez, WS | 3 |
| Bennett, RW | 1 |
| Keating, M | 1 |
| Barlogie, B | 1 |
| Takagi, T | 2 |
| Oguro, M | 1 |
| Omori, Y | 1 |
| Honda, I | 1 |
| Fujita, Y | 1 |
| Köster, O | 1 |
| Harder, T | 1 |
| Burmester, GR | 1 |
| Gramatzki, M | 1 |
| Wirth, A | 1 |
| Kalden, JR | 1 |
| Crawford, DH | 1 |
| Edwards, JM | 1 |
| Sweny, P | 2 |
| Hoffbrand, AV | 2 |
| Janossy, G | 1 |
| Gayraud, M | 1 |
| Guillevin, L | 1 |
| Bletry, O | 1 |
| Ronco, P | 1 |
| Friocourt, L | 1 |
| Godeau, P | 1 |
| Sumi, SM | 1 |
| Farrell, DF | 1 |
| Knauss, TA | 1 |
| Warde, P | 1 |
| Powderly, WG | 1 |
| Fennelly, JJ | 1 |
| Cunningham, S | 1 |
| McKenna, TJ | 1 |
| Kasahara, M | 1 |
| Mizoguchi, Y | 1 |
| Kuroda, M | 1 |
| Miki, Y | 1 |
| Yamamoto, N | 1 |
| Horibe, Y | 1 |
| Watanabe, H | 1 |
| Hondo, R | 1 |
| Aoyama, U | 1 |
| Heinz, R | 4 |
| Stacher, A | 2 |
| Anderson, JR | 3 |
| Wilson, JF | 2 |
| Jenkin, DT | 1 |
| Meadows, AT | 3 |
| Kersey, J | 1 |
| Chilcote, RR | 2 |
| Coccia, P | 2 |
| Exelby, P | 4 |
| Kushner, J | 2 |
| Siegel, S | 2 |
| Hammond, D | 2 |
| Oken, MM | 2 |
| Costello, WG | 2 |
| Johnson, GJ | 2 |
| Lenhard, RE | 4 |
| Ezdinli, EZ | 5 |
| Orlow, E | 1 |
| Barnes, JM | 2 |
| Berard, CW | 6 |
| Glick, JH | 4 |
| Burgers, JM | 3 |
| Somers, R | 3 |
| Quasim, MM | 1 |
| van Glabbekke, M | 1 |
| Sullivan, KM | 1 |
| Neiman, PE | 1 |
| Kadin, ME | 2 |
| Dahlberg, S | 1 |
| Farewell, VT | 1 |
| Rudolph, RH | 1 |
| Bagley, CM | 2 |
| Appelbaum, FR | 2 |
| Thomas, ED | 2 |
| Corder, MP | 2 |
| Leimert, JT | 2 |
| Tewfik, HH | 2 |
| Lovett, JM | 1 |
| Weick, JK | 1 |
| Antunez, A | 1 |
| Kraus, TA | 1 |
| Fabian, CJ | 2 |
| Jackson, DV | 1 |
| Muss, HB | 1 |
| Richards, F | 1 |
| White, DR | 1 |
| Spurr, CL | 1 |
| Cooper, MR | 1 |
| Christian, RM | 1 |
| Trahey, TF | 1 |
| Case, LD | 1 |
| Wells, HB | 1 |
| Jacquillat, C | 1 |
| Khayat, D | 1 |
| Desprez-Curely, JP | 1 |
| Weil, M | 1 |
| Brocheriou, C | 1 |
| Auclerc, G | 1 |
| Chamseddine, N | 1 |
| Bernard, J | 1 |
| Jenkin, RD | 2 |
| Coccia, PF | 1 |
| Exelby, PR | 2 |
| Kersey, JH | 2 |
| Kushner, JH | 1 |
| Siegel, SE | 1 |
| Sposto, R | 1 |
| Glimelius, B | 2 |
| Gronowitz, S | 1 |
| Killander, A | 2 |
| Källander, C | 1 |
| Schröder, T | 1 |
| Cohen, DJ | 1 |
| Loertscher, R | 1 |
| Rubin, MF | 1 |
| Tilney, NL | 1 |
| Carpenter, CB | 1 |
| Strom, TB | 1 |
| Carde, P | 3 |
| van Glabbeke, M | 2 |
| Hayat, M | 2 |
| Cosset, JM | 4 |
| Sizoo, W | 1 |
| Qasim, MM | 1 |
| Lefur, R | 1 |
| Abbatucci, JS | 1 |
| Emmerich, B | 1 |
| Pemsl, M | 1 |
| Wüst, I | 1 |
| Lechner, S | 1 |
| Thiel, E | 2 |
| Georgii, A | 1 |
| Gössner, W | 1 |
| Rastetter, J | 1 |
| Nissen, NI | 3 |
| Ersbøll, J | 1 |
| Hansen, HS | 1 |
| Walbom-Jørgensen, S | 1 |
| Pedersen-Bjergaard, J | 1 |
| Hansen, MM | 1 |
| Rygård, J | 1 |
| Aderka, D | 1 |
| Kraus, M | 1 |
| Avidor, I | 1 |
| Sidi, Y | 2 |
| Weinberger, A | 2 |
| Pinkhas, J | 3 |
| Sunderrajan, EV | 1 |
| Passamonte, PM | 1 |
| Kuraishi, Y | 1 |
| Ozeki, H | 1 |
| Takasaki, N | 1 |
| Mashizu, N | 1 |
| Nagamine, D | 1 |
| Usui, N | 1 |
| Yamazaki, H | 1 |
| Nakamura, T | 1 |
| Aiba, K | 1 |
| Yokoyama, K | 1 |
| Breslau, NA | 1 |
| McGuire, JL | 1 |
| Zerwekh, JE | 1 |
| Frenkel, EP | 1 |
| Pak, CY | 1 |
| Toki, H | 2 |
| Okabe, K | 2 |
| Ishikawa, M | 1 |
| Fujii, M | 1 |
| Waxman, M | 1 |
| Fatteh, S | 1 |
| Elias, JM | 1 |
| Vuletin, JC | 1 |
| Voltarelli, JC | 1 |
| Falcão, RP | 1 |
| Bottura, C | 1 |
| Koziner, B | 1 |
| Sklaroff, R | 1 |
| Little, C | 1 |
| Labriola, D | 1 |
| Thaler, HT | 1 |
| Straus, DJ | 3 |
| Young, CW | 2 |
| Nisce, LZ | 3 |
| Oettgen, H | 1 |
| Lee, BJ | 2 |
| Lamb, DS | 1 |
| Hudson, GV | 1 |
| Easterling, MJ | 1 |
| MacLennan, KA | 1 |
| Jelliffe, AM | 1 |
| Tester, WJ | 1 |
| Kinsella, TJ | 2 |
| Waller, B | 1 |
| Makuch, RW | 1 |
| Kelley, PA | 1 |
| Glatstein, E | 2 |
| DeVita, VT | 13 |
| Leung, AC | 1 |
| McKean, M | 1 |
| Mactier, R | 1 |
| Dobbie, JW | 1 |
| Plenert, W | 1 |
| Zintl, F | 1 |
| Katenkamp, D | 1 |
| Mead, GM | 2 |
| Macbeth, FR | 1 |
| Williams, CJ | 1 |
| Ryall, RD | 1 |
| Wright, DH | 1 |
| Whitehouse, JM | 1 |
| Hanak, H | 3 |
| Shitara, T | 1 |
| Kuribayashi, T | 1 |
| Oshima, Y | 1 |
| Suetake, N | 1 |
| Hiraishi, Y | 1 |
| Shimizu, Y | 1 |
| Hashida, T | 1 |
| Esumi, N | 1 |
| Morioka, Y | 1 |
| Nagai, T | 1 |
| Arakawa, S | 1 |
| Imashuku, S | 1 |
| Fushiki, S | 1 |
| Ikuta, H | 1 |
| Miyake, M | 1 |
| Armata, J | 2 |
| Balwierz, W | 1 |
| Ciepielewska, D | 1 |
| Kaczmarek-Kanold, M | 1 |
| Ochocka, M | 1 |
| Radwańska, U | 1 |
| Duque-Hammershaimb, L | 1 |
| Wollner, N | 4 |
| Miller, DR | 1 |
| Levine, AM | 4 |
| Forman, SJ | 1 |
| Meyer, PR | 1 |
| Koehler, SC | 1 |
| Liebman, H | 1 |
| Paganini-Hill, A | 1 |
| Pockros, A | 1 |
| Lukes, RJ | 1 |
| Feinstein, DI | 1 |
| Fisher, RI | 6 |
| Hubbard, SM | 3 |
| Longo, DL | 5 |
| Wesley, R | 1 |
| Chabner, BA | 8 |
| Young, RC | 8 |
| Doyle, LA | 1 |
| Berg, C | 1 |
| Bottino, G | 1 |
| Chabner, B | 1 |
| Murphy, SB | 5 |
| Hustu, HO | 4 |
| Rivera, G | 2 |
| Horikoshi, N | 4 |
| Inagaki, J | 3 |
| Ogawa, M | 5 |
| Foucar, K | 1 |
| Dick, FR | 1 |
| Miller, TP | 3 |
| Child, JA | 1 |
| Barnard, DL | 1 |
| Cartwright, SC | 1 |
| Lauder, I | 1 |
| Simmons, AV | 1 |
| Stone, J | 1 |
| Thorogood, J | 1 |
| Kratzer, H | 1 |
| Hehenwarter, W | 1 |
| Denz, H | 1 |
| Bliem, J | 1 |
| Tschurtschenthaler, G | 1 |
| Nitsche, D | 1 |
| Huber, H | 1 |
| Michlmayr, G | 1 |
| Hérics, I | 1 |
| Szántó, I | 1 |
| Liszka, G | 1 |
| Fosser, VP | 1 |
| Salvagno, L | 1 |
| Segati, R | 1 |
| Pappagallo, GL | 1 |
| Ferrazzi, E | 1 |
| Sileni, VC | 1 |
| Fiorentino, MV | 1 |
| Mandelli, F | 3 |
| Biagini, C | 2 |
| Baroni, CD | 1 |
| Bosman, C | 1 |
| Anselmo, AP | 2 |
| de Luca, AM | 1 |
| Granati, L | 1 |
| Petti, N | 1 |
| Papa, G | 3 |
| Schoengen, A | 1 |
| Rosenthal, RC | 1 |
| Hamminga, L | 1 |
| Hermans, J | 1 |
| Noordijk, EM | 1 |
| Meijer, CJ | 1 |
| Scheffer, E | 1 |
| Van Vloten, WA | 1 |
| Popp, MB | 1 |
| Simon, RM | 1 |
| Brennan, MF | 1 |
| O'Connell, MJ | 2 |
| Anderson, J | 2 |
| Merrill, JM | 1 |
| Bennett, JM | 5 |
| Neiman, RS | 1 |
| Brodovsky, HS | 1 |
| Johansson, RT | 1 |
| Joensuu, H | 1 |
| Abdel Karim, FW | 1 |
| Ayash, RE | 1 |
| Allam, C | 1 |
| Salem, PA | 1 |
| Rahmani, R | 1 |
| Brenner, S | 1 |
| Krakowski, A | 1 |
| Lipitz, R | 1 |
| Ilie, B | 1 |
| Behar, AJ | 1 |
| Da Silva, AM | 1 |
| Weiner, J | 1 |
| Dean, P | 1 |
| Kerwin, DM | 1 |
| Sant, GR | 1 |
| Ucci, AA | 1 |
| Meares, EM | 1 |
| McDonald, MI | 1 |
| Moore, JO | 1 |
| Harrelson, JM | 1 |
| Browning, CP | 1 |
| Gallis, HA | 1 |
| Nesse, RM | 1 |
| Carli, T | 1 |
| Curtis, GC | 1 |
| Kleinman, PD | 1 |
| Comella, P | 2 |
| Scoppa, G | 1 |
| Abate, G | 2 |
| Comella, G | 2 |
| Apice, G | 1 |
| Castello, G | 1 |
| Pergola, M | 2 |
| Giordano, GG | 1 |
| Coucourde, F | 1 |
| Zarrilli, D | 2 |
| Kantor, G | 1 |
| Masselot, J | 1 |
| Kuhlmann, J | 1 |
| Wilke, J | 1 |
| Rietbrock, N | 1 |
| Büchi, G | 2 |
| Mazza, U | 1 |
| Camaschella, C | 1 |
| Saglio, G | 1 |
| Cambrin, GR | 1 |
| Termine, G | 2 |
| Enrico, E | 1 |
| Autino, R | 1 |
| Zappala, C | 1 |
| Hulhoven, R | 1 |
| Michaux, JL | 2 |
| Cornu, G | 1 |
| Delannoy, A | 1 |
| Sokal, G | 1 |
| Castleberry, RP | 1 |
| McCaffrey, R | 1 |
| Bell, R | 1 |
| Lillquist, A | 1 |
| Wright, G | 1 |
| Baril, E | 1 |
| Stutzman, L | 2 |
| Moayeri, H | 1 |
| Shimaoka, K | 1 |
| Plager, J | 1 |
| Naeher, C | 1 |
| Henderson, E | 1 |
| Stein, RS | 3 |
| Flexner, JM | 3 |
| Collins, RD | 1 |
| Silverstein, MN | 1 |
| Berard, C | 4 |
| Hartsock, RJ | 1 |
| Sokal, JE | 1 |
| Chilcote, R | 1 |
| Leikin, S | 1 |
| Streuli, RA | 1 |
| Liffers, R | 1 |
| Farrington, K | 1 |
| Younis, F | 1 |
| Varghese, Z | 1 |
| Baillod, RA | 1 |
| Fernando, ON | 1 |
| Moorhead, JF | 1 |
| Hayhoe, FG | 1 |
| Orlow, EL | 1 |
| Sakano, T | 2 |
| Evans, WE | 1 |
| Tsiatis, A | 1 |
| Dahl, GV | 2 |
| Denison, M | 1 |
| Crom, WR | 1 |
| Barker, LF | 1 |
| Mauer, AM | 1 |
| Vollenweider, A | 1 |
| Largiadèr, F | 1 |
| Uhlschmid, G | 1 |
| Binswanger, U | 1 |
| Briner, J | 1 |
| Deonarine, L | 1 |
| Weinerman, BH | 1 |
| MacDougall, BK | 1 |
| Kemel, S | 1 |
| Parlier, Y | 1 |
| Gorin, NC | 1 |
| Najman, A | 1 |
| Stachowiak, J | 1 |
| Duhamel, G | 1 |
| Fauci, AS | 1 |
| Haynes, BF | 1 |
| Costa, J | 1 |
| Katz, P | 1 |
| Wolff, SM | 1 |
| Gelmann, E | 1 |
| Anderson, T | 3 |
| Jaffe, E | 1 |
| Broder, S | 2 |
| Izzi, T | 1 |
| Porcellini, A | 1 |
| Delfini, C | 1 |
| Lucarelli, G | 1 |
| Kim, TH | 1 |
| Michel, RP | 1 |
| Melnychuk, D | 1 |
| Freeman, CR | 1 |
| Ng, PR | 1 |
| Todd, D | 1 |
| Khoo, RK | 1 |
| Seewann, HL | 1 |
| Tilz, GP | 1 |
| Becker, H | 1 |
| Lehnert, M | 1 |
| Bruni, GS | 1 |
| Hoppe, RT | 2 |
| Kushlan, P | 1 |
| Kaplan, HS | 4 |
| Rosenberg, SA | 8 |
| Brown, BW | 1 |
| Foon, KA | 1 |
| Filderman, A | 1 |
| Gale, RP | 1 |
| Pettingale, KW | 1 |
| Krajewska, B | 1 |
| Solska, E | 1 |
| Dziewulska-Bokiniec, A | 1 |
| Bishop, JF | 1 |
| Schimpff, SC | 1 |
| Diggs, CH | 1 |
| Wiernik, PH | 2 |
| Somoza, N | 3 |
| Pavlovsky, S | 4 |
| Suárez, A | 3 |
| Morgenfeld, M | 1 |
| Besuschio, SC | 1 |
| Bezares, R | 1 |
| Quiroga Micheo, E | 1 |
| Lein, JM | 2 |
| De María, H | 2 |
| Sigg, C | 1 |
| Plüss, HJ | 1 |
| Hitzig, WH | 1 |
| Voakes, JB | 1 |
| McKelvey, EM | 4 |
| Callihan, TR | 2 |
| Jaffe, ES | 3 |
| Strober, W | 1 |
| Bartter, FC | 1 |
| Waldmann, TA | 1 |
| Kuo, HC | 1 |
| Chou, CY | 1 |
| Chang, CH | 1 |
| Liu, MT | 1 |
| Tzeng, CC | 1 |
| Huang, KE | 1 |
| Chan, T | 1 |
| Juneja, S | 1 |
| Wolf, M | 1 |
| Januszewicz, E | 1 |
| Cooper, I | 1 |
| Martin, RH | 1 |
| Rademaker, AW | 1 |
| Leonard, NJ | 1 |
| Fernández, A | 1 |
| Rosas, A | 1 |
| Schleiffenbaum, B | 1 |
| Rüegg, R | 1 |
| Zimmermann, D | 1 |
| Fehr, J | 1 |
| Nademanee, A | 1 |
| Schmidt, GM | 1 |
| Parker, P | 1 |
| Dagis, AC | 1 |
| Stein, A | 1 |
| Snyder, DS | 1 |
| O'Donnell, M | 1 |
| Smith, EP | 1 |
| Stepan, DE | 1 |
| Molina, A | 1 |
| Kang, YK | 1 |
| Zhan, Z | 3 |
| Regis, J | 3 |
| Alvarez, M | 1 |
| Robey, R | 1 |
| Meadows, B | 1 |
| Dickstein, B | 2 |
| Lee, JS | 1 |
| Otsuki, T | 1 |
| Stetler-Stevenson, M | 1 |
| Jamis-Dow, C | 1 |
| Bryant, G | 2 |
| Balis, FM | 1 |
| Klecker, RW | 1 |
| Bates, SE | 3 |
| Kohler, DR | 1 |
| Wittes, RE | 2 |
| Fojo, A | 1 |
| Herdt, J | 1 |
| Cavalli, F | 1 |
| Remuzzi, G | 1 |
| Gotti, E | 1 |
| Malik, IA | 1 |
| Shamsi, Z | 1 |
| Shafquat, A | 1 |
| Aziz, Z | 1 |
| Jafri, W | 1 |
| Khan, MA | 1 |
| Khan, AH | 1 |
| Tarella, C | 2 |
| Boccadoro, M | 1 |
| Omedé, P | 1 |
| Bondesan, P | 1 |
| Caracciolo, D | 1 |
| Frieri, R | 1 |
| Bregni, M | 1 |
| Siena, S | 1 |
| Gianni, AM | 1 |
| Pileri, A | 1 |
| Bertini, M | 2 |
| Miyaguchi, M | 1 |
| Takeda, J | 1 |
| Furuta, H | 1 |
| Uozumi, N | 1 |
| Miyabe, K | 1 |
| Sakai, S | 1 |
| Gould, WJ | 1 |
| Flanders, JA | 1 |
| Chamberlain, MC | 1 |
| Kalaycioglu, M | 1 |
| Kavuru, M | 1 |
| Tuason, L | 1 |
| Bolwell, B | 1 |
| Lichtman, SM | 1 |
| McLaughlin, P | 1 |
| Swan, F | 1 |
| Moore, DF | 1 |
| Sarris, AH | 1 |
| Younes, A | 1 |
| Hill, D | 1 |
| Lachance, DH | 1 |
| Brizel, DM | 1 |
| Gockerman, JP | 1 |
| Halperin, EC | 1 |
| Burger, PC | 1 |
| Boyko, OB | 1 |
| Brown, MT | 1 |
| Schold, SC | 1 |
| Asensio, AJ | 1 |
| Besses, C | 1 |
| Palacín, A | 1 |
| Sans-Sabrafen, J | 2 |
| Shih, LY | 1 |
| Liaw, SJ | 1 |
| Dunn, P | 1 |
| Kuo, TT | 1 |
| Bezwoda, WR | 1 |
| Rastogi, RB | 1 |
| Cohen, Y | 1 |
| Goldenberg, N | 1 |
| Kasis, S | 1 |
| Shpilberg, D | 1 |
| Oren, M | 1 |
| Cherlow, JM | 1 |
| Steinherz, PG | 1 |
| Sather, HN | 1 |
| Gaynon, PS | 1 |
| Grossman, NJ | 1 |
| Johnstone, HS | 1 |
| Breneman, JC | 1 |
| Trigg, ME | 1 |
| Hammond, GD | 1 |
| Matsuzuka, F | 1 |
| Miyauchi, A | 1 |
| Katayama, S | 1 |
| Narabayashi, I | 1 |
| Ikeda, H | 1 |
| Kuma, K | 1 |
| Sugawara, M | 1 |
| Ringle, MJ | 1 |
| Lindley, DM | 1 |
| Krohne, SG | 1 |
| Fidias, P | 1 |
| Wright, C | 1 |
| Harris, NL | 2 |
| Urba, W | 1 |
| Grossbard, ML | 1 |
| Bocchi, EA | 1 |
| Bellotti, G | 1 |
| Mocelin, AO | 1 |
| Uip, D | 1 |
| Bacal, F | 1 |
| Higuchi, ML | 1 |
| Amato-Neto, V | 1 |
| Fiorelli, A | 1 |
| Stolf, NA | 1 |
| Jatene, AD | 1 |
| Pileggi, F | 1 |
| Léone, J | 1 |
| Pennaforte, JL | 1 |
| Hamon, R | 1 |
| Cleenewerck, N | 1 |
| Vallerand, H | 1 |
| Détrée, F | 1 |
| Eschard, JP | 1 |
| Etienne, JC | 1 |
| Bagga, S | 1 |
| Gupta, SM | 1 |
| Johns, W | 1 |
| Hering, M | 1 |
| Hagel, E | 1 |
| Zwicker, C | 1 |
| Krieger, G | 1 |
| Anhalt, GJ | 1 |
| Valerius, KD | 1 |
| Ogilvie, GK | 1 |
| Mallinckrodt, CH | 1 |
| Getzy, DM | 1 |
| Macpherson, N | 1 |
| Meurman, JH | 1 |
| Laine, P | 1 |
| Keinànen, S | 1 |
| Pyrhönen, S | 1 |
| Lindqvist, C | 1 |
| Sandor, VA | 1 |
| Gamelin, E | 1 |
| Wilson, W | 1 |
| Fojo, AT | 1 |
| Maeda, Y | 2 |
| Kuriyama, M | 1 |
| Ono, Y | 2 |
| Furuta, T | 2 |
| Ohmoto, T | 2 |
| Gruessner, RW | 1 |
| Kingreen, D | 1 |
| Nitsche, A | 1 |
| Beyer, J | 1 |
| Siegert, W | 1 |
| Brada, M | 2 |
| Hjiyiannakis, D | 1 |
| Hines, F | 1 |
| Traish, D | 1 |
| Ashley, S | 1 |
| Herrlinger, U | 1 |
| Schabet, M | 1 |
| Clemens, M | 1 |
| Kortmann, RD | 1 |
| Petersen, D | 1 |
| Will, BE | 1 |
| Meyermann, R | 1 |
| Dichgans, J | 1 |
| Rapoport, AP | 1 |
| Constine, LS | 1 |
| Packman, CH | 1 |
| Rosier, RN | 1 |
| O'Keefe, R | 1 |
| Hicks, DG | 1 |
| Rubin, SJ | 1 |
| Bairey, O | 1 |
| Gabbay, U | 1 |
| Blickstein, D | 1 |
| Stark, P | 1 |
| Prokocimer, M | 1 |
| Epstein, O | 1 |
| Shaklai, M | 1 |
| Lahav, J | 1 |
| Gómez, H | 1 |
| Colomer, R | 1 |
| Fajardo Montañana, C | 1 |
| Merino Torres, JF | 1 |
| Campos Alborg, V | 1 |
| Garcerá Juan, S | 1 |
| Piñón Sellés, F | 1 |
| Zwahlen, CH | 1 |
| Lucroy, MD | 1 |
| Kraegel, SA | 1 |
| Madewell, BR | 2 |
| Wada, M | 1 |
| Onda, M | 1 |
| Tokunaga, A | 1 |
| Kiyama, T | 1 |
| Yoshiyuki, T | 1 |
| Matsukura, N | 1 |
| Furukawa, K | 1 |
| Egami, K | 1 |
| Yamashita, K | 1 |
| Alpaslan, G | 1 |
| Alpaslan, C | 1 |
| Gögen, H | 1 |
| Oğuz, A | 1 |
| Cetiner, S | 1 |
| Karadeniz, C | 1 |
| Kinoshita, T | 1 |
| Kagami, Y | 1 |
| Bauduer, F | 1 |
| Desablens, B | 1 |
| Koniaris, LG | 1 |
| Lillemoe, KD | 1 |
| Yeo, CJ | 1 |
| Abrams, RA | 1 |
| Colemann, J | 1 |
| Nakeeb, A | 1 |
| Pitt, H | 1 |
| Cameron, JL | 1 |
| Lederlin, P | 2 |
| Brière, J | 1 |
| Dupriez, B | 1 |
| Sebban, C | 1 |
| Biron, P | 1 |
| Nouvel, C | 1 |
| Herbrecht, R | 1 |
| Bordessoule, D | 1 |
| Hayabuchi, N | 1 |
| Onizuka, Y | 1 |
| Jantunen, E | 1 |
| Myllykangas-Luosujärvi, R | 1 |
| Kaipiainen-Seppänen, O | 1 |
| Nousiainen, T | 1 |
| Lopez-Picazo, JM | 1 |
| Gonzalez Manzano, R | 1 |
| Ordoñez Tres, JM | 1 |
| Jimenez, MM | 1 |
| Calvo, JP | 1 |
| Brugarolas, A | 1 |
| Mhawech, P | 1 |
| Bueso-Ramos, C | 1 |
| Coffey, DM | 1 |
| Gei, AF | 1 |
| Shahab, I | 1 |
| Brousse, C | 1 |
| Baumelou, E | 1 |
| Morel, P | 1 |
| Wong, KF | 1 |
| Cheung, MM | 1 |
| So, JC | 1 |
| Kato, Y | 1 |
| Hakamada, M | 1 |
| Hattori, Y | 1 |
| Sato, A | 1 |
| Shimizu, N | 1 |
| Imamura, A | 2 |
| Mihara, H | 1 |
| Kato, H | 2 |
| Morishita, M | 1 |
| Miwa, H | 1 |
| Nitta, M | 1 |
| Bayrakci, K | 1 |
| Yildiz, Y | 1 |
| Saglik, Y | 1 |
| Altay, M | 1 |
| Ogüt, H | 1 |
| Samur, M | 1 |
| Erekul, S | 1 |
| Wilder, RB | 1 |
| Ha, CS | 1 |
| Pro, B | 1 |
| Hess, MA | 1 |
| Cox, JD | 1 |
| Alvarez-Larrán, A | 1 |
| Villamor, N | 1 |
| Hernández-Boluda, JC | 1 |
| Ferrer, A | 1 |
| Camós, M | 1 |
| Campo, E | 1 |
| López-Guillermo, A | 1 |
| Mayer, A | 1 |
| Dumontet, C | 1 |
| Barbier, Y | 1 |
| Callet-Bauchu, E | 1 |
| Berger, F | 2 |
| Ducottet, X | 1 |
| Salles, G | 1 |
| Orgiazzi, J | 1 |
| Feldman, L | 1 |
| Basok, A | 1 |
| Kachko, L | 1 |
| Tovbin, D | 1 |
| Bernasconi, P | 1 |
| Alessandrino, EP | 1 |
| Gargantini, L | 1 |
| Astori, C | 1 |
| Pagnucco, G | 1 |
| Colombo, AA | 1 |
| Calatroni, S | 1 |
| Iacona, I | 1 |
| Regazzi, MB | 1 |
| Yoshimura, C | 1 |
| Nomura, S | 1 |
| Kanazawa, S | 1 |
| Kuwana, M | 1 |
| Yamaguchi, K | 1 |
| Fukuhara, S | 1 |
| Kodama, F | 1 |
| Mohri, H | 1 |
| Motomura, S | 1 |
| Fukawa, H | 1 |
| Tanabe, J | 1 |
| Koharasawa, H | 1 |
| Kanamori, H | 1 |
| Hashimoto, Y | 1 |
| Harano, H | 1 |
| Sakai, R | 1 |
| Fujimaki, K | 1 |
| Takemura, S | 1 |
| Lepage, E | 1 |
| Molina, T | 1 |
| Gabarre, J | 1 |
| Guilmin, F | 1 |
| Hermine, O | 1 |
| Kochi, M | 1 |
| Ushio, Y | 1 |
| Vettore, L | 1 |
| Pizzolo, G | 1 |
| Battelli, T | 1 |
| Bonsignori, M | 1 |
| Manocchi, P | 1 |
| Gutterman, JU | 3 |
| Bakemeier, RF | 1 |
| Carbone, PP | 5 |
| Ezdinli, E | 2 |
| Schein, PS | 4 |
| Hubbard, S | 1 |
| Barduagni, A | 1 |
| Marolla, A | 1 |
| Calabresi, F | 1 |
| Terzoli, E | 1 |
| Rodriguez, V | 8 |
| Valdivieso, M | 1 |
| Hellman, S | 2 |
| Chaffey, JT | 2 |
| Schmidt, CG | 2 |
| Bender, RA | 1 |
| Norton, L | 1 |
| Coltman, CA | 4 |
| Luce, JK | 1 |
| Moon, TE | 4 |
| Pocock, SJ | 2 |
| Pajak, T | 1 |
| Glidewell, O | 1 |
| Blom, H | 1 |
| Flaherty, M | 1 |
| Hayes, D | 1 |
| McIntyre, R | 1 |
| Holland, JF | 1 |
| Bonadonna, G | 4 |
| Villa, E | 1 |
| Gamble, JF | 2 |
| Sinkovics, JG | 1 |
| Wallace, S | 1 |
| Gehan, EA | 1 |
| Ortega, J | 1 |
| Rossof, AH | 1 |
| Kerr, RO | 1 |
| Braine, HG | 1 |
| Kurvink, K | 1 |
| Bloomfield, CD | 1 |
| Keenan, KM | 1 |
| Levitt, S | 1 |
| Cervenka, J | 1 |
| Stolzenbach, G | 2 |
| Garbrecht, M | 2 |
| Müllerleile, U | 1 |
| Fisher, R | 1 |
| Haskins, CL | 1 |
| Brooks, RJ | 1 |
| Gaines, JA | 1 |
| Spiegel, RJ | 1 |
| Vigersky, RA | 1 |
| Oliff, AI | 1 |
| Echelberger, CK | 1 |
| Bruton, J | 1 |
| Poplack, DG | 1 |
| Brunner, KW | 2 |
| Wagner, HP | 1 |
| Jellinger, K | 1 |
| Kothbauer, P | 1 |
| Weiss, R | 1 |
| Sunder-Plassmann, E | 1 |
| Fleischer, J | 1 |
| Sutow, WW | 1 |
| Sullivan, MP | 3 |
| Cuni, LJ | 1 |
| Rosner, F | 1 |
| Chawla, SK | 1 |
| Meyskens, FL | 1 |
| Hutter, JJ | 1 |
| Hays, T | 1 |
| Rosen, RC | 1 |
| Shende, A | 1 |
| Lanzkowsky, P | 1 |
| Corrigan, JJ | 1 |
| Fonseca, JG | 1 |
| Miranda, D | 1 |
| de Faria, O | 1 |
| Sieber, SM | 1 |
| Le Bourgeois, JP | 1 |
| Durant, JR | 2 |
| Gams, RA | 2 |
| Bartolucci, AA | 2 |
| Dorfman, RF | 3 |
| Laurens, A | 1 |
| Thevenot, J | 1 |
| Charron, D | 1 |
| Jorry, F | 1 |
| Dumonchel, P | 1 |
| Martola, R | 1 |
| Rubio-Félix, D | 1 |
| Maicas, M | 1 |
| Rubio-Vitaller, A | 1 |
| Gil, JL | 1 |
| Giralt, M | 1 |
| Raichs, A | 1 |
| Brecher, ML | 1 |
| Sinks, LF | 1 |
| Thomas, RR | 1 |
| Freeman, AI | 1 |
| Sweet, DL | 2 |
| Ultmann, JE | 3 |
| Hartwich, G | 1 |
| Neidhardt, B | 1 |
| Costello, W | 1 |
| Horton, J | 1 |
| Amorisi, EL | 1 |
| Stolbach, L | 1 |
| Wolter, J | 1 |
| Brücher, H | 1 |
| Shank, BB | 1 |
| Kelley, CD | 1 |
| Nori, D | 1 |
| Weiden, PL | 1 |
| Storb, R | 2 |
| Deeg, HJ | 1 |
| Graham, TC | 1 |
| Modolell Roig, A | 1 |
| Rosell Costa, R | 1 |
| Boleda Relats, M | 1 |
| Buxó Costa, J | 1 |
| Pardo Peret, P | 1 |
| Rodríguez Ferrera, JC | 1 |
| Durand, M | 1 |
| Chauvergne, J | 1 |
| Hoerni-Simon, G | 1 |
| Meugé, C | 1 |
| De Mascarel, A | 1 |
| Richaud, P | 1 |
| Brunet, R | 1 |
| Hoerni, B | 1 |
| Lagarde, C | 1 |
| Duménil, D | 1 |
| Sainteny, F | 1 |
| Frindel, E | 1 |
| Bamberg, M | 2 |
| Donhuijsen, K | 1 |
| Höher, PG | 1 |
| Holfeld, H | 2 |
| Hossfeld, DK | 1 |
| Kotlarek-Haus, S | 1 |
| Nowicka, J | 1 |
| Gabryś, K | 1 |
| Starzyk, H | 1 |
| Becker, M | 1 |
| Kaiser, A | 1 |
| Hinrle, Z | 1 |
| Hultén, L | 1 |
| Ridell, B | 1 |
| Weinfeld, A | 1 |
| Branehög, I | 1 |
| Kluin-Neleman, JC | 1 |
| Neleman, FA | 1 |
| Meuwissen, OJ | 1 |
| Maes, RA | 1 |
| Hartmann, O | 1 |
| Parmentier, C | 1 |
| Lemerle, J | 2 |
| Gout, M | 1 |
| Schweisguth, O | 1 |
| Janka, GE | 1 |
| Lau, BM | 1 |
| Meister, P | 1 |
| Lampert, F | 1 |
| Haas, RJ | 1 |
| Guthrie, R | 1 |
| Maguire, LC | 1 |
| Gingrich, RD | 1 |
| DeBeer, R | 1 |
| Friedfeld, L | 1 |
| Kabakow, B | 1 |
| Burke, JS | 1 |
| Smith, TL | 1 |
| Nathwani, BN | 1 |
| Rappaport, H | 2 |
| Moran, EM | 2 |
| Pangalis, GA | 1 |
| Kim, H | 1 |
| Weiss, RB | 1 |
| Shah, S | 1 |
| Cebrian-Bonesana, A | 1 |
| Schvartzman, E | 1 |
| Roca-Garcia, C | 1 |
| Pependieck, C | 1 |
| Sackmann-Muriel, S | 1 |
| Ojeda, FG | 1 |
| Kvicala, R | 1 |
| Penchansky, L | 1 |
| Young, NA | 1 |
| Kwon-Chung, KJ | 1 |
| Kubota, TT | 1 |
| Jennings, AE | 1 |
| Houston, KA | 1 |
| O'duffy, JD | 1 |
| McDuffie, FC | 1 |
| Jauregui, HO | 1 |
| Morgenfeld, MC | 2 |
| Magnasco, J | 1 |
| Cavagnaro, FJ | 1 |
| Saslavsky, J | 1 |
| Macchi, A | 1 |
| Neretto, G | 1 |
| Giovanelli, E | 1 |
| Agricola, R | 1 |
| Furno, F | 1 |
| Ohl, S | 1 |
| Höffken, K | 1 |
| Scherer, E | 1 |
| Klein, HO | 1 |
| Gottlieb, JA | 2 |
| Wilson, HE | 1 |
| Talley, RW | 1 |
| Stephens, R | 1 |
| Lane, M | 1 |
| Gutterman, J | 2 |
| Coltman, C | 1 |
| Schultz, DR | 1 |
| Yunis, AA | 1 |
| Bar-Meir, S | 1 |
| Golan, A | 1 |
| Vries, A | 1 |
| Plesnicar, S | 1 |
| Sumi-Kriznik, T | 1 |
| Golouh, R | 1 |
| Barosi, G | 1 |
| Morandi, S | 1 |
| Ascari, E | 1 |
| Rambaud, JC | 1 |
| Seligmann, M | 1 |
| Adolphs, HD | 1 |
| Lindenfelser, R | 1 |
| Steffens, L | 1 |
| Rübben, H | 1 |
| Zelechowska, JA | 1 |
| Leszczyk, C | 1 |
| Madej, G | 1 |
| Pieńkowska, F | 1 |
| Nozdryn-Plotnicki, B | 1 |
| Maj, S | 1 |
| Leszko, B | 1 |
| Lewicka, T | 1 |
| Janowska-Wieczorek, A | 1 |
| Sobczyńska, Z | 1 |
| Pawelski, S | 1 |
| Roth, DG | 1 |
| Desser, RK | 1 |
| Miller, JB | 1 |
| Roth, Z | 1 |
| Trepel, F | 1 |
| Schick, P | 1 |
| Lattuada, A | 1 |
| Banfi, A | 1 |
| Samuels, BI | 1 |
| Culbert, SJ | 1 |
| Okamura, J | 1 |
| Viollier, AF | 1 |
| Senn, HJ | 2 |
| Kremer, WB | 1 |
| Bláha, M | 1 |
| Vanásek, J | 1 |
| Mazák, J | 1 |
| Matĕja, F | 1 |
| Jungi, WF | 1 |
| Simon, R | 1 |
| Pavlovsky, A | 1 |
| Palau, M | 1 |
| Barros, CA | 1 |
| Young, RD | 1 |
| Loeb, V | 1 |
| Dorfman, R | 1 |
| Chan, YK | 1 |
| Sahakian, GJ | 1 |
| Carcassonne, Y | 1 |
| Favre, R | 1 |
| Meyer, G | 1 |
| Serafino, X | 1 |
| Frizzera, G | 2 |
| Ihde, DC | 3 |
| Burchenal, JH | 2 |
| Lieberman, PH | 2 |
| D'Angio, GJ | 1 |
| Murphy, ML | 2 |
| Cohen, H | 1 |
| Schmidt, CE | 1 |
| Lucas, SR | 1 |
| Palmer, JL | 1 |
| D'Angio, G | 1 |
| Urba, WJ | 1 |
| Duffey, PL | 2 |
| Wittes, R | 1 |
| Guglielmi, C | 2 |
| Amadori, S | 2 |
| Martelli, M | 1 |
| Martin, JB | 1 |
| Riskind, PN | 1 |
| Sonqishe, M | 1 |
| Belbusti, F | 1 |
| Signoretti, P | 1 |
| Fabi, MT | 1 |
| Domenichini, M | 1 |
| Manresa, JM | 1 |
| Contreras, E | 1 |
| Caballol, R | 1 |
| Sirvent, JJ | 1 |
| Dearnaley, D | 1 |
| Horwich, A | 1 |
| Bloom, HJ | 1 |
| Solidoro, A | 1 |
| Payet, C | 1 |
| Sanchez-Lihon, J | 1 |
| Montalbetti, JA | 1 |
| Arai, N | 1 |
| Hara, A | 1 |
| Umeda, M | 1 |
| Shirai, T | 1 |
| Hsu, JR | 1 |
| Chang, SC | 1 |
| Perng, RP | 1 |
| Benito, C | 1 |
| Hernandez, JL | 1 |
| Sola, J | 1 |
| Albiach, M | 1 |
| Gonzalez, J | 1 |
| De Villa, V | 1 |
| Voltas, J | 1 |
| Arranz, R | 1 |
| Pérez, G | 1 |
| Steegmann, JL | 1 |
| Cámara, R | 1 |
| Tomás, JF | 1 |
| Figuera, A | 1 |
| Vazquez, L | 1 |
| Fernández-Rañada, JM | 1 |
| Schürmann, D | 1 |
| Dienemann, D | 1 |
| Jautzke, G | 1 |
| Cervos-Navarro, J | 1 |
| Langford, A | 1 |
| Stein, H | 1 |
| Pohle, HD | 1 |
| Ruf, B | 1 |
| Kashimura, M | 1 |
| Kusano, S | 1 |
| Hamasaki, K | 1 |
| Sato, Y | 1 |
| Schulman, P | 1 |
| Kerr, LD | 1 |
| Spiera, H | 1 |
| Dhabhar, BN | 1 |
| Malhotra, H | 1 |
| Hegde, U | 1 |
| Advani, SH | 1 |
| Emery, RW | 1 |
| Graif, JL | 1 |
| Hale, K | 1 |
| Eales, F | 1 |
| Von Rueden, TJ | 1 |
| Pritzker, MR | 1 |
| Love, K | 1 |
| Arom, KV | 1 |
| Mitrou, PS | 1 |
| Serke, M | 1 |
| Pohl, C | 1 |
| Becker, K | 1 |
| Schrappe-Bächer, M | 1 |
| Knauf, W | 1 |
| Westerhausen, M | 1 |
| Clemens, MR | 1 |
| Helm, EB | 1 |
| Fischer, T | 1 |
| Delaporte, E | 1 |
| Piette, F | 1 |
| Bergoend, H | 1 |
| Nemunaitis, J | 1 |
| Buckner, CD | 1 |
| Higano, CS | 1 |
| Mori, M | 1 |
| Bianco, J | 1 |
| Epstein, C | 1 |
| Lipani, J | 1 |
| Hansen, J | 1 |
| Kusumoto, S | 1 |
| Watanabe, K | 1 |
| Mulligan, SP | 1 |
| Matutes, E | 2 |
| Dearden, C | 1 |
| Catovsky, D | 2 |
| Li, XJ | 1 |
| Zhao, BL | 1 |
| Hou, JW | 1 |
| Xin, WJ | 1 |
| Xie, RF | 1 |
| Chen, YR | 1 |
| Atkin, SR | 1 |
| Pinto, PC | 1 |
| Hu, E | 1 |
| Bernstein-Singer, M | 1 |
| Pinter-Brown, L | 1 |
| Govindarajan, S | 1 |
| Mandell, L | 1 |
| Filippa, D | 1 |
| McGowan, N | 1 |
| Lieberman, P | 1 |
| Pescovitz, MD | 1 |
| Snover, DC | 1 |
| Orchard, P | 1 |
| Neglia, JP | 1 |
| Najarian, JS | 1 |
| Payne, WD | 1 |
| Kataoka, M | 1 |
| Kawamura, M | 1 |
| Itoh, H | 1 |
| Tsuda, T | 1 |
| Komatsu, A | 1 |
| Hamamoto, K | 1 |
| Gajl-Peczalska, K | 1 |
| Sibley, RK | 1 |
| Rosai, J | 1 |
| Cherwitz, D | 1 |
| Hurd, DD | 1 |
| Dłuzniewska, A | 1 |
| Depowska, T | 1 |
| González Brito, G | 1 |
| Marsá Vilá, L | 1 |
| Chávez, MI | 1 |
| Batista López, N | 1 |
| Hernández Nieto, L | 1 |
| Shirakawa, S | 1 |
| Tanaka, I | 1 |
| Kita, K | 1 |
| Lowenthal, RM | 1 |
| Jestrimski, KW | 1 |
| Vandenheule, B | 1 |
| Stryckmans, P | 1 |
| Extra, JM | 1 |
| Gentilhomme, O | 1 |
| Magaud, JP | 1 |
| Weisenburger, DD | 1 |
| Hutchins, M | 1 |
| Moravec, DF | 1 |
| Dowling, M | 1 |
| Sorensen, S | 1 |
| Mailliard, J | 1 |
| Okerbloom, J | 1 |
| Johnson, PS | 1 |
| Howe, D | 1 |
| Ibrahim, EM | 1 |
| Satti, MB | 1 |
| Al-Idrissi, HY | 1 |
| Abdel Satir, A | 1 |
| Al-Mohaya, SA | 1 |
| Al-Qourain, A | 1 |
| Al-Freihi, H | 1 |
| Abssod, GH | 1 |
| Jagannath, S | 1 |
| Tucker, SL | 1 |
| McLaughlin, PW | 1 |
| North, LB | 1 |
| Cabanillas, FC | 1 |
| Borden, EC | 1 |
| Hawkins, MJ | 1 |
| Schuurmans Stekhoven, JH | 1 |
| Langenhuysen, CA | 1 |
| Bakkeren, JA | 1 |
| Holland, R | 1 |
| Höller, I | 1 |
| De Vaan, GA | 1 |
| Schretlen, ED | 1 |
| Dutcher, JP | 1 |
| Gerhartz, HH | 1 |
| Hiller, E | 1 |
| Nerl, C | 1 |
| Wilmanns, W | 2 |
| Huhn, D | 1 |
| Vigliotti, A | 1 |
| Kong, JS | 1 |
| Lee, R | 1 |
| Hryniuk, WM | 1 |
| Kuki, K | 1 |
| Fukuda, Y | 1 |
| Maeda, S | 1 |
| Yamada, N | 1 |
| Asano, G | 1 |
| Masugi, Y | 1 |
| Oosono, E | 1 |
| Yoshikawa, A | 1 |
| Shimizu, K | 1 |
| Shoji, T | 1 |
| Lawlor, E | 1 |
| O'Briain, DS | 1 |
| Finn, T | 1 |
| Ward, R | 1 |
| Rogers, FM | 1 |
| O'Brien, AA | 1 |
| Daly, PA | 1 |
| Gill, PS | 1 |
| Krailo, M | 1 |
| Rarick, MU | 1 |
| Loureiro, C | 1 |
| Deyton, L | 1 |
| Meyer, P | 1 |
| Rasheed, S | 1 |
| Boyd, DB | 2 |
| Papish, SW | 1 |
| Topilow, A | 1 |
| Kopel, SK | 1 |
| Bernhardt, B | 1 |
| Files, JC | 1 |
| Schwartz, S | 1 |
| Gaynor, M | 1 |
| McDermott, D | 1 |
| el Saghir, NS | 1 |
| Jessen, K | 1 |
| Mass, RE | 1 |
| al-Mofleh, I | 1 |
| Santhosh-Kumar, CR | 1 |
| Hall, AD | 1 |
| Stuart, AE | 1 |
| Marks, DI | 1 |
| Sheridan, WP | 1 |
| Ellis, DW | 1 |
| Boyd, AW | 1 |
| Morstyn, G | 1 |
| Green, MD | 1 |
| Fox, RM | 1 |
| Vitolo, U | 1 |
| Bertoncelli, MC | 1 |
| Gallamini, A | 1 |
| Gallo, E | 1 |
| Gatti, AM | 1 |
| Ghio, R | 1 |
| Levis, A | 1 |
| Luxi, G | 1 |
| Johnston, C | 1 |
| Senekjian, EK | 1 |
| Ratain, MJ | 1 |
| Talerman, A | 1 |
| Asakura, H | 1 |
| Nakazono, M | 1 |
| Masuda, T | 1 |
| Yamamoto, T | 1 |
| Tazaki, H | 1 |
| Tomita, Y | 1 |
| Tagami, H | 1 |
| Kobayashi, R | 1 |
| Osada, T | 1 |
| Hamaguchi, M | 1 |
| Ohi, T | 1 |
| Inden, Y | 1 |
| Hara, K | 1 |
| Tomiyama, J | 1 |
| Kitayama, J | 1 |
| Tsukui, G | 1 |
| Kobori, O | 1 |
| Akiyoshi, T | 1 |
| Hisano, S | 1 |
| Kawara, T | 1 |
| Morioka, E | 1 |
| Ishibashi, M | 1 |
| Kyoshoin, K | 1 |
| Kikuchi, M | 2 |
| Okumura, M | 1 |
| Moulonguet, I | 1 |
| Perrin, P | 1 |
| Iskandar, MJ | 1 |
| Flageul, B | 1 |
| Verola, O | 1 |
| Maillet, M | 1 |
| Civatte, J | 1 |
| Longo, D | 1 |
| Háber, J | 1 |
| Hattori, T | 1 |
| Ishikawa, Y | 1 |
| Nishi, M | 1 |
| Nakadate, H | 1 |
| Hatae, Y | 1 |
| Takeda, T | 1 |
| Royer, P | 1 |
| Bagot, M | 1 |
| Wechsler, J | 1 |
| Roujeau, JC | 1 |
| Fraitag, S | 1 |
| Revuz, J | 1 |
| Takahashi, M | 1 |
| Mogi, Y | 1 |
| Goto, Y | 1 |
| Tsushima, N | 1 |
| Takahashi, Y | 1 |
| Fujikawa, K | 1 |
| Watanabe, N | 1 |
| Kohgo, Y | 1 |
| Sugiyama, S | 1 |
| Niitsu, Y | 1 |
| Smith, JL | 1 |
| Wilkinson, AH | 1 |
| Hunsicker, LG | 1 |
| Tobacman, J | 1 |
| Kapelanski, DP | 1 |
| Johnson, M | 1 |
| Wright, FH | 1 |
| Behrendt, DM | 1 |
| Corry, RJ | 1 |
| Wurtz, A | 1 |
| Chambon, JP | 1 |
| Fenaux, P | 1 |
| Bauters, F | 1 |
| Gosselin, B | 1 |
| Ohnoshi, T | 2 |
| Ueno, K | 1 |
| Tada, A | 1 |
| Murashima, M | 1 |
| Mizuta, J | 1 |
| Tagawa, S | 1 |
| Kimura, I | 2 |
| Raskin, RE | 1 |
| Tvedten, HW | 1 |
| Bull, RW | 1 |
| Crow, SE | 1 |
| Dunstan, RW | 1 |
| Krehbiel, JD | 1 |
| Lloyd, AR | 1 |
| Breit, SN | 1 |
| Rozenberg, MC | 1 |
| Furman, WL | 1 |
| Fitch, S | 1 |
| Callihan, T | 1 |
| Gilliom, M | 1 |
| Brummer, DG | 1 |
| Moise, NS | 1 |
| Jaffe, R | 1 |
| Demetris, AJ | 1 |
| Porter, K | 1 |
| Burnham, JA | 1 |
| Makowka, L | 1 |
| Locker, J | 1 |
| Dearden, CE | 1 |
| Ganeshaguru, K | 1 |
| Brozovic, M | 1 |
| Williams, HJ | 1 |
| Traub, N | 1 |
| Mills, M | 1 |
| Linch, DC | 1 |
| Love, RR | 1 |
| Leventhal, H | 1 |
| Easterling, DV | 1 |
| Nerenz, DR | 1 |
| Mooney, SC | 1 |
| Hayes, AA | 1 |
| MacEwen, EG | 1 |
| Matus, RE | 1 |
| Geary, A | 1 |
| Shurgot, BA | 1 |
| Sheldon, PJ | 1 |
| Coppeto, JR | 1 |
| Monteiro, ML | 1 |
| Cannarozzi, DB | 1 |
| Hainsworth, JD | 3 |
| Wolff, SN | 2 |
| Greer, JP | 2 |
| Cousar, JB | 1 |
| Greco, FA | 2 |
| Tungekar, MF | 1 |
| Wysenbeek, AJ | 1 |
| Leibovici, L | 1 |
| Mor, F | 1 |
| Atsmon, A | 1 |
| Jacobson, JO | 1 |
| Aisenberg, AC | 1 |
| Lamarre, L | 1 |
| Willett, CG | 1 |
| Linggood, RM | 1 |
| Miketic, LM | 1 |
| Kanda, H | 1 |
| Hachisuka, K | 1 |
| Yamaguchi, A | 1 |
| Isogai, M | 1 |
| Kato, J | 1 |
| Matsushita, M | 1 |
| Oda, T | 1 |
| Harakawa, I | 1 |
| Kuze, S | 1 |
| Mayumi, T | 1 |
| Tan, TB | 1 |
| Spaander, PJ | 1 |
| Blaisse, M | 1 |
| Gerritzen, FM | 1 |
| Vannier, JP | 1 |
| Patte, C | 1 |
| Philip, T | 1 |
| Zucker, JM | 1 |
| Gentet, JC | 1 |
| Lamagnière, JP | 1 |
| Pein, F | 1 |
| Rodary, C | 1 |
| Klimo, P | 2 |
| Fairey, RN | 1 |
| De Vita, VT | 2 |
| Radi, MJ | 1 |
| Foucar, E | 1 |
| Palmer, CH | 1 |
| Gooding, RA | 1 |
| Ota, K | 2 |
| Yunoki, K | 1 |
| Konda, S | 1 |
| Takatsuki, K | 1 |
| Tominaga, S | 2 |
| Tsugane, S | 1 |
| Minato, K | 2 |
| Borenstein, D | 1 |
| Costa, M | 1 |
| Jannotta, F | 1 |
| Rizzoli, H | 1 |
| Furukawa, Y | 1 |
| Takagi, S | 1 |
| Tsuboyama, A | 1 |
| Tsunoda, S | 1 |
| Komatsu, N | 1 |
| Takeda, K | 1 |
| Muroi, K | 1 |
| Ohsaka, A | 1 |
| Miwa, A | 1 |
| Yoshida, M | 1 |
| Harris, JC | 1 |
| Carel, CA | 1 |
| Rosenberg, LA | 1 |
| Joshi, P | 1 |
| Leventhal, BG | 1 |
| Bennett, CL | 1 |
| Putterman, A | 1 |
| Bitran, JD | 1 |
| Recant, W | 1 |
| Shapiro, CM | 1 |
| Karesh, J | 1 |
| Kalokhe, U | 1 |
| Oyama, A | 1 |
| Yumoto, Y | 1 |
| Morita, M | 1 |
| Ogushi, I | 1 |
| Koike, S | 1 |
| Takashima, S | 1 |
| Sato, G | 1 |
| Moriwaki, S | 1 |
| Reddy, S | 1 |
| Krishnamsetty, RM | 1 |
| Barcos, M | 1 |
| Nava, H | 1 |
| Tubiana, M | 2 |
| Masaoka, T | 1 |
| Namba, K | 1 |
| Shimada, Y | 1 |
| Nagai, M | 2 |
| Irino, S | 1 |
| Uda, H | 1 |
| Richardson, JL | 2 |
| Marks, G | 2 |
| Johnson, CA | 2 |
| Graham, JW | 1 |
| Chan, KK | 1 |
| Selser, JN | 2 |
| Kishbaugh, C | 2 |
| Barranday, Y | 1 |
| Chan, K | 1 |
| Graham, J | 1 |
| Shelton, DR | 1 |
| Kamholz, S | 1 |
| Sher, A | 1 |
| Barland, P | 1 |
| Rosen, N | 1 |
| Rakoff, S | 1 |
| Becker, N | 1 |
| Suganuma, Y | 1 |
| Ise, T | 1 |
| Akiyama, Y | 1 |
| Bessho, F | 1 |
| Fukazawa, K | 1 |
| Hirotsu, T | 1 |
| Kitamura, T | 1 |
| Koide, A | 1 |
| Matsuyama, K | 1 |
| Muchi, H | 1 |
| Bernstein, JI | 1 |
| Coleman, CN | 1 |
| Strickler, JG | 1 |
| Bunin, NJ | 1 |
| Hvizdala, E | 2 |
| Link, M | 1 |
| Wharam, M | 1 |
| Warnke, RA | 1 |
| Eridani, S | 2 |
| Singh, AK | 1 |
| Grosso, E | 1 |
| Geda, C | 1 |
| Ferrari, G | 1 |
| Hautekeete, ML | 1 |
| Berneman, ZN | 1 |
| Bieger, R | 1 |
| Stevens, WJ | 1 |
| Bridts, C | 1 |
| Buyssens, N | 1 |
| Peetermans, ME | 1 |
| Sweetenham, JW | 1 |
| Ewins, DL | 1 |
| Furlong, M | 1 |
| Lowes, JA | 1 |
| Shiu, MH | 1 |
| Pinna, A | 1 |
| Tome, M | 1 |
| Filippa, DA | 1 |
| Asada, E | 1 |
| Koide, M | 1 |
| Kobayashi, I | 1 |
| Hasegawa, G | 1 |
| Toner, GC | 1 |
| Sinclair, RA | 1 |
| Sutherland, RC | 1 |
| Schwarz, MA | 1 |
| Pereira, A | 1 |
| Montserrat, E | 1 |
| Cervantes, F | 1 |
| Rozman, C | 1 |
| Schreiber, DP | 1 |
| Jacobs, C | 1 |
| Cox, RS | 1 |
| Ozanne, F | 1 |
| Henry-Amar, M | 1 |
| Amiel, JL | 2 |
| Habrand, JL | 1 |
| Perri, RT | 1 |
| Allen, JI | 1 |
| Limas, C | 1 |
| Kay, NE | 1 |
| Melvin, F | 1 |
| Davis, TE | 1 |
| Acquatella, G | 1 |
| Urdaneta, N | 1 |
| Rosas Uribe, A | 1 |
| García Guevara, R | 1 |
| Economopoulos, T | 1 |
| Alexopoulos, C | 1 |
| Stathakis, N | 1 |
| Styloyannis, S | 1 |
| Dervenoulas, J | 1 |
| Tsousis, S | 1 |
| Raptis, S | 1 |
| Albada, J | 1 |
| Hordijk, GJ | 1 |
| van Unnik, JA | 1 |
| Dekker, AW | 1 |
| Bowen, DC | 1 |
| Grant, MC | 1 |
| Binsack, T | 1 |
| Sauer, H | 1 |
| Kondo, M | 1 |
| Ando, Y | 1 |
| Yamashita, S | 1 |
| Uematsu, M | 1 |
| Shigematsu, N | 1 |
| Nishiguchi, I | 1 |
| Hashimoto, S | 1 |
| Yoshida, T | 1 |
| Haraguchi, Y | 1 |
| Iwashita, T | 1 |
| Kodama, K | 1 |
| Nakatsu, T | 1 |
| Tanigawa, H | 1 |
| Katsuki, T | 1 |
| Kawakami, Y | 1 |
| Tabuchi, K | 1 |
| Ohnishi, R | 1 |
| Asari, S | 1 |
| Nishimoto, A | 1 |
| Pui, CH | 1 |
| Touboul, E | 1 |
| Ghenim, C | 1 |
| Chantelar, JV | 1 |
| Nizri, D | 1 |
| Zribi, A | 1 |
| Guerin, RA | 1 |
| Guilbert, F | 1 |
| Bertrand, JC | 1 |
| Szpirglas, H | 1 |
| Beral, HM | 1 |
| Dabich, L | 2 |
| Ensminger, WD | 1 |
| Nakajima, H | 1 |
| Miyamoto, H | 1 |
| Ben-Izhak, C | 1 |
| Shechter, Y | 1 |
| Tatarsky, I | 1 |
| Tura, S | 1 |
| Mazza, P | 1 |
| Lauria, F | 1 |
| Fiacchini, M | 1 |
| Pileri, S | 1 |
| Poletti, G | 1 |
| Gherlinzoni, F | 1 |
| Cantore, M | 1 |
| Bandini, G | 1 |
| Trepińska, E | 2 |
| Burchardt, K | 2 |
| Sokołowski, K | 1 |
| Boyett, J | 1 |
| Pullen, J | 1 |
| Crist, W | 1 |
| Doering, EJ | 1 |
| Trueworthy, R | 1 |
| Ruymann, F | 1 |
| Steuber, CP | 1 |
| Johnson, DH | 1 |
| Linde, R | 1 |
| Vale, W | 1 |
| Rivier, J | 1 |
| Stein, R | 1 |
| Flexner, J | 1 |
| Van Welch, R | 1 |
| Castro, CJ | 1 |
| Worth, A | 1 |
| Lindemalm, C | 1 |
| Mellstedt, H | 1 |
| Krueger, TC | 1 |
| Tallent, MB | 1 |
| Richie, RE | 1 |
| Johnson, HK | 1 |
| MacDonell, RC | 1 |
| Turner, B | 1 |
| Neumann, E | 1 |
| Aiginger, P | 1 |
| Schüller, J | 1 |
| Walcher, G | 1 |
| Radaszkiewicz, T | 1 |
| Sinn, E | 1 |
| Wirth, M | 1 |
| Song, SZ | 1 |
| Rusthoven, JJ | 1 |
| MacKenzie, R | 1 |
| Qiu, W | 1 |
| Rainey, M | 1 |
| Dandy, M | 1 |
| Silberman, H | 1 |
| Omura, G | 1 |
| Van Slyck, EJ | 1 |
| Balcerzak, SP | 1 |
| Costanzi, JJ | 1 |
| Eyre, HJ | 1 |
| Shelley, WB | 1 |
| Shelley, ED | 1 |
| Möller, TR | 1 |
| Loeffler, JS | 1 |
| Tarbell, NJ | 1 |
| Kozakewich, H | 1 |
| Cassady, JR | 1 |
| Weinstein, HJ | 1 |
| Cimino, G | 1 |
| Ruco, LP | 1 |
| Takenaka, T | 1 |
| Kitahara, T | 1 |
| Konda, C | 1 |
| Hansz, J | 1 |
| Komarnicki, M | 1 |
| Psuja, P | 1 |
| Berliner, S | 1 |
| Mor, C | 1 |
| Galili, N | 1 |
| Schneck, SA | 2 |
| Penn, I | 2 |
| Goldberg, AI | 1 |
| Glynn, JP | 1 |
| Kende, M | 1 |
| Mantel, N | 1 |
| Goldin, A | 2 |
| Rudders, RA | 1 |
| Tashima, CK | 1 |
| Bunting, WL | 1 |
| Sonnet, J | 1 |
| Hekster, C | 1 |
| Mathé, G | 1 |
| Schwarzenberg, L | 1 |
| Schneider, M | 1 |
| Cattan, A | 1 |
| Schlumberger, JR | 1 |
| Kiely, JM | 1 |
| Cline, MJ | 1 |
| Sisca, TS | 1 |
| Winkelmann, RK | 1 |
| Perry, HO | 1 |
| Muller, SA | 1 |
| Schroeter, AL | 1 |
| Jordon, RE | 1 |
| Rogers, RS | 1 |
| Druet, P | 1 |
| Dryll, A | 1 |
| Ryckewaert, A | 1 |
| de Sèze, S | 1 |
| Kahn, MF | 1 |
| Ching, LT | 1 |
| Burgert, EO | 1 |
| Mills, SD | 1 |
| Bergsagel, DE | 1 |
| Hoogstraten, B | 1 |
| Wiljasalo, M | 1 |
| Ikkala, E | 1 |
| Schabel, FM | 2 |
| Skipper, HE | 1 |
| Trader, MW | 1 |
| Laster, WR | 1 |
| Cheeks, JB | 1 |
| Adams, RA | 1 |
| Flowers, A | 1 |
| Sundeen, R | 1 |
| Merk, LP | 1 |
| Gold, E | 1 |
| Hamlin, JA | 1 |
| Kagan, AR | 1 |
| Friedman, NB | 1 |
| Walbom-Jorgensen, S | 1 |
| Lawhorn, TI | 1 |
| Stone, HH | 1 |
| Martin, JD | 1 |
| Fortuny, IE | 1 |
| Theologides, A | 2 |
| Kennedy, BJ | 2 |
| Rhodes, J | 1 |
| Trueblood, HW | 1 |
| Guernsey, JM | 1 |
| Cohn, R | 1 |
| Rubin, P | 1 |
| Novis, BH | 1 |
| Kahn, LB | 1 |
| Bank, S | 1 |
| Carter, SK | 1 |
| Schein, PJ | 1 |
| Aungst, CW | 1 |
| Knospe, WH | 1 |
| Fairley, GH | 2 |
| Freeman, JE | 1 |
| Mavligit, GM | 1 |
| Reed, RC | 1 |
| Hersh, EM | 1 |
| Savage, J | 1 |
| Black, MM | 1 |
| Sybesma, JP | 1 |
| Holtzer, JD | 1 |
| Borst-Eilers, E | 1 |
| Moes, M | 1 |
| Zegers, BJ | 1 |
| McCredie, KB | 1 |
| Squire, RA | 2 |
| Bush, M | 2 |
| Melby, EC | 1 |
| Neeley, LM | 1 |
| Yarbrough, B | 1 |
| Reich, NE | 1 |
| McCormack, LJ | 1 |
| Van Ordstrand, HS | 1 |
| Israel, HL | 1 |
| Jencks, JA | 1 |
| Binder, RA | 1 |
| McElwain, TJ | 1 |
| Esposito, R | 1 |
| Ponti, GB | 1 |
| Giangrande, A | 1 |
| Greally, JF | 1 |
| Hammond, W | 1 |
| Brettschneider, L | 1 |
| Goldfinger, D | 1 |
| McGinniss, MH | 1 |
| Lowe, DK | 1 |
| Fletcher, WS | 1 |
| Horowitz, IJ | 1 |
| Hyman, MD | 1 |
| Brincker, H | 1 |
| Kurnick, JE | 1 |
| Robinson, WA | 1 |
| Marks, L | 1 |
| Rzeszutko, Z | 1 |
| Zlotnick, A | 1 |
| Levy, M | 1 |
| Honetz, N | 1 |
| Brun, F | 1 |
| Galton, DA | 1 |
| Bollag, W | 1 |
| White, LP | 1 |
| Hall, TC | 1 |
| Choi, OS | 1 |
| Abadi, A | 1 |
| Krant, MJ | 1 |
| Todd, ID | 1 |
| Moe, PJ | 1 |
| Muggia, FM | 1 |
| Heinemann, HO | 1 |
| Rübesamen, M | 1 |
| Wessel, G | 1 |
| Bourgeois-Spinasse, J | 1 |
| Durepaire, RM | 1 |
| Grupper, MC | 1 |
| Ryan, SJ | 1 |
| Frank, RN | 1 |
| Green, WR | 1 |
| Hadida, E | 1 |
| Béranger, J | 1 |
| Sayag, J | 1 |
| Vallette, MP | 1 |
| Mach, J | 1 |
| Kaplan, D | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase 1/2 Study of Decitabine Alone and/or in Combination With Chemotherapy and/or Cytokine Induced Killer Cell Transfusion in Patients With Relapsed or Refractory Solid Tumors and B Cell Lymphomas[NCT01799083] | Phase 1/Phase 2 | 100 participants (Anticipated) | Interventional | 2012-12-31 | Recruiting | ||
| Addition of Decitabine to Carboplatin-Paclitaxel in First-Line Treatment of Advanced Ovarian Cancer: A Phase 2-3, Open-label, Randomised Controlled Trial[NCT02159820] | Phase 2/Phase 3 | 500 participants (Anticipated) | Interventional | 2014-06-30 | Recruiting | ||
| Randomized Phase II Study About the Application of Pegfilgrastim (Neulasta) at Day 2 or Day 4 Within the Treatment in Patients With Aggressive Non-Hodgkin's Lymphoma Aged 61 to 80 Years With 6 or 8 Cycles of Chemotherapy With CHOP (Cyclophosphamide, Doxor[NCT00726700] | Phase 2 | 109 participants (Actual) | Interventional | 2004-05-31 | Completed | ||
| Telomerase Activity Of CD34+ Cells - Marker For Mobilization Quality And Predictor For Engraftment After Autologous Hematopoietic Cell Transplantation[NCT01555359] | 50 participants (Anticipated) | Observational | 2012-02-29 | Recruiting | |||
| Safety and Efficacy of Ibritumomab Tiuxetan (Zevalin®) in Association With a Fludarabine Based Reduced Conditioning Regimen and Allogenic Stem Cell Support in Chemo-sensitive Relapsed CD20 Positive Aggressive Non-Hodgkin's Lymphoma Patients.[NCT00607854] | Phase 2 | 31 participants (Actual) | Interventional | 2008-02-29 | Completed | ||
| Phase II, Randomised, Multicentre Study With Two Treatment Arms (R-COMP Versus R-CHOP) in Newly Diagnosed Elderly Patients (≥60 Years) With Non-localised Diffuse Large B-cell Lymphoma (DLBCL)/Follicular Lymphoma Grade IIIb.[NCT02012088] | Phase 2 | 91 participants (Actual) | Interventional | 2013-10-11 | Active, not recruiting | ||
| Rituximab, Cyclophosphamide, Vincristine, and Prednisone in Combination With Doxorubicin (R-CHOP) Versus in Combination With Pegylated-liposomal Doxorubicin (R-CDOP) as First-line Treatment for Elderly Patients With Diffuse Large-B-cell Lymphoma: a Random[NCT02428751] | Phase 3 | 216 participants (Anticipated) | Interventional | 2015-09-30 | Recruiting | ||
| Chidamide Combined With Cyclophosphamide, Prednisone, Thalidomide in Treatment of Fragile Patients With Relapse/Refratory Peripheral T Cell Lymphoma :a Phase II, Single-arm, Open-label, Muti-center Study[NCT02879526] | Phase 2 | 45 participants (Anticipated) | Interventional | 2016-08-31 | Recruiting | ||
| A Phase II Study of MK 2206 in Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma[NCT01466868] | Phase 2 | 22 participants (Actual) | Interventional | 2011-11-30 | Terminated (stopped due to Regarding the comments of the iDSMB, the sponsor decided to stop the inclusions) | ||
| Phase II of Immunochemotherapy, in Vivo Purging, PBSC Mobilization and Autotransplant in Patients With Relapsed or Refractory Follicular Lymphoma[NCT00366275] | Phase 2 | 64 participants (Actual) | Interventional | 2002-01-31 | Completed | ||
| Evaluation of Efficacy and Hypothalamus-pituitary-adrenal Axis Suppression Due to a Single Intrabursal Injection of Corticosteroids in Patients With Shoulder Calcific Tendinopathy[NCT01652495] | Phase 4 | 44 participants (Actual) | Interventional | 2012-03-31 | Completed | ||
| Candidate Gene Polymorphisms and Response to Rituximab-CHOP in Patients With Diffuse Large Cell Lymphoma[NCT00590941] | 52 participants (Actual) | Interventional | 2005-02-28 | Completed | |||
| Phase II Trial Investigating Tailoring First-Line Therapy For Advanced Stage Diffuse Large B-Cell Non-Hodgkin's Lymphoma Based on Mid-Treatment Positron Emission Tomography (PET) Scan Results[NCT00324467] | Phase 2 | 150 participants (Actual) | Interventional | 2006-08-31 | Active, not recruiting | ||
| A Phase II Trial of Combined Weekly Bortezomib and Tositumomab I-131 in Patients With Relapsed or Refractory Follicular Non-Hodg[NCT00479167] | Phase 2 | 1 participants (Actual) | Interventional | 2007-05-31 | Terminated (stopped due to Lack of accrual and interest in study) | ||
| Evaluation of [123I] IMPY and SPECT as a Marker of Beta-amyloid Protein Deposition in the Brain of Healthy Subjects and Patients With Alzheimer Disease[NCT00287248] | Phase 1 | 38 participants (Actual) | Interventional | 2006-02-28 | Completed | ||
| Accelerating COVID-19 Clinical Recovery in the Outpatient Setting: Retrospective Data Collection and Analysis of COVID-19 Patients Treated With ClorNovir® (Chlorpheniramine Maleate (0.4% Nasal Spray)[NCT05520944] | 1,000 participants (Anticipated) | Observational | 2021-08-26 | Active, not recruiting | |||
| Comprehensive Outcomes for After Cancer Health (COACH): The Feasibility and Impact of an mHealth Augmented Coaching Program for Self-Management in Cancer Survivors[NCT05349227] | 660 participants (Anticipated) | Interventional | 2022-06-23 | Recruiting | |||
| Influence of Rivaroxaban 2.5 mg Two Times a Day for Intermittent Claudication and Exercise Tolerance in Patients With Symptomatic Peripheral Arterial Disease (PAD) - a Randomised Controlled Trial[NCT04305028] | 100 participants (Anticipated) | Observational | 2021-03-10 | Not yet recruiting | |||
| Immunogenicity and Safety of HBAI20 Hepatitis B Vaccine in Non-responders[NCT03415672] | Phase 2 | 133 participants (Actual) | Interventional | 2017-10-11 | Completed | ||
| Voriconazole vs. Amphotericin B in the Treatment of Invasive Aspergillosis[NCT00001646] | Phase 3 | 10 participants | Interventional | 1997-08-31 | Completed | ||
| Building Strength Through Rehabilitation for Heart Failure Patients[NCT03615469] | 15 participants (Actual) | Interventional | 2018-09-06 | Terminated (stopped due to Low recruitment numbers) | |||
| Impact of Treatment of Mild Sleep-Disordered Breathing on Children's Health[NCT02562040] | 459 participants (Actual) | Interventional | 2016-06-01 | Completed | |||
| EN20-01: A 24 Week Study to Evaluate the Safety and Efficacy of CNTX-6970 in Subjects With Moderate to Severe Knee Osteoarthritis Pain.[NCT05025787] | Phase 2 | 77 participants (Anticipated) | Interventional | 2021-10-25 | Recruiting | ||
| A Randomized Phase III Trial of Erlotinib Versus Docetaxel in Patients With Advanced Squamous Cell Non-small Cell Lung Cancer Who Failed First Line Platinum Based Doublet Chemotherapy Stratified by VeriStrat Good vs VeriStrat Poor[NCT01652469] | Phase 3 | 81 participants (Actual) | Interventional | 2012-08-31 | Completed | ||
| Healthy Weight and Stress Management Study[NCT05279989] | 25 participants (Actual) | Interventional | 2021-12-01 | Completed | |||
| Way to Quit - Comparative Efficacy, Acceptance and Effectiveness of Health Incentive Structures[NCT01526265] | 2,185 participants (Anticipated) | Interventional | 2012-02-29 | Completed | |||
| A Phase II Study of Lenalidomide, Ixazomib, Dexamethasone, and Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma[NCT04009109] | Phase 2 | 188 participants (Anticipated) | Interventional | 2020-10-21 | Recruiting | ||
| Randomized Phase III Clinical Trial of Weekly Versus Tri-weekly Cisplatin Based Chemoradiation in Locally Advanced Cervical Cancer[NCT01561586] | Phase 3 | 374 participants (Anticipated) | Interventional | 2012-03-31 | Recruiting | ||
| Comparison of Surgical Wound Healing and Complications Following Revision Hip and Knee Replacements, Utilising a 7-day Versus 14-day Negative Pressure Wound Therapy (NPWT) Dressing. A Randomised Controlled Trial.[NCT05389410] | 100 participants (Anticipated) | Interventional | 2022-09-30 | Not yet recruiting | |||
| OMEGA, A Randomized Trial of Local Ablative Therapy Vs. Conventional Treatment in Oligometastatic NSCLC[NCT03827577] | Phase 3 | 195 participants (Anticipated) | Interventional | 2019-10-01 | Recruiting | ||
| A Phase II Multi-Center Study of Bevacizumab in Combination With Ixabepilone in Subjects With Advanced Renal Cell Carcinoma[NCT00923130] | Phase 2 | 30 participants (Actual) | Interventional | 2009-01-07 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"PFS is calculated according to the Kaplan-Meier estimator. The observation time of each subject is defined as the time from entry into the study until lymphoma progression or death as a result of any cause whichever occurs first.~The 5-year PFS is the estimated cumulative probability of surviving at least 5 years without progression." (NCT00366275)
Timeframe: every 3 months for the first year after autotransplant and every 6 months after the first year of follow up
| Intervention | percent chance of PFS at 5 years (Number) |
|---|---|
| Immunochemotherapy, in Vivo Purging and Autotransplant | 59 |
"Patients will be evaluated clinically by Constant Score~Constant score: range 0 (total shoulder impairment) to 100 (non impaired shoulder). The score is obtained from two subjective (pain and relation between pain and daily-life activities) - and two objective physician-assessed (strength and range of motion) measurements~Reference: Constant CR and Murley AH. A clinical method of functional assessment of the shoulder. Clin Orthop Relat Res. 1987 Jan;(214):160-4." (NCT01652495)
Timeframe: 180 days after treatment
| Intervention | percentage of improvement Constant score (Mean) |
|---|---|
| Methylprednisolone Acetate Group | 99 |
| Triamcinolone Acetonide Group | 95 |
"Evaluation of blood cortisol and ACTH, free urinary cortisol, urinary levels of methylprednisolone or triamcinolone (depending on the administered drug) by RIA immunoassay and tandem mass assays~Persistent suppression of the HPA axis at the end of the follow up is based on the evidence of ACTH, plasmatic and urinary cortisol levels under reference values" (NCT01652495)
Timeframe: 45 days after treatment
| Intervention | % of patients with HPA suppression (Number) |
|---|---|
| Methylprednisolone Acetate Group | 0 |
| Triamcinolone Acetonide Group | 15 |
"VAS score~VAS score is a 10 -cm graduated scale with scores ranging from 0 (no pain) to 10 (unbearable pain) self- reported by patients~Reference: Langley GB and Sheppeard H. The visual analogue scale: its use in pain measurement. Rheumatol Int 1985;5(4):145-148." (NCT01652495)
Timeframe: 180 days after treatment
| Intervention | percentage of pain reduction (Mean) |
|---|---|
| Methylprednisolone Acetate Group | 82 |
| Triamcinolone Acetonide Group | 96 |
The 6-min walk test (6MWT) estimates the person's ability to perform everyday activities by measuring the distance walked in a set time period. It will be used to measure exercise capacity, specific aim 2. Participants will be allowed use of an assistive device and will be instructed to move as quickly as they feel safe and comfortable over the 100-meter course for 6 minutes. As per the protocol, participants will be allowed to stop and rest if necessary. This test is recommended by the American Thoracic Society for patients with moderate to severe heart or lung disease. (NCT03615469)
Timeframe: From Baseline to 5-6 months
| Intervention | meters walked (Mean) |
|---|---|
| Neuromusclar Electrical Stimulation | 324 |
| Transcutaneous Electrical Stimulation | 250.6 |
Defined as time from the date of randomization until death from any cause. (NCT01652469)
Timeframe: All patients will be followed for survival status every 12 weeks up to 24 months after the last patient is randomized
| Intervention | months (Median) |
|---|---|
| A: Erlotinib | 7.1 |
| B: Docetaxel | 7.1 |
"Time from the date of randomization until documented progression or death without documented progression.~Assessment of Progressive Disease (PD) based on Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) Target lesions:At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.(Note: the appearance of one or more new lesions is also considered progression).~Non-target lesions:Unequivocal progression of existing non-target lesions. (Note:the appearance of one or more new lesions is also considered progression). To achieve 'unequivocal progression', there must be an overall level of substantial worsening in non-target disease such that,even in presence of SD or PR in target disease, the overall tumour burden has increased sufficiently" (NCT01652469)
Timeframe: The combined run in period, treatment and follow-up for PFS is expected to extend the study duration to a total of 24 months.
| Intervention | months (Median) |
|---|---|
| A: Erlotinib | 1.6 |
| B: Docetaxel | 3.0 |
Adverse events classified according to NCI CTCAE version 4 (NCT01652469)
Timeframe: Same as primary outcome: 24 months
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| Experienced AE/SAE | No AE/SAE | Experienced SAE | |
| A: Erlotinib | 36 | 2 | 7 |
| B: Docetaxel | 39 | 2 | 19 |
Here is the number of participants with adverse events. For the detailed list of adverse events, see the adverse event module. Adverse events are assessed by the Common Terminology Criteria for Adverse Events (CTCAE) v4.0. (NCT00923130)
Timeframe: Date treatment consent signed to date off study, approximately 84 months and 25 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Bevacizumab With Ixabepilone | 30 |
Time between the first day of treatment and the day of death. (NCT00923130)
Timeframe: Time between the first day of treatment and the day of death, assessed up to approximately 7 years.
| Intervention | months (Median) |
|---|---|
| Bevacizumab With Ixabepilone | 15.0 |
The time between the first day of treatment to the day of disease progression. Progression is defined by the Response Evaluation Criteria in Solid Tumors (RECIST). Progression is at least a 20% increase in the sum of the longest diameter (LD) of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions. (NCT00923130)
Timeframe: up to 44 months
| Intervention | months (Median) |
|---|---|
| Bevacizumab With Ixabepilone | 8.3 |
Response (complete response (CR) and partial response (PR)) was measured by the RECIST. Complete response is the disappearance of all target lesions. Partial response is at least a 30% decrease in the sum of the longest diameter (LD) of target lesions taking as reference the baseline sum LD. (NCT00923130)
Timeframe: Two Years
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Complete Response | Partial Response | |
| Bevacizumab With Ixabepilone | 0 | 3 |
95 reviews available for prednisone and Lymphoma
| Article | Year |
|---|---|
The physical exam's role in determining dose-limiting toxicity prior to immunochemotherapy administration in lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; COVID-19; Cyclophosphamide; Doxorubicin; Huma | 2023 |
Patient characteristics and outcome of CD20-positive HIV-associated lymphoma: a single-center KwaZulu-Natal, South African hospital 12-year retrospective review.
Topics: Adult; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclo | 2022 |
The use of frailty assessments in treating older adults with aggressive lymphomas.
Topics: Age Factors; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemo | 2021 |
Indolent Lymphomas That Present With Clinically Aggressive Features: A Subset of Low-Grade Lymphomas With a Behavior Inconsistent With the Histologic Diagnosis.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Biomar | 2016 |
Aidi injection combined with CHOP chemotherapy regimen in the treatment of malignant lymphoma: A meta-analysis based on randomized controlled trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Drugs, Chinese Herbal | 2016 |
[Antibody therapy in hematology and oncology - part 1].
Topics: Aged; Alemtuzumab; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, M | 2008 |
Lymphoma: which chemotherapy protocol and why?
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dog Diseases; Dogs; Doxor | 2009 |
Myasthenia gravis, an autoimmune manifestation of lymphoma and lymphoproliferative disorders: case reports and review of literature.
Topics: 2-Chloroadenosine; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Prot | 2012 |
Lymphoma study group of JCOG.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemother | 2012 |
Therapeutic strategies in elderly and very elderly patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; C | 2012 |
EBV-associated lymphomas in adults.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Epstein-Barr V | 2012 |
Positron emission tomographic scans in lymphoma: convention and controversy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cyclophosphamide; Doxorubi | 2012 |
Focus on lymphomas.
Topics: Alemtuzumab; Anti-Bacterial Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antib | 2002 |
[THERAPY OF HEMOLYMPHOPATHIES WITH PREDNISONE AT HIGH DOSES].
Topics: Hodgkin Disease; Humans; Leukemia; Leukemia, Myeloid; Liver; Lymphoma; Lymphoma, Large B-Cell, Diffu | 1964 |
[Lymphoproliferative lesions of the ocular adnexa. Differential diagnostic guidelines].
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Child; Cli | 2004 |
New treatment strategies in lymphomas: aggressive lymphomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cyclophosphamide; Disease- | 2004 |
[Monoclonal antibody treatment of malignant lymphoma].
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Muri | 2004 |
Clinicopathologic features of six cases of primary cervical lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; | 2005 |
[Gastric lyphoma - still a result of surgery?].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplasti | 2006 |
Treatment of non-Hodgkin's lymphoma: a look over the past decade.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplasti | 2006 |
Anaplastic thyroid cancer and primary thyroid lymphoma: a review of these rare thyroid malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Combined Modality Therapy; C | 2006 |
[Treatment of aggressive lymphomas].
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclo | 2007 |
[Immunotherapy with monoclonal antibody of malignant lymphoma].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy | 2007 |
Obstructive jaundice caused by primary duodenal lymphoma. Case report and review of the literature.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2007 |
Primary colorectal lymphomas: review of the literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colectomy; Colorectal Neopla | 2007 |
Advances in adult non-Hodgkin's lymphoma. Current concepts of classification, diagnosis, and management.
Topics: Adult; Bleomycin; Cyclophosphamide; Dexamethasone; Doxorubicin; Drug Therapy, Combination; Humans; L | 1980 |
[Therapy of non-Hodgkin's lymphoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Chlorambucil; Cyclophosphamide; Doxorubic | 1984 |
Non-Hodgkin's lymphomas.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin | 1984 |
The hematologic malignancies. Leukemia, lymphoma, and myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cyclophosphamide; Doxor | 1984 |
"Good risk" non-Hodgkin lymphomas: approaches to management.
Topics: Actuarial Analysis; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophos | 1983 |
Non-Hodgkin's lymphoma occurring after Hodgkin's disease. Four new cases and a review of the literature.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; | 1984 |
Cyclosporine: a new immunosuppressive agent for organ transplantation.
Topics: Animals; Azathioprine; Bone Marrow Transplantation; Chemical and Drug Induced Liver Injury; Cyclospo | 1984 |
Hormones in cancer therapy.
Topics: Adrenal Cortex Hormones; Animals; Cats; Dog Diseases; Dogs; Drug Therapy, Combination; Female; Gonad | 1982 |
[Malignant lymphoma].
Topics: Adolescent; Adult; Antineoplastic Agents; Cyclophosphamide; Drug Therapy, Combination; Hodgkin Disea | 1981 |
[Present status and future problems in non-Hodgkin's lymphoma. III. On the chemotherapy of non-Hodgkin's lymphoma (author's transl)].
Topics: Antineoplastic Agents; Cyclophosphamide; Drug Administration Schedule; Humans; Lymphoma; Prednisone; | 1981 |
[High dose chemotherapy followed by hematopoietic stem cell transplantation for malignant lymphoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Combined Modality Therapy; Cyt | 1995 |
Fourteen years of high-dose CHOP (ACVB regimen): preliminary conclusions about the treatment of aggressive-lymphoma patients. Hamilton Fairley Award Lecture, European Society for Medical Oncology Meeting, Lisbon, November 21, 1994.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Protocols; Clinical Trials as Topic; Cyclop | 1995 |
What treatment for elderly patients with aggressive lymphoma?
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Hu | 1994 |
Lymphoma in the older patient.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Humans; | 1995 |
[Recent progress in the chemotherapy of malignant lymphoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Cyclophosphamid | 1995 |
[Primary testicular lymphoma. A report of 3 cases].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cyclophosphamide; Doxo | 1994 |
Primary tracheal non-Hodgkin's lymphoma. A case report and review of the literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asthma; Bronchoscopy; Combined Modality Therapy; Cyc | 1996 |
Paraneoplastic pemphigus.
Topics: Adult; Anti-Inflammatory Agents; Autoantigens; Autoimmune Diseases; Autoimmunity; Cell Adhesion Mole | 1997 |
Malignant lymphomas in the elderly.
Topics: Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplas | 1997 |
Chemotherapy: the more, the better in malignant lymphoma?
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Cyclophosphamid | 1997 |
[Treatment of lymphoma in the aged].
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubi | 1998 |
Can we cure indolent lymphomas?
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Clinical Protocols; Clinical Trials as To | 1997 |
[Clinical features of extranodal malignant lymphoma--staging classification and treatment strategies].
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Combined Modality Therapy; | 1999 |
[Treatment of malignant lymphoma with extranodal lesions--indications and timing for local therapies].
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Doxorub | 1999 |
Blastic natural killer cell leukemia/lymphoma presenting as overt leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antigens, CD; Antineoplastic Combined Chemotherapy Proto | 2001 |
[Chemo-radiotherapy for malignant brain tumors].
Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Central Nervous System | 2002 |
Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Topics: Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carboplatin | 2002 |
The place of radiation therapy in the treatment of non-Hodgkin's lymphomas.
Topics: Bleomycin; Cyclophosphamide; Cytarabine; Doxorubicin; Drug Therapy, Combination; Female; Humans; Lym | 1977 |
Chemotherapy of non-Hodgkin's lymphomas: Eastern Cooperative Oncology Group experience.
Topics: Altretamine; Bleomycin; Carmustine; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Drug Ad | 1977 |
Overview of four clinical studies of chemotherapy for stage III and IV non-Hodgkin's lymphomas by the Cancer and Leukemia Group B.
Topics: Adult; Bleomycin; Clinical Trials as Topic; Cyclophosphamide; Drug Administration Schedule; Drug The | 1977 |
The action of antitumor agents: a double-edged sword?
Topics: Alkylating Agents; Animals; Antineoplastic Agents; Azathioprine; Burkitt Lymphoma; Choriocarcinoma; | 1977 |
Chemotherapy of non-Hodgkin lymphoma: the diffuse types.
Topics: Antineoplastic Agents; Central Nervous System Diseases; Cyclophosphamide; Cytarabine; Drug Therapy, | 1978 |
[Chemotherapy of malignant lymphomas].
Topics: Cyclophosphamide; Drug Therapy, Combination; Hodgkin Disease; Humans; Leukopenia; Lymphoma; Neoplasm | 1978 |
Approaches to the treatment of acute leukemia and lymphoma in adults.
Topics: Acute Disease; Adult; Animals; BCG Vaccine; Child; Cyclophosphamide; Cytarabine; Daunorubicin; Doxor | 1978 |
[Chemotherapy of malignant lymphomas].
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Cyclophosphamide; Drug Combinations; Hodgkin Dis | 1978 |
Radiation therapy in lymphomatoid granulomatosis.
Topics: Cyclophosphamide; Female; Granuloma; Granulomatosis with Polyangiitis; Humans; Lymphoma; Lymphoproli | 1978 |
Human models of human diseases; breast cancer and the lymphomas.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Disease Models, Animal; Drug Therapy, Combination; | 1979 |
Alpha-chain disease.
Topics: Anti-Bacterial Agents; Cell Transformation, Neoplastic; Cyclophosphamide; Heavy Chain Disease; Human | 1976 |
Neutrophil migration in health and disease.
Topics: Adult; Age Factors; Anemia, Aplastic; Antigens, Bacterial; Cell Movement; Child; Dexamethasone; Eosi | 1975 |
Current status of treatment of lymphomas.
Topics: Adrenal Cortex Hormones; Antineoplastic Agents; Chlorambucil; Cyclophosphamide; Drug Therapy, Combin | 1975 |
Recent National Cancer Institute lymphoma trials of etoposide-containing combination chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Clinical Trials as Topic; Cyclophosphamid | 1992 |
Advances in lymphoma treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Forecasting; Humans; Im | 1992 |
Primary malignant lymphoma of the endometrium: report of a case and review of the literatures.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Humans | 1991 |
[Pemphigus vulgaris induced by radiotherapy].
Topics: Autoantibodies; Humans; Lymphoma; Male; Middle Aged; Pemphigus; Prednisone; Radiotherapy | 1991 |
Canine lymphoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Cyclophosphamide; Cytarabin | 1985 |
Corticosteroid drugs: their role in oncological practice.
Topics: Adrenal Cortex Hormones; Animals; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Breast | 1986 |
[Non-Hodgkin's lymphomas: recent achievements and therapeutic perspectives].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Cytarabine; Dexamethaso | 1985 |
Chemotherapy of malignant lymphomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Dacarbazine; Doxorubicin; Drug Resistance | 1985 |
[Drug therapy of malignant lymphoma].
Topics: Alkylating Agents; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bleo | 1985 |
Biologic response modifiers as adjuncts to other therapeutic modalities.
Topics: Adjuvants, Immunologic; Animals; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Breast | 1986 |
Treatment of advanced Hodgkin's disease.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Clinical Trials as Top | 1989 |
[Large B cell lymphoma of the mediastinum. 6 cases].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Cyclophosphamide; Doxorubicin; | 1989 |
[Cancer curable by chemotherapy: malignant lymphoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cyclophosphamide; Hodgk | 1989 |
[Current status of chemotherapy in the treatment of malignant lymphomas].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; | 1989 |
The chemotherapy of lymphomas: looking back, moving forward--the Richard and Hinda Rosenthal Foundation award lecture.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Hodgkin Disease; Humans; Lymphoma; Mechlore | 1987 |
Prognostic factors in non-Hodgkin's lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Combined Modality Therapy; | 1986 |
[Advances in the chemotherapy of non-Hodgkin's lymphoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Combined Modality The | 1985 |
Early-stage Hodgkin's disease: current approaches to treatment.
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Fem | 1985 |
Adrenal steroids in the treatment of malignant hematologic disease.
Topics: Adrenal Cortex Hormones; Anemia, Hemolytic; Antineoplastic Agents; Glucocorticoids; Hodgkin Disease; | 1973 |
An assessment of massive-dose chemotherapy of malignant disease.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Bone Marrow; Bone Marrow Cells; Cell Division; Cyclo | 1971 |
Steroid therapy of multiple myeloma and macroglobulinemia.
Topics: Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Anemia; Anemia, Hemolytic, Autoimmune; Blood U | 1973 |
Chemotherapy in solid tumors of childhood.
Topics: Abdominal Neoplasms; Adolescent; Child; Child, Preschool; Cyclophosphamide; Dactinomycin; Eye Neopla | 1972 |
Hodgkin's disease and non-Hodgkin's lymphoma--the surgeon's role in therapy.
Topics: Adolescent; Adult; Alkylating Agents; Child; Female; Hodgkin Disease; Humans; Laparotomy; Lymphoma; | 1972 |
Non-Hodgkin's lymphoma: recent observations on natural history and intensive treatment.
Topics: Antineoplastic Agents; Burkitt Lymphoma; Cyclophosphamide; Follow-Up Studies; Humans; Lymphoma; Lymp | 1972 |
Combination chemotherapy for lymphomas and leukemias.
Topics: Adult; Burkitt Lymphoma; Child; Cyclophosphamide; Cytarabine; Daunorubicin; Drug Combinations; Hodgk | 1973 |
An overview of the status of the nitrosoureas in other tumors.
Topics: Adenocarcinoma; Alkylating Agents; Antineoplastic Agents; Breast Neoplasms; Carcinoma; Carcinoma, Br | 1973 |
Proceedings: Malignant lymphoma: treatment with combination chemotherapy.
Topics: Adolescent; Adult; Aged; Alkylating Agents; Antineoplastic Agents; Carmustine; Cyclophosphamide; Dru | 1972 |
Malignant lymphoma. 2. Therapy.
Topics: Cyclophosphamide; Cytarabine; Drug Therapy, Combination; Hodgkin Disease; Humans; Lymphoma; Nitrogen | 1974 |
Immunochemotherapy of human cancer.
Topics: Acute Disease; Adjuvants, Immunologic; Adult; Animals; Antineoplastic Agents; BCG Vaccine; Cytarabin | 1974 |
Combination chemotherapy in malignant diseases.
Topics: Adult; Antineoplastic Agents; Asparaginase; Carmustine; Child; Cyclophosphamide; Cytarabine; Cytosin | 1971 |
118 trials available for prednisone and Lymphoma
| Article | Year |
|---|---|
Construction and validation of a scoring system to predict resistance to chemotherapeutic drugs using gene expression profiles in canine lymphoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Cyclophosphamide; Dog Disea | 2021 |
Efficacy of prophylactic irradiation to the contralateral testis for patients with advanced-stage primary testicular lymphoma: an analysis of outcomes at a single institution.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chem | 2017 |
Low-dose decitabine-based chemoimmunotherapy for patients with refractory advanced solid tumors: a phase I/II report.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2014 |
Low-dose decitabine-based chemoimmunotherapy for patients with refractory advanced solid tumors: a phase I/II report.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2014 |
Low-dose decitabine-based chemoimmunotherapy for patients with refractory advanced solid tumors: a phase I/II report.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2014 |
Low-dose decitabine-based chemoimmunotherapy for patients with refractory advanced solid tumors: a phase I/II report.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2014 |
Chemotherapy-induced neutropenia is associated with prolonged remission duration and survival time in canine lymphoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dog Diseases; Dogs; Doxor | 2015 |
Plerixafor in combination with granulocyte-colony-stimulating factor after chemotherapy increases mobilization efficiency in patients with lymphoma or myeloma: results of a Phase II clinical trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Autografts; Benzylamines; Cyclams; Cycl | 2015 |
Comparison of efficacy and toxicity of doxorubicin and mitoxantrone in combination chemotherapy for canine lymphoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dog Diseases; Dogs; Doxor | 2016 |
Outcomes of MYC-associated lymphomas after R-CHOP with and without consolidative autologous stem cell transplant: subset analysis of randomized trial intergroup SWOG S9704.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherap | 2016 |
NCRI phase II study of CHOP in combination with ofatumumab in induction and maintenance in newly diagnosed Richter syndrome.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2016 |
A randomized controlled trial of the effect of prednisone omission from a multidrug chemotherapy protocol on treatment outcome in dogs with peripheral nodal lymphomas.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Dog Diseases; Dogs; Female; Lymphoma; Male; | 2016 |
Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 Study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Anti | 2009 |
A phase I trial of UCN-01 and prednisone in patients with refractory solid tumors and lymphomas.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Drug Resistance | 2010 |
Evaluation of a multidrug chemotherapy protocol with mitoxantrone based maintenance (CHOP-MA) for the treatment of canine lymphoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Cyclophosphamide; Dog Disease | 2010 |
Doxorubicin and cyclophosphamide for the treatment of canine lymphoma: a randomized, placebo-controlled study.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Horm | 2010 |
Comparison between L-CHOP and an L-CHOP protocol with interposed treatments of CCNU and MOPP (L-CHOP-CCNU-MOPP) for lymphoma in dogs.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Asparagine; Cyclophosphamide; Dog Diseases; | 2010 |
Randomized comparison of pegfilgrastim day 4 versus day 2 for the prevention of chemotherapy-induced leukocytopenia.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dose-Resp | 2011 |
CHOP is superior to CNOP in elderly patients with aggressive lymphoma while outcome is unaffected by filgrastim treatment: results of a Nordic Lymphoma Group randomized trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Doxor | 2003 |
Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclop | 2004 |
Long-term results of dose density therapy in patients with aggressive lymphoma.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Cause of Death; Cyclophosphamide; | 2005 |
Treatment results in localized primary gastric lymphoma: data of patients registered within the German multicenter study (GIT NHL 02/96).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Th | 2005 |
Primary breast lymphoma: results of a controlled clinical trial.
Topics: Actuarial Analysis; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; C | 2005 |
Four versus six courses of a dose-escalated cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen plus etoposide (megaCHOEP) and autologous stem cell transplantation: early dose intensity is crucial in treating younger patients with po
Topics: Adult; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cy | 2006 |
Evaluation of tumor FDG transport and metabolism in primary central nervous system lymphoma using [18F]fluorodeoxyglucose (FDG) positron emission tomography (PET) kinetic analysis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biological Transport, Active; Brain Neoplasms; | 2005 |
CHOP alone compared with CHOP plus radiotherapy for localized aggressive lymphoma in elderly patients: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubic | 2007 |
A 5-drug regimen maximizing the dose of cyclophosphamide is effective therapy for adult Burkitt or Burkitt-like lymphomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Cyclophosphamide; Dox | 2007 |
Salvage therapy and late neurotoxicity in patients with recurrent primary CNS lymphoma treated with a modified ProMACE-MOPP hybrid regimen.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Combi | 2007 |
Liposome-encapsulated doxorubicin in combination with cyclophosphamide, vincristine, prednisone and rituximab in patients with lymphoma and concurrent cardiac diseases or pre-treated with anthracyclines.
Topics: Aged; Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic | 2007 |
Liposome-encapsulated doxorubicin in combination with cyclophosphamide, vincristine, prednisone and rituximab in patients with lymphoma and concurrent cardiac diseases or pre-treated with anthracyclines.
Topics: Aged; Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic | 2007 |
Liposome-encapsulated doxorubicin in combination with cyclophosphamide, vincristine, prednisone and rituximab in patients with lymphoma and concurrent cardiac diseases or pre-treated with anthracyclines.
Topics: Aged; Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic | 2007 |
Liposome-encapsulated doxorubicin in combination with cyclophosphamide, vincristine, prednisone and rituximab in patients with lymphoma and concurrent cardiac diseases or pre-treated with anthracyclines.
Topics: Aged; Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic | 2007 |
Prednisone, etoposide, procarbazine, and cyclophosphamide (PEP-C) oral combination chemotherapy regimen for recurring/refractory lymphoma: low-dose metronomic, multidrug therapy.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dose-Respons | 2008 |
EBV-positive immunodeficiency lymphoma after alemtuzumab-CHOP therapy for peripheral T-cell lymphoma.
Topics: Adult; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; | 2008 |
Improved complete remission rates and survival for patients with large cell lymphoma treated with chemoimmunotherapy. A Southwest Oncology Group Study.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Bleomycin; Clini | 1983 |
Long-term results of patients with advanced diffuse, non-Hodgkin's lymphoma treated with cyclophosphamide, doxorubicin, vincristine, prednisone and bleomycin (CHOP-Bleo).
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Clini | 1983 |
A comparative study with COP and COP-Bleo combination chemotherapy in advanced (non-Hodgkin's) lymphomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleo | 1983 |
Stages IE and IIE non-Hodgkin's lymphomas of the stomach. Comparison of treatment modalities.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bleomycin; Clinical Trials as T | 1984 |
Childhood non-Hodgkin's lymphoma. The results of a randomized therapeutic trial comparing a 4-drug regimen (COMP) with a 10-drug regimen (LSA2-L2).
Topics: Adolescent; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; | 1983 |
Report on the EORTC lymphoma trial 20751.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials | 1983 |
A randomized clinical trial of cyclosporine in cadaveric renal transplantation.
Topics: Blood Urea Nitrogen; Cadaver; Clinical Trials as Topic; Creatinine; Cyclosporins; Graft Survival; Hu | 1983 |
CCNU in combination chemotherapy for advanced histologically unfavorable non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; C | 1983 |
The treatment of localized non-Hodgkin's lymphoma in children: a report from the Children's Cancer Study Group.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Clinical Trials | 1984 |
Combined radiotherapy-chemotherapy for early stages non-Hodgkin's lymphoma: the 1975-1980 EORTC controlled lymphoma trial.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Combine | 1984 |
A randomized study of radiotherapy versus radiotherapy plus chemotherapy in stage I-II non-Hodgkin's lymphomas.
Topics: Antineoplastic Agents; Cyclophosphamide; Drug Administration Schedule; Drug Therapy, Combination; Hu | 1983 |
NHL-3 protocol. Six-drug combination chemotherapy for non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophospha | 1984 |
Cis-dichlorodiammineplatinum (II), VP 16-213, and prednisone (DVP regimen) in the treatment of pretreated advanced malignant lymphomas.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clini | 1982 |
A prospective randomized study of adjuvant parenteral nutrition in the treatment of diffuse lymphoma: effect on drug tolerance.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin | 1981 |
Comparative trial of two teniposide-based combination chemotherapy regimens for the treatment of advanced malignant lymphomas.
Topics: Adult; Altretamine; Cisplatin; Clinical Trials as Topic; Drug Therapy, Combination; Female; Hematopo | 1982 |
A new therapy schedule for pediatric non-Hodgkin lymphoma toxicity with preliminary results.
Topics: Adolescent; Antineoplastic Agents; Child; Child, Preschool; Clinical Trials as Topic; Cyclophosphami | 1980 |
Sixteen months experience with cyclosporin-A in human kidney transplantation.
Topics: Clinical Trials as Topic; Cyclosporins; Dose-Response Relationship, Drug; Graft Rejection; Hirsutism | 1981 |
Chemotherapy in the management of stage III/IV grade 1 non-Hodgkin's lymphomas (Report no 17).
Topics: Chlorambucil; Clinical Trials as Topic; Cyclophosphamide; Drug Therapy, Combination; Female; Humans; | 1981 |
Nodular mixed lymphoma: results of a randomized trial failing to confirm prolonged disease-free survival with COPP chemotherapy.
Topics: Adult; Aged; Carmustine; Clinical Trials as Topic; Cyclophosphamide; Dose-Response Relationship, Dru | 1981 |
A prospective comparison of combination chemotherapy with total body irradiation in the treatment of advanced non-Hodgkin's lymphoma. British National Lymphoma Investigation Report.
Topics: Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; Female; Humans; Lymphoma; Male; Neoplasm S | 1981 |
Combination chemotherapy with cyclophosphamide, vincristine, prednisone and the contribution of adriamycin in the treatment of adult non-Hodgkin's lymphomas a report of 131 cases.
Topics: Adolescent; Adult; Aged; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Drug Administratio | 1982 |
The treatment of advanced stage favorable histology non-Hodgkin's lymphoma: a preliminary report of a randomized trial comparing single agent chemotherapy, combination chemotherapy, and whole body irradiation.
Topics: Aged; Bone Marrow; Cyclophosphamide; Drug Therapy, Combination; Female; Humans; Leukopenia; Lymphoma | 1981 |
The management of generalised grade 2 non-Hodgkin's lymphomas (Report no 18).
Topics: Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; Humans; Lymphoma; Prednisone; Prospective | 1981 |
Combined therapy for angioimmunoproliferative lesions.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality Therapy; Cyclophosphami | 1994 |
Expression of mdr-1 in refractory lymphoma: quantitation by polymerase chain reaction and validation of the assay.
Topics: Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Membe | 1995 |
Phase I and pharmacokinetic study of the multidrug resistance modulator dexverapamil with EPOCH chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cross-Over Studies; Cyclophosphamide; D | 1995 |
Controlled trial of dexverapamil, a modulator of multidrug resistance, in lymphomas refractory to EPOCH chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfa | 1995 |
Therapeutic strategies in intermediate grade lymphomas in elderly patients. The Italian Multiregional non Hodgkin's Lymphoma Study Group (IMRNHLSG).
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Epir | 1993 |
A phase II trial of oral etoposide with mitoxantrone and ifosfamide/mesna consolidated with intravenous etoposide, methylprednisolone, high-dose arabinoside, and cisplatin as salvage therapy for relapsing and/or refractory lymphomas.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplati | 1994 |
A randomized comparative study of cyclophosphamide, vincristine, doxorubicin, and prednisolone and cyclophosphamide, vincristine, mitoxantrone, and prednisolone regimens in the treatment of intermediate- and high-grade lymphoma with 8 years' follow-up.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Humans; Lymphoma; Mit | 1994 |
The role of radiation therapy in the treatment of acute lymphoblastic leukemia with lymphomatous presentation: a report from the Childrens Cancer Group.
Topics: Actuarial Analysis; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Brain Neoplasms; C | 1993 |
Tacrolimus in pancreas transplantation: a multicenter analysis. Tacrolimus Pancreas Transplant Study Group.
Topics: Adult; Anti-Inflammatory Agents; Azathioprine; Bone Marrow Transplantation; Case-Control Studies; Cy | 1997 |
Short intensive primary chemotherapy and radiotherapy in sporadic primary CNS lymphoma (PCL).
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Brain Neoplasms; | 1998 |
[Primary malignant lymphoma in the central nervous system treated with high dose methotrexate (MTX)-CHOP (M-CHOP)].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cyclophosphamide; Doxo | 1998 |
Granisetron plus or minus alprazolam for emesis prevention in chemotherapy of lymphomas: a randomized multicenter trial. Granisetron Trialists Group.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alprazolam; Anti-Anxiety Agents; Antiemetics; Antineopla | 1999 |
Randomized comparison of ACVBP and m-BACOD in the treatment of patients with low-risk aggressive lymphoma: the LNH87-1 study. Groupe d'Etudes des Lymphomes de l'Adulte.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Dexa | 2000 |
Primary lymphoma of bone: a prospective study of 28 cases.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Neoplasms; | 2000 |
[Clinical usefulness of ondansetron hydrochloride for nausea and vomiting during repeated courses of chemotherapy for malignant lymphoma--impact of prognosis announcement on anti-emetic effect and evaluation of patient perception of chemotherapy-associate
Topics: Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxo | 2002 |
Shortened first-line high-dose chemotherapy for patients with poor-prognosis aggressive lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Blood Cells; Cyclophos | 2002 |
Clinical trials with BCNU (NSC-409962) in malignant lymphomas by the Eastern Cooperative Oncology Group.
Topics: Bleomycin; Carmustine; Chlorambucil; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Drug T | 1976 |
Combined therapy with bleomycin and some immunological implications.
Topics: Adolescent; Adult; Bleomycin; Cell Division; Clinical Trials as Topic; Drug Administration Schedule; | 1976 |
Combination chemotherapy in non-Hodgkin's lymphoma: results of long-term followup.
Topics: Adolescent; Adult; Aged; Bleomycin; Child; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; | 1977 |
Chemotherapy of non-Hodgkin's lymphoma: 10 years' experience in the Southwest Oncology Group.
Topics: Bleomycin; Clinical Trials as Topic; Cyclophosphamide; Cytarabine; Doxorubicin; Drug Administration | 1977 |
Chemotherapy of non-Hodgkin's lymphomas: Eastern Cooperative Oncology Group experience.
Topics: Altretamine; Bleomycin; Carmustine; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Drug Ad | 1977 |
Overview of four clinical studies of chemotherapy for stage III and IV non-Hodgkin's lymphomas by the Cancer and Leukemia Group B.
Topics: Adult; Bleomycin; Clinical Trials as Topic; Cyclophosphamide; Drug Administration Schedule; Drug The | 1977 |
Non-cross-resistant combinations in stage IV non-Hodgkin's lymphomas.
Topics: Adolescent; Adult; Aged; Bleomycin; Child; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; | 1977 |
Team approach to management of non-Hodgkin's lymphomas: past and present.
Topics: BCG Vaccine; Bleomycin; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Drug Therapy, Combi | 1977 |
Protected environment-prophylactic antibiotic program for malignant lymphoma. Randomized trial during chemotherapy to induce remission.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Bacterial Infections; Bleomycin; Cyclophosphamide; D | 1979 |
Superiority of adriamycin-containing combination chemotherapy in the treatment of diffuse lymphoma: a Southwest Oncology Group study.
Topics: Antineoplastic Agents; BCG Vaccine; Bleomycin; Clinical Trials as Topic; Cyclophosphamide; Doxorubic | 1979 |
Effects of BCG on peripheral blood counts and drug tolerance of patients with non-Hodgkin lymphoma receiving combination chemotherapy.
Topics: Antineoplastic Agents; BCG Vaccine; Bleomycin; Blood Cell Count; Clinical Trials as Topic; Cyclophos | 1978 |
Chemoimmunotherapy versus chemotherapy for remission induction in patients with non-Hodgkin's lymphoma: progress report of a Southwest Oncology Group study.
Topics: Antineoplastic Agents; BCG Vaccine; Bleomycin; Cyclophosphamide; Doxorubicin; Drug Therapy, Combinat | 1978 |
[O.E.R.T.C. study on the treatment of non-Hodgkin's lymphomas: origin-aims-means (author's transl)].
Topics: Antineoplastic Agents; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Drug Therapy, Combin | 1977 |
Chemotherapy of the non-Hodgkin's lymphomas: the Stanford experience.
Topics: Adolescent; Adult; Aged; Clinical Trials as Topic; Cyclophosphamide; Cytarabine; Doxorubicin; Drug A | 1977 |
BCNU with and without cyclophosphamide, vincristine, and prednisone (COP) and cycle-active therapy in non-Hodgkin's lymphoma.
Topics: Carmustine; Cell Cycle; Clinical Trials as Topic; Cyclophosphamide; Cytarabine; Drug Therapy, Combin | 1977 |
Treatment of histiocytic and mixed lymphomas: a comparison of two, three and four drug chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Bone Marrow; Carmustine; Cyclophosphamide; Drug Evaluation; Drug | 1978 |
[Results of CAP combination chemotherapy in the treatment of non-Hodgkin's lymphomata in stages III and IV. Report on fifty cases (author's transl)].
Topics: Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Drug Evaluation; Drug Therapy, Combination; | 1978 |
[Polychemotherapy of non-Hodgkin's centrofollicular malignant lymphomas. Review of 37 cases in advanced stage (author's transl)].
Topics: Adult; Aged; Alkylating Agents; Clinical Trials as Topic; Drug Therapy, Combination; Female; Humans; | 1979 |
[Induction chemotherapy of non-Hodgkin malignant lymphomas. Results of a controlled trial comparing two quadruple associations (author's transl)].
Topics: Antineoplastic Agents; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Drug Evaluation; Dru | 1978 |
delta 9-Tetrahydrocannabinol (THC) as an antiemetic in patients treated with cancerchemotherapy; a double-blind cross-over trial against placebo.
Topics: Adult; Antiemetics; Antineoplastic Agents; Double-Blind Method; Dronabinol; Drug Therapy, Combinatio | 1979 |
Non-Hodgkin's lymphoma in children: an analysis of 122 cases from Argentina.
Topics: Adolescent; Antineoplastic Agents; Child; Child, Preschool; Cyclophosphamide; Drug Therapy, Combinat | 1978 |
[Total body irradiation plus combination chemotherapy in patients with low-grade malignant non-Hodgkin's lymphoma (author's transl)].
Topics: Adult; Aged; Cyclophosphamide; Humans; Lymphoma; Middle Aged; Prednisone; Radiotherapy Dosage; Vincr | 1979 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Evaluation Studies as Topic; Humans; Lymphom | 1975 |
F-MACHOP in advanced aggressive lymphoma.
Topics: Actuarial Analysis; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Do | 1992 |
Unexpectedly high toxicity of MACOP-B in young patients with low grade lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubicin; Fem | 1991 |
[Malignant lymphoma associated with HIV infection].
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modalit | 1991 |
Phase I/II trial of recombinant human granulocyte-macrophage colony-stimulating factor following allogeneic bone marrow transplantation.
Topics: Adolescent; Adult; Bone Marrow Transplantation; Child; Child, Preschool; Combined Modality Therapy; | 1991 |
Biologic response modifiers as adjuncts to other therapeutic modalities.
Topics: Adjuvants, Immunologic; Animals; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Breast | 1986 |
[Comparison of CHOP and COP-BLAM chemotherapy in highly malignant non-Hodgkin's lymphoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Clinical Trials as Topic; Cyclophosphamid | 1986 |
Diffuse large-cell lymphoma: more CHOP-Bleo is not better.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Clinical Trials as Topic; Cyclophosphamid | 1986 |
A ten-year update of CHOP-BLEO in the treatment of diffuse large-cell lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Clinical Trials as Topic; Cyclophosphamid | 1987 |
Treatment of advanced Hodgkin's disease.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Clinical Trials as Top | 1989 |
Diffuse large cell lymphoma: a teaching hospital experience.
Topics: Antigens, CD; Antigens, CD19; Antigens, CD20; Antigens, Differentiation; Antigens, Differentiation, | 1989 |
MACOP-B treatment for advanced stage diffuse large cell lymphoma: a multicenter Italian Study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide | 1989 |
Value of prednimustine in treating non Hodgkin's lymphomas of favourable histological type.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Clinical Trials as Topic; | 1985 |
Long-term follow-up and analysis for prognostic factors for patients with limited-stage diffuse large-cell lymphoma treated with initial chemotherapy with or without adjuvant radiotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arizona; British Col | 1989 |
Brief chemotherapy and involved field radiation therapy for limited-stage, histologically aggressive lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as T | 1987 |
Major prognostic factors of adult patients with advanced B-cell lymphoma treated with vincristine, cyclophosphamide, prednisone and doxorubicin (VEPA) or VEPA plus methotrexate (VEPA-M).
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Humans | 1988 |
Prognostic factors in non-Hodgkin's lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Combined Modality Therapy; | 1986 |
[A comparative study of mitoxantrone and adriamycin in patients with non-Hodgkin's lymphoma: a preliminary result].
Topics: Adult; Aged; Anthraquinones; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topi | 1986 |
Moderate versus aggressive chemotherapy of nodular lymphocytic poorly differentiated lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Female; Follow-Up Stud | 1985 |
Pediatric Oncology Group experience with modified LSA2-L2 therapy in 107 children with non-Hodgkin's lymphoma (Burkitt's lymphoma excluded).
Topics: Adolescent; Antineoplastic Agents; Asparaginase; Bone Marrow; Carmustine; Child; Child, Preschool; C | 1985 |
The evolution and summary results of the Stanford randomized clinical trials of the management of Hodgkin's disease: 1962-1984.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Clinical Trials as Topic; Combine | 1985 |
CHOP vs MEV for the treatment of non-Hodgkin's lymphoma of unfavourable histopathology: a randomized clinical trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cyclophospham | 1985 |
CHOP-firstline treatment in NHL with unfavorable prognosis--evaluation of therapeutic response and factors influencing prognosis.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials a | 1985 |
Phase III study of BCOP v CHOP in unfavorable categories of malignant lymphoma: a Southeastern Cancer Study Group trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Clinical Trials | 1985 |
Chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisone alone or with levamisole or with levamisole plus BCG for malignant lymphoma: a Southwest Oncology Group Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Clinical Trials as Topic; Cyclophospham | 1985 |
Treatment of B-cell non-Hodgkin's malignant lymphomas of childhood in Europe: recent and on-going studies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; B-Lymphocytes; Child; Clinical Trials | 1985 |
Prednimustine v cyclophosphamide-vincristine-prednisolone in the treatment of non-Hodgkin's lymphoma with favorable histopathology: results of a national cancer care program in Sweden.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Cyclophospham | 1986 |
Vinca alkaloids. Experimental and clinical trials.
Topics: Animals; Cell Movement; Chlorambucil; Choriocarcinoma; Female; Hematopoiesis; Hematopoietic Stem Cel | 1974 |
Azathioprine in the treatment of Crohn's disease.
Topics: Azathioprine; Clinical Trials as Topic; Colic; Crohn Disease; Humans; Leukopenia; Lymphoma; Placebos | 1972 |
630 other studies available for prednisone and Lymphoma
| Article | Year |
|---|---|
Synchronous colonic B cell lymphoma and adenocarcinoma in an elderly patient treated with R-mini-CHOP followed by resection.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Cyclophosph | 2022 |
Safety and efficacy of a dose-dense short-term therapy in patients with MYC-translocated aggressive lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymp | 2022 |
Combined Hypofractionated Radiotherapy and Chemotherapy Versus Hypofractionated Radiotherapy Alone for Cats with Localized Sinonasal Lymphoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cat Diseases; Cats; Cyclophosphamide; Disea | 2022 |
Clinical presentation, treatment and outcome in 23 cats with laryngeal or tracheal lymphoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cat Diseases; Cats; Cyclophosphamide; Femal | 2023 |
The lymphoma microenvironment comes of age in the R-CHOP era?
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Humans; Lymphoma; Lym | 2023 |
Evaluation of mechlorethamine, vinblastine, procarbazine, and prednisone for the treatment of resistant multicentric canine lymphoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Dog Diseases; Dogs; Doxorubicin; Lymphoma; | 2023 |
Poor Outcome of Adult T-Cell Leukemia/Lymphoma with Current Available Therapy: An Experience of Two Centers.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Humans; Leukem | 2023 |
Development of prednisone resistance in naïve canine lymphoma: Longitudinal evaluation of NR3C1α, ABCB1, and 11β-HSD mRNA expression.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; 11-beta-Hydroxysteroid Dehydrogenase Type 2; Animals; A | 2020 |
Vincristine Shortage: What Other Options We Have?
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Proto | 2020 |
Cardio-oncology for better lymphoma therapy outcomes.
Topics: Cyclophosphamide; Doxorubicin; Humans; Lymphoma; Lymphoma, Non-Hodgkin; Neoplasms; Prednisone; Ritux | 2020 |
Association between weight change during initial chemotherapy and clinical outcome in dogs with multicentric lymphoma.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Do | 2021 |
Effect of lubiprostone on vinca alkaloid-induced constipation in patients with hematological malignancies: a propensity score-matched analysis.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Pro | 2020 |
Dose-adjusted EPOCH with or without rituximab for aggressive lymphoma patients: real world data.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Communic | 2020 |
Liquid biopsy based on small extracellular vesicles predicts chemotherapy response of canine multicentric lymphomas.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Case-Control Studies; Cy | 2020 |
CITCO as an Adjuvant Facilitates CHOP-Based Lymphoma Treatment in hCAR-Transgenic Mice.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Chromatography, Liq | 2020 |
Case 285: Primary Breast Lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Breast; Breast Neoplasms; Cyclophosph | 2021 |
Incidence and treatment of feline renal lymphoma: 27 cases.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cat Diseases; Cats; Cyclophosphamide; Incid | 2021 |
Outcome of Surgical Resection and Chemotherapy Versus Chemotherapy Alone for the Treatment of Isolated Primary Adrenal Lymphoma: A Retrospective Cohort Study of 16 Consecutive Patients.
Topics: Adrenal Gland Neoplasms; Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Combi | 2021 |
[Diagnosis and treatment of HIV-associated lymphoma: Update 202].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin | 2021 |
Maintenance treatment in relapsed canine lymphoma after a short L-CHOP protocol.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dog Diseases; Dogs; Doxor | 2021 |
Evaluation of neutrophilia as a prognostic factor in dogs with multicentric lymphoma treated with a cyclophosphamide, doxorubicin, vincristine, and prednisone-based chemotherapy protocol.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dog Diseases; Dogs; Doxor | 2021 |
MYC-rearranged lymphomas other than Burkitt: Comparison between R-CHOP and Burkitt-type immunochemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chem | 2017 |
[Dose-adjusted EPOCH/EDOCH plus rituximab in untreated double-protein expression lymphoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Etoposide; Humans; Ly | 2017 |
Patient characteristics, prognostic factors and outcome of dogs with high-grade primary mediastinal lymphoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dog Diseases; Dogs; Doxor | 2018 |
Tubulointerstitial capillaries limited intravascular lymphoma of the kidney.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antigens, CD; Antineoplastic Combined Chemotherapy Pro | 2017 |
Orbital T-cell lymphoma versus lupus panniculitits: a T-cell-mediated spectrum of orbital lymphoproliferative disease.
Topics: Administration, Oral; Adult; Diagnosis, Differential; Glucocorticoids; Humans; Immunosuppressive Age | 2018 |
Primary central nervous system vasculitis associated with lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amyloid beta-Peptides; Anti-Inflammatory Agents; Compute | 2018 |
Long-term complete remission following tandem autologous stem cell transplantation and consolidative radiotherapy for refractory mediastinal gray-zone lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Autografts; Chemoradiotherapy; Consolidation | 2018 |
Central nervous system lymphoma in 18 dogs (2001 to 2015).
Topics: Animals; Anti-Inflammatory Agents; Central Nervous System Neoplasms; Decompression, Surgical; Dog Di | 2018 |
Anemia Is a Novel Predictive Factor for the Onset of Severe Chemotherapy-Induced Peripheral Neuropathy in Lymphoma Patients Receiving Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone Therapy.
Topics: Adult; Aged; Anemia; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Pr | 2019 |
Three cases of spontaneous splenic rupture in malignant lymphoma.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Biomar | 2018 |
Towards the better diagnosis of lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Circulating Tumor DNA; Clinical Decision-Making; Cyc | 2018 |
Comparison of combination l-asparaginase plus CHOP or modified MOPP treatment protocols in dogs with multi-centric T-cell or hypercalcaemic lymphoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Cyclophosphamide; Dog Disease | 2019 |
Efficacy and toxicity of mustargen, vincristine, procarbazine and prednisone (MOPP) for the treatment of relapsed or resistant lymphoma in cats.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cat Diseases; Cats; Lymphoma; Mechlorethami | 2020 |
Successful use of an immune checkpoint inhibitor in a patient with myasthenia gravis in remission.
Topics: Antineoplastic Agents, Immunological; Azathioprine; Central Nervous System Neoplasms; Cholinesterase | 2019 |
Gastrointestinal lymphoma: an unusual presentation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonoscopy; Cyclophosphamide; Doxorubicin; Edema; G | 2019 |
A comparison of 12- and 19-week CHOP protocols using non-randomized, contemporaneous controls.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dog Diseases; Dogs; Doxor | 2019 |
Multimodality imaging for early diagnosis and treatment of primary cardiac diffuse 'double-expressor' lymphoma.
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Ea | 2019 |
A case report of a primary lymphoma of the tongue presenting as trigeminal neuralgia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Cyclophosphamide; Diagnosis, Differential; D | 2019 |
Pyothorax-associated lymphoma: complete remission achieved by chemotherapy alone.
Topics: Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Prot | 2014 |
Lymphoma in cats treated with a weekly cyclophosphamide-, vincristine-, and prednisone-based protocol: 114 cases (1998-2008).
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cat Diseases; Cats; Cyclophosphamide; Femal | 2013 |
[Prof. Dr. Hansjörg Riehm, a life devoted to science].
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Daunorubicin; Faculty, Medical; | 2013 |
Unusual breast neoplasm: primary breast lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Breast Neopl | 2013 |
Mechlorethamine, vincristine, melphalan and prednisone (MOMP) for the treatment of relapsed lymphoma in dogs.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Dog Diseases; Dogs; Female; Lymphoma; Lymph | 2015 |
Premature cardiovascular mortality in lymphoma patients treated with (R)-CHOP regimen - a national multicenter study.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; | 2013 |
Primary bone lymphoma: a retrospective analysis of 22 patients treated in a single tertiary center.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chem | 2013 |
Primary hepatic lymphoma mimicking acute hepatitis.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female | 2013 |
Therapeutic options for patients with lymphoma and liver dysfunction or failure during mechlorethamine shortage.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chem | 2014 |
[Clinicopathological and survival features of primary hepatic lymphoma: an analysis of 35 cases].
Topics: Adolescent; Adult; Aged; alpha-Fetoproteins; Antigens, CD20; Antineoplastic Combined Chemotherapy Pr | 2013 |
Glucocorticoid-induced diabetes mellitus in patients with lymphoma treated with CHOP chemotherapy.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherap | 2014 |
Feline mediastinal lymphoma: a retrospective study of signalment, retroviral status, response to chemotherapy and prognostic indicators.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cat Diseases; Cats; Female; Leukemia Virus, | 2014 |
[Fever, atrial fibrillation, and angina pectoris in a 58-year-old man].
Topics: Aged; Angina Pectoris; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy | 2014 |
Single-center experience in the treatment of primary testicular lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; | 2014 |
Evaluation of staging and early response to chemotherapy with whole-body diffusion-weighted MRI in malignant lymphoma patients: A comparison with FDG-PET/CT.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; | 2015 |
Perineal lymphoma: a diagnostic dilemma.
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Biopsy; Bleomycin | 2014 |
[Primary lymphoma of the bladder: a case report].
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophospha | 2014 |
Influence of chemotherapy for lymphoma in canine parvovirus DNA distribution and specific humoral immunity.
Topics: Animals; Antibodies, Viral; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; DNA, V | 2014 |
Right atrial lymphoma: rapid relief of TV obstruction by prednisone.
Topics: Aged; Anti-Inflammatory Agents; Female; Heart Atria; Humans; Lymphoma; Prednisone; Time Factors; Tri | 2015 |
Polymyalgia rheumatica in a patient with splenic marginal zone lymphoma - a case report.
Topics: Drug Therapy, Combination; Female; Humans; Lymphoma; Methotrexate; Middle Aged; Polymyalgia Rheumati | 2015 |
Fifty years from Paris: the remarkable story of the lymphomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Congresses as Topic; History, 19th Century; History, | 2015 |
Long-term ovarian function in women treated with CHOP or CHOP plus etoposide for aggressive lymphoma.
Topics: Adult; Anti-Mullerian Hormone; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dox | 2015 |
[Efficacy of R±BEACOP regimen in patients with
poor-prognosis lymphoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubicin; Etoposide; | 2015 |
Feline discrete high-grade gastrointestinal lymphoma treated with surgical resection and adjuvant CHOP-based chemotherapy: retrospective study of 20 cases.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cat Diseases; Cats; Combined Modality Thera | 2017 |
The significance of pre-therapeutic F-18-FDG PET-CT in lymphoma-associated hemophagocytic lymphohistiocytosis when pathological evidence is unavailable.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Etoposid | 2016 |
Activation of the Constitutive Androstane Receptor Increases the Therapeutic Index of CHOP in Lymphoma Treatment.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Survival; Coculture | 2016 |
Hypersensitivity reactions associated with L-asparaginase administration in 142 dogs and 68 cats with lymphoid malignancies: 2007-2012.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Cat Diseases; Cats; Cyclophos | 2016 |
Treating Adults with Hodgkin Lymphoma in the Developing World: a Hospital-Based Cohort Study from Armenia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Armenia; Bleomycin; Combine | 2016 |
[Evaluation Value of Invasion Area PET-CT Scanning for Chemotherapeutic Efficacy and Prognosis of Patients with Lymphoma].
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophospha | 2016 |
Progressive outer retinal necrosis syndrome in the course of systemic lupus erythematosus.
Topics: Adult; Antiviral Agents; Central Nervous System Neoplasms; Chloroquine; Chorioretinitis; Fatal Outco | 2016 |
Assessment of temporal association of relapse of canine multicentric lymphoma with components of the CHOP protocol: Is cyclophosphamide the weakest link?
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dog Diseases; Dogs; Doxor | 2016 |
Real-World Conundrums and Biases in the Use of White Cell Growth Factors.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Biosimilar P | 2016 |
Dose adjusted-EPOCH-R and mediastinal disease may improve outcomes for patients with gray-zone lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Doxorub | 2017 |
Is Granulocyte Colony-stimulating Factor Safe in the Treatment of Febrile Neutropenia in Lymphoma Patients with Renal Transplantation?
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Febrile Neutropenia; | 2001 |
Lymphoma Secondary to Congenital and Acquired Immunodeficiency Syndromes at a Turkish Pediatric Oncology Center.
Topics: Acquired Immunodeficiency Syndrome; Adolescent; Antibodies, Monoclonal, Murine-Derived; Antineoplast | 2016 |
Dose-Adjusted EPOCH-R and Mid-Cycle High Dose Methotrexate for Patients with Systemic Lymphoma and secondary CNS Involvement.
Topics: Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Combined Modality | 2017 |
Mediastinal Gray Zone Lymphoma with Features Intermediate between Classical Hodgkin Lymphoma and Primary Mediastinal B-Cell Lymphoma.
Topics: Adult; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclo | 2016 |
[A Case of Primary Adrenal Malignant Lymphoma with Inferior Vena Cava Thrombus].
Topics: Adrenal Gland Neoplasms; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemo | 2016 |
Radioimmunotherapy of lymphoma: an underestimated therapy option.
Topics: Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents, Im | 2017 |
Comparison of a CHOP-LAsp-based protocol with and without maintenance for canine multicentric lymphoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dog Diseases; Dogs; Doxor | 2017 |
Factors and Costs Associated With Delay in Treatment Initiation and Prolonged Length of Stay With Inpatient EPOCH Chemotherapy in Patients With Hematologic Malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Etoposid | 2017 |
Case of polyostotic primary bone lymphoma successfully treated with immunochemotherapy and consolidation radiotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Combined Modality Therapy; Cyclophos | 2017 |
Bilateral primary renal lymphoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplasti | 2008 |
Breast lymphoma.
Topics: Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigen | 2008 |
Bronchus-associated lymphoid tissue lymphoma in a patient with primary Sjögren's syndrome.
Topics: Biopsy; Bronchi; Female; Glucocorticoids; Humans; Lung Neoplasms; Lymphoma; Middle Aged; Prednisone; | 2008 |
Actinomycin D as rescue therapy in dogs with relapsed or resistant lymphoma: 49 cases (1999--2006).
Topics: Animals; Antibiotics, Antineoplastic; Dactinomycin; Disease-Free Survival; Dog Diseases; Dogs; Dose- | 2008 |
Splenic marginal zone lymphoma: transformation to diffuse large B-cell lymphoma with isolated cerebral manifestation.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy | 2008 |
Images for surgeons. Thyroid lymphoma arising from Hashimoto's thyroiditis.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Fine-Needle; Cyclophosphamide; Doxoru | 2008 |
Mechlorethamine, procarbazine and prednisone for the treatment of resistant lymphoma in dogs.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; | 2009 |
Sinonasal lymphoma masquerading as persistent blepharoconjunctivitis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Blepharitis; Combined Modality Therapy; Conjun | 2009 |
Primary malignant lymphoma of the breast.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Diagnosis, Diffe | 2009 |
An atypical presentation of a blastic plasmacytoid dendritic cell tumors.
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biopsy, Needle | 2010 |
[Application of 18F-FDG PET for the assessment of early response to the treatment and prognosis of patients].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-D | 2009 |
Entecavir as prophylaxis against hepatitis B virus reactivation following chemotherapy for lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Chemoprevention; Cyclophosphamide; | 2010 |
Long term outcome of patients with localized aggressive non-Hodgkin lymphoma treated with PROMECE-CYTABOM plus involved-field radiation therapy: a study by the Gruppo Italiano Studio Linfomi.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Cytarabine; Disea | 2010 |
[Management of lymphoma with respect to pathologic classification: updates and controversies].
Topics: Anaplastic Lymphoma Kinase; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineopl | 2009 |
Sequential therapy of primary cardiac lymphoma with cardiectomy, total artificial heart support, and cardiac transplantation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cardiac Surgical Procedures; Cyclophosphamide; Doxor | 2010 |
Recurrent pericardial effusion after treatment for primary effusion lymphoma-like lymphoma: an autopsied case.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemoth | 2011 |
Cerebral vasculitis associated with amyloid angiopathy: case report.
Topics: Aged; Anti-Inflammatory Agents; Aphasia, Broca; Brain Neoplasms; Cerebral Amyloid Angiopathy; Dement | 2010 |
Breast lymphoma in Sjögren's syndrome complicated by acute monocular blindness.
Topics: Aged; Blindness; Breast Neoplasms; Combined Modality Therapy; Diagnosis, Differential; Female; Human | 2010 |
[Pericardial tamponade and third-degree atrioventricular block revealing a primary cardiac lymphoma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Atrioventricular Block; Biopsy; Cardiac Tampon | 2010 |
Primary cardiac lymphoma complicated with inferior vena cava thrombosis: a case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Heart Neoplasms; Huma | 2010 |
Outcome and toxicity associated with a dose-intensified, maintenance-free CHOP-based chemotherapy protocol in canine lymphoma: 130 cases.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Cyclophosphamide; Dog Disease | 2010 |
Assessment of circulating biomarkers for potential pharmacodynamic utility in patients with lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic C | 2011 |
Evaluation of factors associated with second remission in dogs with lymphoma undergoing retreatment with a cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy protocol: 95 cases (2000-2007).
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Do | 2011 |
Treatment of a patient with adnexal lymphoma with Rituximab.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2011 |
[Primary lymphoma of breast: a clinicopathologic and prognostic study of 40 cases].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antigens, CD20; Antineoplastic Combined Chemotherapy Pro | 2011 |
How I treat primary CNS lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; | 2011 |
Predictive models for pulmonary function changes after radiotherapy for breast cancer and lymphoma.
Topics: Adolescent; Adult; Age Factors; Aged; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Bl | 2012 |
Evaluation of the University of Florida lomustine, vincristine, procarbazine, and prednisone chemotherapy protocol for the treatment of relapsed lymphoma in dogs: 33 cases (2003-2009).
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Dog Diseases; Dogs; Drug Resistance, Neopla | 2011 |
Fluorodeoxyglucose positron emission tomography in primary thyroid lymphoma with coexisting lymphocytic thyroiditis.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Comorbidity; Cyclophosphamide; Diagnosis, Dif | 2011 |
Early-stage primary bone lymphoma: a retrospective, multicenter Rare Cancer Network (RCN) Study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Analysis of Variance; Antibodies, Monoclonal, Murine-Der | 2012 |
A case of successful management of HHV-8⁺, EBV⁺ germinotropic lymphoproliferative disorder (GLD).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Germinal Center | 2012 |
Dose-adjusted EPOCH-rituximab combined with fludarabine provides an effective bridge to reduced-intensity allogeneic hematopoietic stem-cell transplantation in patients with lymphoid malignancies.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined | 2012 |
Select interviews from the 2011 San Antonio Breast Cancer Symposium (SABCS) and American Society of Hematology (ASH) Annual Meeting.
Topics: Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined C | 2011 |
Orbital plasmablastic lymphoma with remission following chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Etoposide; Fil | 2011 |
Metronomic therapy for refractory/relapsed lymphoma: the PEP-C low-dose oral combination chemotherapy regimen.
Topics: Antineoplastic Agents; Cyclophosphamide; Drug Therapy, Combination; Endothelial Cells; Etoposide; Ge | 2012 |
Evaluation of a 15-week CHOP protocol for the treatment of canine multicentric lymphoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dog Diseases; Dogs; Doxor | 2013 |
An unexpected trismus.
Topics: Accidental Falls; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined | 2012 |
Primary lymphoma arising in a mature cystic teratoma of the ovary.
Topics: Adult; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Combi | 2012 |
A case of central nervous system lymphoma manifesting as multiple patchy white matter lesions with a past history of tonsil lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Cyclophosphamide; | 2012 |
[Primary lymphoma of the thyroid gland].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Cyclophosphamide; Doxorubicin; Fatal O | 2002 |
Treatment of HBV-carrying lymphoma patients with Rituximab and CHOP: a diagnostic and therapeutic challenge.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplasti | 2002 |
Myelodysplastic syndrome and acute myeloid leukemia after autotransplantation for lymphoma: a multicenter case-control study.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemoth | 2003 |
VIII International Conference on malignant lymphoma. June 12-15, 2002 Lugano, Switzerland.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2002 |
Excellent long-term survival in patients with early-stage primary bone lymphoma treated with doxorubicin-based chemotherapy and local radiotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Neoplasms; | 2002 |
Granulocyte colony-stimulating factor administration upregulates telomerase activity in CD34+ haematopoietic cells and may prevent telomere attrition after chemotherapy.
Topics: Aged; Aged, 80 and over; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow | 2003 |
[Pancytopenia after viral infection in St. n. malignant lymphoma].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality The | 2003 |
When lymphoma and heart failure cross paths.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Echocardiograph | 2003 |
Do the immunosuppressive drugs used as treatment for graft-versus-host disease directly inhibit lymphoid tumor cell growth?
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Division; Cyclosporine; Graft vs Host | 2003 |
Not just another fall in the elderly. Bilateral adrenal lymphoma presenting with adrenal insufficiency causing weakness.
Topics: Accidental Falls; Adrenal Gland Neoplasms; Adrenal Insufficiency; Aged; Aged, 80 and over; Antineopl | 2003 |
Intravascular lymphoma presenting with cauda equina syndrome: treated with CHOP and rituxan.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2003 |
Increasing chemotherapy intensity in aggressive lymphomas: a renewal?
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Cyclophosphamide | 2003 |
An extremely rare case of synchronous occurrence in the larynx of intravascular lymphoma and in situ squamous cell carcinoma.
Topics: Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carcinoma in Situ; Carcinoma, | 2003 |
Therapeutic trials for a rabbit model of EBV-associated Hemophagocytic Syndrome (HPS): effects of vidarabine or CHOP, and development of Herpesvirus papio (HVP)-negative lymphomas surrounded by HVP-infected lymphoproliferative disease.
Topics: Animals; Antibodies, Viral; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Cell L | 2003 |
Clinical and metabolic effects of prednisone.
Topics: Humans; IgA Vasculitis; Leukemia; Leukemia, Lymphoid; Lymphoma; Prednisone; Purpura; Steroids | 1955 |
Massive prednisone and prednisolone therapy in leukemia and lymphomas in the adult.
Topics: Humans; Leukemia; Lymphoma; Prednisolone; Prednisone; Steroids | 1956 |
The effect of massive prednisone and prednisolone therapy on acute leukemia and malignant lymphomas.
Topics: Acute Disease; Hodgkin Disease; Humans; Leukemia; Lymphoma; Prednisolone; Prednisone | 1957 |
The effect of massive prednisone and prednisolone therapy on acute leukemia and malignant lymphomas.
Topics: Acute Disease; Hodgkin Disease; Humans; Leukemia; Lymphoma; Prednisolone; Prednisone | 1957 |
The effect of massive prednisone and prednisolone therapy on acute leukemia and malignant lymphomas.
Topics: Acute Disease; Hodgkin Disease; Humans; Leukemia; Lymphoma; Prednisolone; Prednisone | 1957 |
The effect of massive prednisone and prednisolone therapy on acute leukemia and malignant lymphomas.
Topics: Acute Disease; Hodgkin Disease; Humans; Leukemia; Lymphoma; Prednisolone; Prednisone | 1957 |
[Massive dosage of prednisone in lymphogranuloma, lymphosarcoma and reticulum cell sarcoma].
Topics: Hodgkin Disease; Humans; Lymphoma; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Neoplasms | 1957 |
[Possibilities & limitations in the treatment of malignant lymphomas with massive doses of prednisone].
Topics: Humans; Lymphoma; Prednisone | 1958 |
Large doses of prednisone and prednisolone in the treatment of malignant lymphoproliferative disorders.
Topics: Humans; Leukemia; Leukemia, Lymphoid; Lymphoma; Lymphoma, Non-Hodgkin; Lymphoproliferative Disorders | 1962 |
Polyneuritis preceding lymphoblastic lymphoma.
Topics: Humans; Lymphoma; Lymphoma, Non-Hodgkin; Neuritis; Polyradiculopathy; Precursor Cell Lymphoblastic L | 1963 |
[The use of Degranol pills in hemoblastosis and other neoplastic diseases].
Topics: Humans; Leukemia; Leukemia, Lymphoid; Lymphogranuloma Venereum; Lymphoma; Lymphoma, Large B-Cell, Di | 1963 |
[THERAPY OF HEMATODERMIAS].
Topics: Busulfan; Chlorambucil; Cortisone; Cyclophosphamide; Dermatology; Hydrocortisone; Leukemia; Lymphoma | 1963 |
WEEKLY HIGH-DOSAGE GLUCOCORTICOSTEROID TREATMENT OF LYMPHOCYTIC LEUKEMIAS AND LYMPHOMAS.
Topics: Anemia; Anemia, Hemolytic; Betamethasone; Chlorambucil; Dexamethasone; Geriatrics; Humans; Leukemia; | 1964 |
SPINAL-CORD COMPRESSION IN THE MALIGNANT LYMPHOMAS.
Topics: Chlorambucil; Hematopoiesis; Hodgkin Disease; Humans; Lymphoma; Lymphoma, Non-Hodgkin; Mercaptopurin | 1964 |
[EXPERIENCES IN THE TREATMENT OF MALIGNANT DISEASES OF THE RETICULOENDOTHELIAL SYSTEM AND LEUKEMIAS. (I)].
Topics: Antineoplastic Agents; Cortisone; Hodgkin Disease; Leukemia; Lung Neoplasms; Lymphoma; Lymphoma, Lar | 1964 |
NONSURGICAL TREATMENT OF PULMONARY CANCER.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Adrenal Cortex Hormones; Alkylating Agents; Antineoplastic Agen | 1964 |
[THE SIGNIFICANCE OF RETICULOSES IN THE AREA OF MALIGNANT HEMATOLOGICAL DISEASES IN CHILDHOOD].
Topics: Child; Cyclophosphamide; Genetic Diseases, X-Linked; Hematologic Diseases; Histiocytosis, Langerhans | 1963 |
[THE RETICULO-ENDOTHELIAL SYSTEM AND LYMPHOSARCOMAS].
Topics: Adolescent; Adrenal Cortex Hormones; Geriatrics; Hodgkin Disease; Humans; Lymphoma; Lymphoma, Follic | 1964 |
[THE COLD HEMAGGLUTININ SYNDROME].
Topics: Anemia, Hemolytic; Autoimmune Diseases; Blood Transfusion; Cold Temperature; Cyanosis; Hemagglutinat | 1964 |
METABOLIC RELATIONSHIPS BETWEEN TUMOR AND HOST DURING MASSIVE DOSES OF PREDNISONE IN HUMAN NEOPLASTIC DISEASE.
Topics: 17-Ketosteroids; Adenocarcinoma; Biomedical Research; Blood; Calcium; Chlorides; Creatine; Creatinin | 1964 |
POLYMYOSITIS ASSOCIATED WITH ACUTE MONOCYTIC LEUKEMIA: CASE REPORT AND REVIEW OF THE LITERATURE.
Topics: Biopsy; Bone Marrow Cells; Carcinoma; Humans; Leukemia; Leukemia, Monocytic, Acute; Leukemia, Myeloi | 1964 |
THE ROLE OF THE PHAGOCYTE IN HOST-PARASITE INTERACTIONS. I. THE PHAGOCYTIC CAPABILITIES OF LEUKOCYTES FROM LYMPHOPROLIFERATIVE DISORDERS.
Topics: Chlorambucil; Drug Therapy; Escherichia coli Infections; Geriatrics; Host-Parasite Interactions; Hum | 1964 |
THE SUPERIOR MEDIASTINAL SYNDROME IN CHILDREN WITH CANCER.
Topics: Adolescent; Child; Hodgkin Disease; Humans; Leukemia; Lymphoma; Lymphoma, Non-Hodgkin; Mediastinal N | 1965 |
TREATMENT OF COMPLICATIONS OF GASTRODUODENAL "STEROID ULCERS".
Topics: Adenocarcinoma; Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Arthritis; Arthritis, Rheumato | 1965 |
MALIGNANT LYMPHOMA PRESENTING AS NECROTIZING EOSINOPHILIC GRANULOMATOSIS.
Topics: Bone Marrow Examination; Drug Therapy; Eosinophilic Granuloma; Lymphoma; Mechlorethamine; Mercaptopu | 1965 |
[Primary cardiac lymphoma: diagnosis by transjugular biopsy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Cyclophosphamide; Doxorubicin; Echoc | 2003 |
What is your diagnosis? Ocular lymphoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Diagnosis, Differential; | 2003 |
45th annual meeting of the American Society of Hematology. December 6-9, 2003, San Diego, California.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Anti | 2003 |
Rituximab-CHOP or two-weekly CHOP + G-CSF in aggressive lymphoma of the elderly?
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2004 |
Vaginal bleeding as a first symptom of malignant lymphoma: case reports, diagnosis and successful treatment.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Combined Modality Therapy; Cycl | 2004 |
Who should receive myeloablative therapy for lymphoma?
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Doxorub | 2004 |
Preemptive use of interferon or lamivudine for hepatitis B reactivation in patients with aggressive lymphoma receiving chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Cy | 2004 |
Combination of rituximab, cyclophosphamide, and vincristine induces complete hematologic remission of splenic marginal zone lymphoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplastic Combi | 2004 |
Clivus lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cranial Fossa, Posterior; Cyclophosphamide; Doxorubi | 2004 |
Intensive therapy for aggressive lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Cytarab | 2004 |
Intensive therapy for aggressive lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Doxorub | 2004 |
Intensive therapy for aggressive lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Doxorub | 2004 |
Rituximab-CHOP or 2-weekly CHOP + G-CSF in aggressive lymphoma of the elderly?
Topics: Age Factors; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Co | 2004 |
Developing new monoclonal antibodies for aggressive lymphoma: a challenging road in the rituximab era.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy | 2004 |
Cyclooxygenase-2 (Cox-2) expression in lymphomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclooxygenase 2; Cyclophosp | 2004 |
Aggressive systemic mastocytosis mimicking sclerosing cholangitis.
Topics: Abdominal Pain; Adrenal Cortex Hormones; Adult; Amino Acid Substitution; Antineoplastic Combined Che | 2004 |
Posttransplant lymphoma--a single-center experience of 500 liver transplantations.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antine | 2004 |
The effects of IL-2, IL-6 and IL-10 levels on prognosis in patients with aggressive Non-Hodgkin's Lymphoma (NHL).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Cytarabine; Disea | 2004 |
PET imaging with F-18 fluorodeoxyglucose for primary lymphoma of bone.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cyclophosphamide; Doxorubicin | 2005 |
The treatment of primary central nervous system lymphoma in 122 immunocompetent patients: a population-based study of successively treated cohorts from the British Colombia Cancer Agency.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Cohor | 2005 |
Modified ProMACE-MOPP hybrid regimen with moderate-dose methotrexate for patients with primary CNS lymphoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Centra | 2005 |
A new schedule of CHOP/rituximab plus granulocyte-macrophage colony-stimulating factor is an effective rescue for patients with aggressive lymphoma failing autologous stem cell transplantation.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; | 2005 |
Unusual chest lesion: giant primary pulmonary lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Humans | 2005 |
Primary skeletal muscle marginal zone lymphoma with persistent tissue tropism and PET-avidity.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Fluorodeoxyglucose F1 | 2006 |
[Two cases of malignant lymphoma with high fever and C-reactive protein (CRP) elevation after treatment with granulocyte colony-stimulating factor (G-CSF)].
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemo | 2006 |
Breast lymphoma: favorable prognosis after treatment with standard combination chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Fem | 2006 |
Clinical outcome of primary gastric lymphoma treated with chemotherapy alone or surgery followed by chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cyclophosphamid | 2006 |
Primary laryngeal lymphoma: case report.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Cyclophosphamide; Doxorubicin; Hoarsen | 2006 |
HAART and CHOP improve survival in AIDS-related lymphoma.
Topics: Acquired Immunodeficiency Syndrome; Antineoplastic Combined Chemotherapy Protocols; Antiretroviral T | 2006 |
A case of neurolymphomatosis involving cranial nerves: MRI and fusion PET-CT findings.
Topics: Aged; Antigens, CD20; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Cranial Nerve N | 2006 |
Organizing pneumonia in patients with hematologic malignancies: a steroid-responsive lesion.
Topics: Acute Disease; Adult; Aged; Biopsy; Bronchi; Cryptogenic Organizing Pneumonia; Diagnosis, Differenti | 2007 |
Severe neutropenia in CHOP occurs most frequently in cycle 1: a predictive model.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-D | 2006 |
Meeting highlights from: 47th Annual Meeting of the American Society of Hematology December 2005, Atlanta, GA.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplasti | 2006 |
Sequential multidrug chemotherapy (CHOP-VA-MB) in patients with high-grade non-Hodgkin's lymphoma--a 20-year follow-up.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomyci | 2006 |
Role of radiation therapy in localized aggressive lymphoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; D | 2007 |
The treatment of lymphoma complicating autoimmune disease: two birds with one stone?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy | 2007 |
Safe administration of iodine-131 tositumomab after repeated infusion-related reactions to rituximab.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antine | 2007 |
Dose dense CHOP: when more is not always better!
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; C | 2007 |
Doxorubicin pharmacokinetics in lymphoma patients treated with doxorubicin-loaded eythrocytes.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antineoplastic Combined Che | 2007 |
[The standard treatments for patients with hematological malignancies in Japan].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy | 2007 |
Lomustine and prednisone as a first-line treatment for dogs with multicentric lymphoma: 17 cases (2004-2005).
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Dog Diseases; Dogs; Dos | 2007 |
Achievement of optimal average relative dose intensity and correlation with survival in diffuse large B-cell lymphoma patients treated with CHOP.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality Therapy; Cycloph | 2008 |
Prognostic implication of p27 expression in primary central nervous system lymphoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cell Nuc | 2006 |
Increased incidence of interstitial pneumonia by CHOP combined with rituximab.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Anti | 2008 |
Results of treatment of 112 cases of primary CNS lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Central Nervous Syst | 2008 |
Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy.
Topics: Adolescent; Adult; Cadaver; Cyclosporins; Female; Heart Transplantation; Herpesviridae Infections; H | 1984 |
[Preliminary therapeutic results of treatment of non-Hodgkin lymphoma in children according to the BACOP program].
Topics: Adolescent; Bleomycin; Burkitt Lymphoma; Child; Child, Preschool; Cyclophosphamide; Doxorubicin; Dru | 1980 |
Therapy of non-Hodgkin's lymphomas in relapse.
Topics: Cyclophosphamide; Drug Therapy, Combination; Humans; Imidazoles; Lymphoma; Neoplasm Recurrence, Loca | 1980 |
Management of the indolent non-Hodgkin's lymphomas.
Topics: Antineoplastic Agents; Bleomycin; Carmustine; Cyclophosphamide; Doxorubicin; Drug Therapy, Combinati | 1980 |
[Chemotherapy of non-Hodgkin lymphoma with poor prognosis].
Topics: Antineoplastic Agents; Asparaginase; Bleomycin; Cyclophosphamide; Cytarabine; Doxorubicin; Drug Ther | 1980 |
Methotrexate as a single agent and in combination chemotherapy for the treatment of non-Hodgkin's lymphoma of unfavorable histology.
Topics: Adult; Aged; Antineoplastic Agents; Bleomycin; Cyclophosphamide; Doxorubicin; Drug Administration Sc | 1981 |
[The effect of therapy on the behavior of T and B-lymphocytes in patients with non-Hodgkin's lymphoma].
Topics: B-Lymphocytes; Chlorambucil; Cyclophosphamide; Humans; Lymphoma; Prednisone; Rosette Formation; T-Ly | 1981 |
[Lymphomas. Treatment of malignant lymphomas. Current observations and future prospects].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; | 1982 |
Nonrandom chromosome abnormalities in angioimmunoblastic lymphadenopathy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Chromosome Aberrations; Cyclophosph | 1982 |
Primary conjunctival lymphoma: response to chemotherapy in 4 cases.
Topics: Adult; Bleomycin; Conjunctival Neoplasms; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; | 1982 |
Combination chemotherapy of refractory lymphoma with cis-dichlorodiamineplatinum, vinblastine, and bleomycin.
Topics: Adult; Aged; Bleomycin; Cisplatin; Doxorubicin; Drug Therapy, Combination; Female; Humans; Lymphoma; | 1982 |
Clinical and histological staging as prognostic determinants in advanced cutaneous T cell lymphomas treated by sequential polychemotherapy with bleomycin, vinblastine and prednisone. Preliminary results.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Drug Therapy, Combination; Female; | 1982 |
Sequential chemotherapy and late intensification for malignant lymphomas of aggressive histologic type.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclo | 1983 |
[Results of treating lymphomas with high degree of malignancy using COPP, CHOP-Bleo and MEV protocols].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; | 1982 |
[Rare organ manifestation of an immunoblastoma of the breast].
Topics: Bleomycin; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Female; Humans; Lymphoma; Mammography; M | 1983 |
[Combination chemotherapy using peplomycin for the treatment of non-Hodgkin's lymphoma including adult T cell leukemia].
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherap | 1983 |
[Cyclophosphamide, adriamycin, vincristine, bleomycin and prednisolone (CHOP-Bleo) combination chemotherapy for advanced non-Hodgkin's lymphoma].
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleo | 1983 |
[Highly malignant non-Hodgkin's lymphoma. Treatment by intensive sequential chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Cytarabine; Doxorubicin | 1983 |
Combined modality therapy in Stage III and Stage IIIE diffuse large cell lymphomas.
Topics: Abdominal Neoplasms; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combine | 1984 |
[Adriamycin-based combination chemotherapy in the treatment of advanced malignant lymphoma. A progress report].
Topics: Adolescent; Adult; Aged; Anthraquinones; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; | 1984 |
A clinicopathologic study in advanced non-Hodgkin's lymphomas treated with sequential non-cross-resistant regimens: comparison of the working formulation with the Rappaport and Kiel classifications.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide | 1984 |
[Clinical aspects and therapy of anaplastic T-zone lymphoma].
Topics: Alopecia; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubicin; | 1984 |
Treatment of refractory lymphoproliferative diseases with daily, low-dose vincristine, continuous infusion of bleomycin, and high-dose prednisone.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Blood Cell Count; Female; Ho | 1984 |
[Results of the treatment of primary gastric lymphomas--chemotherapy after gastrectomy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality Therapy; Cyclopho | 1984 |
[Computed tomographic and sonographic control of the treatment of non-Hodgkin's lymphoma of the stomach].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Humans; Lympho | 1982 |
[Immunological characterization of unusual plasmacytic tumor cells in a disseminated non-Hodgkin's lymphoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Cyclophosphamide; Doxorubicin; Histoc | 1984 |
Studies on long-term T-cell-mediated immunity to Epstein-BArr virus in immunosuppressed renal allograft recipients.
Topics: Azathioprine; Cyclosporins; Herpesviridae Infections; Herpesvirus 4, Human; Humans; Kidney Transplan | 1981 |
[Hypergammaglobulinemia and monoclonal gammopathy in Gougerot-Sjögren syndrome. Three case-reports. [author's transl)].
Topics: Adult; Aged; Blood Viscosity; Female; Humans; Hypergammaglobulinemia; Immunoglobulin G; Lymphoma; Pl | 1982 |
Lymphoma and leukemia manifested by steroid-responsive polyneuropathy.
Topics: Chronic Disease; Humans; Leukemia, Lymphoid; Lymphatic Diseases; Lymphoma; Male; Middle Aged; Neopla | 1983 |
Hypothalamic-pituitary-adrenal function in patients receiving intermittent high dose prednisone therapy for lymphoma.
Topics: Adrenocorticotropic Hormone; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Hodgkin Di | 1984 |
Adult-type systemic varicella in a female patient in course of treatment of her so-called reactive lymphocytic (T-cell) hyperplasia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chickenpox; Connective Tissue; Cyclophosphami | 1984 |
Current problems in the management of non-Hodgkin's lymphomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Etoposide; Humans; Le | 1984 |
The influence of histologic subtype on toxicity and response to chemotherapy in non-hodgkin's lymphoma. An Eastern Cooperative Oncology Group Study utilizing the BCVP regimen.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; | 1983 |
Combined modality therapy of advanced non-Hodgkin's lymphoma: an analysis of remission duration and survival in 95 patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Humans; | 1983 |
Multimodality therapy of favorable prognosis non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide | 1983 |
The combined modality therapy of diffuse histology non-Hodgkin's lymphoma with cyclophosphamide, adriamycin, vincristine, prednisone (CHOP) and total body irradiation.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide | 1983 |
Biochemical markers in non-Hodgkin's lymphoma stages III and IV and prognosis: a multivariate analysis.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; beta 2-Microglobulin; Blood | 1984 |
Conversion of an IGM secreting immunocytoma in a high grade malignant lymphoma of immunoblastic type.
Topics: Aged; Cyclophosphamide; Fluocortolone; Humans; Immunoglobulin kappa-Chains; Immunoglobulin M; Lympho | 1983 |
Hodgkin's and non-Hodgkin's lymphomas masquerading as "idiopathic" liver granulomas.
Topics: Adult; Aged; Diagnosis, Differential; Female; Granuloma; Hepatitis; Hodgkin Disease; Humans; Lymphom | 1984 |
Lymphomatoid granulomatosis presenting as central neurogenic hyperventilation.
Topics: Adult; Brain Neoplasms; Cyclophosphamide; Diagnosis, Differential; Humans; Hyperventilation; Lymphom | 1984 |
[VCP therapy for non-Hodgkin's lymphoma advanced more than stage IIB].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Admi | 1984 |
Hypercalcemia associated with increased serum calcitriol levels in three patients with lymphoma.
Topics: Aged; Calcitriol; Creatinine; Female; Humans; Hypercalcemia; Lymphoma; Male; Middle Aged; Parathyroi | 1984 |
[Remission maintenance therapy of non-Hodgkin's lymphoma with CHOP protocol].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Drug Administration S | 1984 |
Malignant lymphoma of skin associated with postmastectomy lymphedema.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Doxorubici | 1984 |
Antibody-dependent cellular cytotoxicity in some lymphoreticular diseases.
Topics: Antibody-Dependent Cell Cytotoxicity; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphami | 1984 |
Comparison of M-2 protocol with COP in patients with nodular lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Carmustine; Cyclophos | 1984 |
Localised grade 2 non-Hodgkin's lymphoma: results of treatment with radiotherapy (BNLI Report No. 24).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Combined Modality Therapy | 1984 |
Second malignant neoplasms complicating Hodgkin's disease: the National Cancer Institute experience.
Topics: Adolescent; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Combine | 1984 |
[CVP or C-MOPP combination chemotherapy in the treatment of advanced Hodgkin's disease and non-Hodgkin's lymphoma (intermediate grade of working formulation)].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Hodgkin Disease; Hum | 1984 |
Acute oliguric renal failure secondary to lymphomatous infiltration of the kidneys.
Topics: Acute Kidney Injury; Aged; Antineoplastic Combined Chemotherapy Protocols; Humans; Kidney Neoplasms; | 1984 |
Diagnostics and therapy of non-Hodgkin lymphomas in childhood.
Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Child; Combined Modality Therapy; Cyclo | 1984 |
Poor prognosis non-Hodgkin's lymphoma in the elderly: clinical presentation and management.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Combined Modality Therapy; Cyclo | 1984 |
Non-Hodgkin lymphoma following Hodgkin's disease. A case report.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Hodgkin Dis | 1984 |
[Results of modified LSA2L2 therapy in children with non-Hodgkin's lymphoma].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Diseases; Child; | 1984 |
[Therapeutic results of 36 malignant lymphomas and 8 histiocytic medullary reticulosis in childhood].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cyclophosphamid | 1984 |
Evaluation of the LSA2L2 protocol for treatment of childhood non-Hodgkin's lymphoma. A report from the Polish Children's Leukemia/Lymphoma Study Group.
Topics: Abdominal Neoplasms; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Central Nervous Syste | 1984 |
LSA2-L2 protocol treatment of stage IV non-Hodgkin's lymphoma in children with partial and extensive bone marrow involvement.
Topics: Adolescent; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marro | 1983 |
Successful therapy of convoluted T-lymphoblastic lymphoma in the adult.
Topics: Adolescent; Adult; Asparaginase; Brain; Cyclophosphamide; Cytarabine; Doxorubicin; Female; Humans; I | 1983 |
Diffuse aggressive lymphomas: increased survival after alternating flexible sequences of proMACE and MOPP chemotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bloo | 1983 |
Erythema and desquamation after high-dose methotrexate.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxor | 1983 |
End results of treating children with localized non-Hodgkin's lymphomas with a combined modality approach of lessened intensity.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Combined Modali | 1983 |
[Adjuvant chemotherapy for localized non-Hodgkin's lymphoma with CVP therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Therapy, Combination; Humans; | 1983 |
[Chemotherapy for advanced non-Hodgkin's lymphoma with CVP therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Therapy, Combination; Humans; | 1983 |
Malignant lymphoma, diffuse mixed small and large cell. A clinicopathologic study of 47 cases.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxor | 1983 |
Initial chemotherapy for clinically localized lymphomas of unfavorable histology.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; | 1983 |
[Combination chemotherapy for advanced diffuse non-Hodgkin's lymphomas in relapse following local radiotherapy].
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxo | 1983 |
A pilot study of cyclical chemotherapy with high-dose methotrexate and CHOP (MTX-CHOP) in poor-prognosis non-Hodgkin's lymphoma (NHL).
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dose-Resp | 1983 |
[Results of cytostatic polychemotherapy in non-Hodgkin lymphomas].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Cyclophosphamide; Doxorubicin; Drug Th | 1983 |
[Steroid-induced aseptic necrosis in patients with malignant lymphoma].
Topics: Adult; Female; Humans; Lymphoma; Male; Middle Aged; Osteonecrosis; Prednisone | 1984 |
Treatment of non Hodgkin's lymphoma with "PROVECIP" (procarbazine, vinblastine, cyclophosphamide and prednisone).
Topics: Adolescent; Adult; Aged; Child; Child, Preschool; Cyclophosphamide; Drug Therapy, Combination; Femal | 1980 |
[Chemotherapy of non-Hodgkin lymphomas].
Topics: Adult; Burkitt Lymphoma; Child; Cyclophosphamide; Drug Therapy, Combination; Humans; Leukemia, Hairy | 1980 |
Cutaneous T-cell lymphoma: clinicopathological relationships, therapy and survival in ninety-two patients.
Topics: Adult; Age Factors; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyc | 1982 |
The need of adequate staging and aggressive therapy in non-Hodgkin's lymphomas. Report of 66 cases.
Topics: Adolescent; Adult; Aged; Child; Cyclophosphamide; Female; Humans; Lymphoma; Male; Middle Aged; Neopl | 1983 |
Pulmonary fibrosis after prolonged treatment with low-dose cyclophosphamide. A case report.
Topics: Adult; Cyclophosphamide; Female; Humans; Lymphoma; Prednisone; Pulmonary Fibrosis; Radiography | 1983 |
Angioimmunoblastic lymphadenopathy with scleromyxedema-like lesions and serum monoclonal protein.
Topics: Bone Marrow Examination; Cyclophosphamide; Doxorubicin; Humans; Immunoblastic Lymphadenopathy; Immun | 1983 |
Lymphomatoid granulomatosis beginning as adult respiratory distress syndrome and rapidly progressing to lymphoma.
Topics: Adult; Antineoplastic Agents; Female; Humans; Intubation, Intratracheal; Lung; Lung Neoplasms; Lymph | 1983 |
Renal immunoblastic sarcoma complicating immunosuppressive therapy for Wegener granulomatosis.
Topics: Aged; Cyclophosphamide; Female; Granulomatosis with Polyangiitis; Humans; Kidney Neoplasms; Lymphoma | 1983 |
Septic arthritis due to Mycoplasma hominis.
Topics: Arthritis, Infectious; Biopsy; Female; Hip Joint; Humans; Lymph Nodes; Lymphoma; Middle Aged; Mycopl | 1983 |
Pretreatment nausea in cancer chemotherapy: a conditioned response?
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Conditioning, Psycholo | 1980 |
Combination chemotherapy (CVP or CHOP)- radiotherapy approach in early stage non-Hodgkins's lymphomas.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cobalt Radioisotopes; Cycloph | 1982 |
[Advantages of thoracic CT scanning in the treatment of mediastinal lymphomas].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Humans; Lymphoma; Mechlorethamine | 1982 |
Cytostatic drugs are without significant effect on digitoxin plasma level and renal excretion.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabin | 1982 |
Chemotherapy of advanced non-Hodgkin lymphomas: a report of 35 cases.
Topics: Antineoplastic Agents; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; Female; Humans; Lym | 1982 |
A phase II study of vindesine in patients with hematological malignancies.
Topics: Child; Dose-Response Relationship, Drug; Drug Evaluation; Drug Therapy, Combination; Humans; Leukemi | 1980 |
Current trends in childhood acute lymphocytic leukemia and non-hodgkin's lymphoma.
Topics: Adult; Age Factors; Asparaginase; Blood Cell Count; Bone Marrow Examination; Child; Child, Preschool | 1981 |
The Bollum enzyme in leukemia and lymphoma cells: the first decade.
Topics: Clinical Enzyme Tests; DNA Nucleotidylexotransferase; DNA Nucleotidyltransferases; Humans; Leukemia; | 1982 |
Combinations of methotrexate (COP or CHOP) in the treatment of previously untreated and treated lymphomas.
Topics: Adult; Aged; Antineoplastic Agents; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; Female | 1982 |
Effective multidrug, multimodality consolidation therapy of adult acute lymphocytic leukemia: a preliminary report.
Topics: Adult; Antineoplastic Agents; Doxorubicin; Drug Evaluation; Drug Therapy, Combination; Female; Human | 1982 |
[Chemotherapy of malignant lymphoma].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; | 1982 |
Moderate versus intensive chemotherapy of prognostically favorable non-Hodgkin's lymphoma: a progress report.
Topics: Cyclophosphamide; Drug Therapy, Combination; Humans; Lymphoma; Lymphoma, Large B-Cell, Diffuse; Lymp | 1980 |
[Results of chemotherapy with cyclophosphamide, vincristine, methotrexate and prednisone in recurring or disseminated non-Hodgkin lymphomas in the University of Kiel Radiology Clinic].
Topics: Cyclophosphamide; Drug Therapy, Combination; Humans; Lymphoma; Lymphoma, Non-Hodgkin; Methotrexate; | 1981 |
Anaphylactoid reactions to Escherichia coli and Erwinia asparaginase in children with leukemia and lymphoma.
Topics: Adolescent; Adult; Anaphylaxis; Antineoplastic Agents; Asparaginase; Child; Child, Preschool; Drug A | 1982 |
Deferral of initial therapy for advanced indolent lymphomas.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Therap | 1982 |
Role of combined-modality therapy in the curative management of advanced-stage "favorable" non-Hodgkin's lymphomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Therapy, Combination; Humans; | 1982 |
[Malignant tumors in bearers of kidney grafts in immunosuppressive therapy].
Topics: Adult; Antilymphocyte Serum; Azathioprine; Breast Neoplasms; Dysgerminoma; Female; Humans; Immunosup | 1982 |
Non-Hodgkin's lymphoma in Manitoba, 1968-77: the impact of chemotherapy.
Topics: Antineoplastic Agents; Cyclophosphamide; Drug Therapy, Combination; Follow-Up Studies; Histiocytes; | 1982 |
Lymphomatoid Granulomatosis. Prospective clinical and therapeutic experience over 10 years.
Topics: Adolescent; Adult; Aged; Cyclophosphamide; Female; Follow-Up Studies; Humans; Lymphoma; Lymphomatoid | 1982 |
Chemotherapy for lymphoma in a patient with common variable immunodeficiency: case report, literature review, and recommendations for chemotherapy in immunodeficient patients.
Topics: Adult; Agammaglobulinemia; Aged; Child, Preschool; Cyclophosphamide; Drug Therapy, Combination; Fema | 1982 |
[Therapy of non-Hodgkin lymphomas].
Topics: Antineoplastic Agents; Cyclophosphamide; Cytarabine; Doxorubicin; Drug Therapy, Combination; Humans; | 1982 |
Non-Hodgkin's lymphoma in couples.
Topics: Aged; Cyclophosphamide; Drug Therapy, Combination; Female; Humans; Lymphoma; Male; Marriage; Middle | 1982 |
Salvage chemotherapy for non-Hodgkin's lymphoma.
Topics: Adult; Aged; Cytarabine; Drug Therapy, Combination; Female; Humans; Leukopenia; Lomustine; Lymphoma; | 1982 |
[IgD-paraproteinemia in lymphoplasmacytoid immunocytoma].
Topics: Chlorambucil; Cyclophosphamide; Diagnosis, Differential; Humans; Immunoglobulin D; Lymphoma; Male; M | 1982 |
Combination chemotherapy with cyclophosphamide, adriamycin, vincristine and prednisone (CHOP) for non-Hodgkin's lymphomas with unfavorable histology: preliminary results.
Topics: Adult; Aged; Antineoplastic Agents; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Dru | 1980 |
Histiocytic lymphoma following resolution of sarcoidosis.
Topics: Adult; Cyclophosphamide; Doxorubicin; Female; Histiocytes; Humans; Lymphoma; Mediastinal Neoplasms; | 1981 |
[Chemotherapy of non-Hodgkin lymphoma by the COP schedule].
Topics: Adolescent; Adult; Aged; Cyclophosphamide; Drug Administration Schedule; Drug Therapy, Combination; | 1981 |
Infections during intensive chemotherapy for non-Hodgkin's lymphoma.
Topics: Agranulocytosis; Bone Marrow Diseases; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; Fem | 1981 |
Evaluation of two combination chemotherapies in previously untreated non Hodgkin's lymphoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Daunorubici | 1981 |
[Prognostic changes in juvenile abdominal non-Hodgkin's lympomas (NHL)].
Topics: Adolescent; Child; Child, Preschool; Cyclophosphamide; Cytarabine; Daunorubicin; Female; Humans; Lym | 1980 |
The chemotherapy of lymphoblastic lymphoma.
Topics: Adolescent; Adult; Aged; Child; Child, Preschool; Cyclophosphamide; Doxorubicin; Drug Therapy, Combi | 1981 |
Resolution of longstanding protein-losing enteropathy in a patient with intestinal lymphangiectasia after treatment for malignant lymphoma.
Topics: Adult; Antineoplastic Agents; Breast Neoplasms; Cyclophosphamide; Drug Therapy, Combination; Female; | 1981 |
Primary malignant lymphoma of the uterine cervix shows favorable response to neoadjuvant chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Chemotherapy, Adjuvant; Cyclophosp | 1994 |
Secondary myelodysplastic syndrome following bone marrow transplantation: report of two cases.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow Transplantation; Combi | 1994 |
Analysis of chromosomal abnormalities in human sperm after chemotherapy by karyotyping and fluorescence in situ hybridization (FISH).
Topics: Aneuploidy; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Chromosome Aberrations; Cyclo | 1995 |
High grade malignant lymphoma with clinical characteristics and immunophenotype of natural killer cells.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow; Cyclophosphamide; Dox | 1995 |
The outcome of matched unrelated donor bone marrow transplantation in patients with hematologic malignancies using molecular typing for donor selection and graft-versus-host disease prophylaxis regimen of cyclosporine, methotrexate, and prednisone.
Topics: Adolescent; Adult; Bone Marrow Transplantation; Cyclosporine; Female; Graft Survival; Graft vs Host | 1995 |
Recent advances in the management of lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Doxorub | 1995 |
Clinical problem solving. The girl with the curl.
Topics: Acyclovir; Antitubercular Agents; Cyclosporine; Female; Fever; Herpesvirus 4, Human; Humans; Immunos | 1995 |
Clinicopathological features and management of immunoproliferative small intestinal disease and primary small intestinal lymphoma in Pakistan.
Topics: Adult; Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Disease Prog | 1995 |
Role of chemotherapy and GM-CSF on hemopoietic progenitor cell mobilization in multiple myeloma.
Topics: Adult; Aged; Antigens, CD; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Blood Cel | 1993 |
[Appropriate administration of granulocyte colony stimulating factor for malignant lymphoma of the head and neck].
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Cyclophosphamide; Cytarabine; Doxorubi | 1993 |
Use of a vascular access system for administration of chemotherapeutic agents to a ferret with lymphoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Catheters, Indwelling; Chlora | 1995 |
CNS lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Cyclophosphamide; | 1995 |
Empiric prednisone therapy for pulmonary toxic reaction after high-dose chemotherapy containing carmustine (BCNU).
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carmustine; Forced Expirato | 1995 |
Cyclophosphamide, doxorubicin, vincristine, and prednisone for primary central nervous system lymphoma: short-duration response and multifocal intracerebral recurrence preceding radiotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Cyclophospha | 1994 |
Primary small-intestinal lymphomas in Taiwan: immunoproliferative small-intestinal disease and nonimmunoproliferative small-intestinal disease.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; De | 1994 |
[Primary breast lymphoma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; C | 1993 |
Clinical aspects of primary thyroid lymphoma: diagnosis and treatment based on our experience of 119 cases.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Cycl | 1993 |
Lymphoplasmacytic keratitis in a ferret with lymphoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Ferrets; Keratitis; Lymph | 1993 |
Heart transplantation for chronic Chagas' heart disease.
Topics: Actuarial Analysis; Adolescent; Adult; Azathioprine; Cause of Death; Chagas Cardiomyopathy; Child; C | 1996 |
[Pulmonary manifestations of primary Gougerot-Sjögren syndrome. Apropos of 8 cases in a series of 35 patients].
Topics: Aged; Bronchi; Bronchoalveolar Lavage Fluid; Cyclophosphamide; Diagnosis, Differential; Drug Therapy | 1996 |
Scintigraphic detection of a disseminated synovial lymphoma in a postrenal transplant patient.
Topics: Adult; Anti-Inflammatory Agents; Biopsy; Cyclosporine; Female; Gallium Radioisotopes; Humans; Immuno | 1996 |
[Bilateral highly malignant centroblastic lymphoma of the breast].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Breast Neoplasms; Cyclophosphamide; Doxor | 1996 |
Doxorubicin alone or in combination with asparaginase, followed by cyclophosphamide, vincristine, and prednisone for treatment of multicentric lymphoma in dogs: 121 cases (1987-1995).
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; | 1997 |
[Lymphoma in the elderly].
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Fe | 1996 |
Five-year follow-up of saliva in patients treated for lymphomas.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Amylases; Analysis of Variance; Antineoplastic Combined Ch | 1997 |
Expression of the multidrug resistance-associated protein gene in refractory lymphoma: quantitation by a validated polymerase chain reaction assay.
Topics: Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Membe | 1997 |
[Clinical study of primary central nervous system lymphoma: the role of chemotherapy].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neop | 1997 |
Herpes simplex infection of the jejunum occurring in the early post-transplantation period.
Topics: Adult; Anti-Inflammatory Agents; Bone Marrow Transplantation; Diagnosis, Differential; DNA, Viral; E | 1997 |
Clinical presentation and therapeutic outcome in 26 patients with primary CNS lymphoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protoc | 1998 |
Treatment of multifocal lymphoma of bone with intensified ProMACE-CytaBOM chemotherapy and involved field radiotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Neoplasms; Combined Mod | 1998 |
Levels of proteins C and S do not decline subsequent to first line chemotherapy in lymphoma patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; alpha-2-Antiplasmin; Antineoplastic Combined Chemotherap | 1997 |
[Thyroid lymphoma: a not so unusual disease].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; | 1998 |
Results of chemotherapy for cats with alimentary malignant lymphoma: 21 cases (1993-1997)
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Cat Diseases; Cats; Cyclophos | 1998 |
Spontaneous gastrointestinal perforation in patients with lymphoma receiving chemotherapy and steroids. Report of three cases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Fatal Ou | 1999 |
Disturbances in oral and dental structures in patients with pediatric lymphoma after chemotherapy: a preliminary report.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bleomycin; Case-Control St | 1999 |
Is there a role for surgical resection in the treatment of early-stage pancreatic lymphoma?
Topics: Adult; Aged; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; | 2000 |
Primary central nervous system lymphoma in Japan: a nationwide survey.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Ne | 1999 |
Autologous stem cell transplantation in a lymphoma patient with a long history of ankylosing spondylitis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Antirheumatic Agents; Combined Modality Therap | 2000 |
Epoch-cyclosporin A induces high response rates in relapsed lymphomas.
Topics: Actuarial Analysis; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cyclosporine; | 2000 |
Natural killer-cell lymphoma involving the gynecologic tract.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cervix Uteri; Cyclophospha | 2000 |
Bone marrow involvement by nasal NK cell lymphoma at diagnosis is uncommon.
Topics: Adult; Aged; Aged, 80 and over; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Bleomycin | 2001 |
Malignant lymphoma of the bone associated with systemic sarcoidosis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Neoplasms; Cyclophosphamide; Doxor | 2001 |
Primary lymphoma of bones.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Bone Neopla | 2001 |
Bulky disease is an adverse prognostic factor in patients treated with chemotherapy comprised of cyclophosphamide, doxorubicin, vincristine, and prednisone with or without radiotherapy for aggressive lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined | 2001 |
Primary thyroid lymphoma is a heterogeneous disease.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Goiter, Nodul | 2002 |
Lymphomatous infiltration of the kidney associated with glomerulopathy presenting as acute renal failure.
Topics: Acute Kidney Injury; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; | 2001 |
A sequence of immuno-chemotherapy with Rituximab, mobilization of in vivo purged stem cells, high-dose chemotherapy and autotransplant is an effective and non-toxic treatment for advanced follicular and mantle cell lymphoma.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antine | 2002 |
Comparison of interleukin-12 with lung cancer and malignant lymphoma undergoing autologous peripheral blood stem cell transplantation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cyclophospham | 2002 |
[Criteria for choice of therapeutic procedures in lymphomas].
Topics: Antineoplastic Agents; Bleomycin; Cobalt Radioisotopes; Doxorubicin; Drug Therapy, Combination; Hodg | 1975 |
[Treatment of malignant lymphomas with shock doses of peptichemio].
Topics: Adult; Aged; Antineoplastic Agents; Bleomycin; Blood Cells; Drug Therapy, Combination; Hodgkin Disea | 1975 |
New agents and combination chemotherapy of non-Hodgkin's lymphoma.
Topics: Animals; Antineoplastic Agents; Bleomycin; Cyclophosphamide; Doxorubicin; Drug Synergism; Drug Thera | 1975 |
Bleomycin, adriamycin, cyclophosphamide, vincristine, and prednisone (BACOP) combination chemotherapy in the treatment of advanced diffuse histiocytic lymphoma.
Topics: Adult; Aged; Bleomycin; Cyclophosphamide; Dose-Response Relationship, Drug; Doxorubicin; Drug Admini | 1976 |
Combination chemotherapy ("CHOP-Bleo") in advanced (non-Hodgkin) malignant lymphoma.
Topics: Adult; Aged; Alopecia; Bleomycin; Bone Marrow; Cell Transformation, Neoplastic; Cyclophosphamide; Do | 1977 |
Imidazole carboxamide (DTIC) in the treatment of advanced lymphomas. Efficacy of DTIC in cases which fail to respond to conventional chemotherupetic combinations.
Topics: Adult; Bleomycin; Cyclophosphamide; Dacarbazine; Drug Evaluation; Drug Resistance; Drug Therapy, Com | 1977 |
Combination chemotherapy of advanced non-Hodgkin lymphoma with bleomycin, adriamycin, cyclophosphamide, vincristine, and prednisone (BACOP).
Topics: Adolescent; Adult; Aged; Bleomycin; Central Nervous System Diseases; Cyclophosphamide; Doxorubicin; | 1977 |
[Chemotherapy in non-Hodgkin's lymphomas (author's transl)].
Topics: Antineoplastic Agents; Bleomycin; Burkitt Lymphoma; Chlorambucil; Cyclophosphamide; Doxorubicin; Dru | 1977 |
Multiple agent chemotherapy including bleomycin of non-Hodgkin's lymphoma during pregnancy.
Topics: Adult; Antineoplastic Agents; Bleomycin; Cyclophosphamide; Drug Therapy, Combination; Female; Fetus; | 1977 |
A kinetically designed chemotherapeutic regimen for advanced refractory lymphoma patients.
Topics: Adolescent; Adult; Aged; Bleomycin; Doxorubicin; Drug Administration Schedule; Female; Hodgkin Disea | 1978 |
Sister chromatid exchange in lymphocytes from patients with malignant lymphoma.
Topics: Adolescent; Adult; Aged; Bleomycin; Chromosomes, Human; Crossing Over, Genetic; Cyclophosphamide; Do | 1978 |
[Intermittent chlorambucil-prednisone therapy in low malignancy non-Hodgkin lymphoma and cyclic induction chemotherapy with COP-bleomycin of severe non-Hodgkin lymphoma according to the Kiel classification].
Topics: Bleomycin; Chlorambucil; Drug Therapy, Combination; Lymphoma; Neoplasm Invasiveness; Neoplasm Stagin | 1978 |
Adrenal suppression after short-term corticosteroid therapy.
Topics: Adolescent; Adrenal Cortex Function Tests; Adrenal Glands; Adrenal Insufficiency; Adrenocorticotropi | 1979 |
[Chemotherapy of malignant skeletal tumors (author's transl)].
Topics: Bone Neoplasms; Breast Neoplasms; Cyclophosphamide; Humans; Lymphoma; Melphalan; Multiple Myeloma; N | 1979 |
Primary malignant lymphoma of the CNS and polyneuropathy in a patient with necrotizing vasculitis treated with immunosuppression.
Topics: Azathioprine; Brain Neoplasms; Female; Humans; Immunosuppressive Agents; Lymphoma; Middle Aged; Necr | 1979 |
Combination chemotherapy of advanced, diffuse, non-Hodgkin's lymphoma: results with cyclo-phosphamide, adriamycin, vincristine, prednisone, and bleomycin (CHOP-Bleo).
Topics: Adult; Aged; Antineoplastic Agents; Bleomycin; Cyclophosphamide; Doxorubicin; Drug Therapy, Combinat | 1979 |
[Therapy of non-Hodgkin lymphomas].
Topics: Bleomycin; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; Humans; Lymphoma; Mustard Compo | 1979 |
Childhood cancer: the improving prognosis.
Topics: Asparaginase; Child; Cyclophosphamide; Cytosine; Daunorubicin; Doxorubicin; Drug Therapy, Combinatio | 1976 |
Fatal strongyloidiasis. In immunosuppressed patients.
Topics: Adult; Female; Humans; Immunity; Immunosuppression Therapy; Lymphoma; Male; Middle Aged; Prednisone; | 1977 |
Terminal transferase: its evolving role.
Topics: DNA Nucleotidyltransferases; Humans; Leukemia, Myeloid; Leukocytes; Lymphoma; Oligonucleotides; Pred | 1978 |
Myelogenous leukemia evolving during the course of lymphoid malignancy in children.
Topics: Child, Preschool; Cyclophosphamide; Female; Humans; Leukemia, Lymphoid; Leukemia, Myeloid; Leukemia, | 1979 |
[Angioimmunoblastic lymphadenopathy. An important differential diagnosis lymphoma].
Topics: Aged; Diagnosis, Differential; Humans; Immunoblastic Lymphadenopathy; Lymphoma; Male; Prednisone | 1979 |
[Combination of adriamycin, VM 26, cyclophosphamide and prednisone in the treatment of hematosarcomas].
Topics: Adolescent; Adult; Aged; Cyclophosphamide; Doxorubicin; Drug Evaluation; Drug Therapy, Combination; | 1977 |
[Therapy of non-Hodgkin lymphomas with COP and COPP regimens (author's transl)].
Topics: Antineoplastic Agents; Cyclophosphamide; Drug Therapy, Combination; Humans; Lymphoma; Lymphoma, Larg | 1977 |
Non-Hodgkin's lymphoma in children.
Topics: Adolescent; Antineoplastic Agents; Child; Child, Preschool; Cyclophosphamide; Drug Therapy, Combinat | 1978 |
Improvement in complete response rate, duration of response and survival with adriamycin combination chemotherapy for non-Hodgkin lymphoma: a prognostic factor comparison of two regimens.
Topics: Antineoplastic Agents; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; Female; Humans; Lym | 1978 |
Prolonged disease-free survival in dogs with lymphoma after total-body irradiation and autologous marrow transplantation consolidation of combination-chemotherapy-induced remissions.
Topics: Animals; Antineoplastic Agents; Asparaginase; Bone Marrow Transplantation; Cyclophosphamide; Dogs; D | 1979 |
Intermittent combination chemotherapy with chlorambucil and prednisone of low-grade malignant non-Hodgkin's lymphomas according to the Kiel classification.
Topics: Adult; Aged; Bone Marrow; Chlorambucil; Drug Administration Schedule; Drug Therapy, Combination; Fem | 1979 |
Some effects of chemotherapeutic drugs on bone marrow stem cells. II. Effect on non-Hodgkin lymphoma chemotherapy on various hemopoietic compartments of the mouse.
Topics: Animals; Antineoplastic Agents; Bone Marrow; Bone Marrow Diseases; Colony-Forming Units Assay; Doxor | 1979 |
Malignant progression of angioimmunoblastic lymphadenopathy.
Topics: Aged; Biopsy; Cell Transformation, Neoplastic; Chromosome Aberrations; Female; Humans; Immunoblastic | 1979 |
[Results of treatment of advanced cases of non-Hodgkin's-lymphoma (author's transl)].
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Cyclophosphamide; Doxorubicin; Drug Administration S | 1979 |
Regression of lymphomatous polyposis of the rectum after COP-treatment.
Topics: Aged; Cyclophosphamide; Drug Therapy, Combination; Humans; Lymphoma; Male; Prednisone; Rectal Neopla | 1979 |
Sequential study of the bone marrow granulocytic progenitor cells (CFC *) in children treated by chemotherapy for non-hodgkin malignant lymphomas.
Topics: Adolescent; Antineoplastic Agents; Bone Marrow; Child; Child, Preschool; Cyclophosphamide; Doxorubic | 1979 |
[Non-Hodgkin's lymphoma in children: improved prognosis through aggressive multiple drug combination and irradiation (author's transl)].
Topics: Adolescent; Age Factors; Child; Child, Preschool; Cyclophosphamide; Female; Humans; Lymphoma; Male; | 1979 |
Total body irradiation and cyclophosphamide, vincristine, prednisone in the treatment of favorable prognosis non-Hodgkin's lymphomas.
Topics: Adult; Antineoplastic Agents; Bone Marrow; Cyclophosphamide; Drug Therapy, Combination; Female; Huma | 1979 |
Complete sternal collapse associated with lymphomatous involvement of the bony thorax--case report and review of the literature.
Topics: Body Height; Bone Neoplasms; Cyclophosphamide; Drug Therapy, Combination; Fractures, Bone; Humans; K | 1977 |
Factors predicting for response and survival in adults with advanced non-Hodgkin's lymphoma.
Topics: Cyclophosphamide; Drug Therapy, Combination; Female; Hemoglobins; Humans; Leukocyte Count; Lymphoma; | 1978 |
Malignant lymphoma arising in angioimmunoblastic lymphadenopathy.
Topics: Adult; Aged; Antineoplastic Agents; Female; Humans; Immune System Diseases; Lymphatic Diseases; Lymp | 1978 |
When "lymphoma" is not lymphoma: diagnosing immunoblastic lymphadenopathy.
Topics: Adult; Biopsy; Diagnosis, Differential; Female; Humans; Lymph Nodes; Lymphatic Diseases; Lymphoma; M | 1978 |
Disseminated infection by Fusarium moniliforme during treatment for malignant lymphoma.
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Agents; Fusarium; Humans; Lymphoma; Male; Mycoses | 1978 |
Behçet's disease associated with a lymphoproliferative disorder, mixed cryoglobulinemia, and an immune complex mediated vasculitis.
Topics: Antigen-Antibody Complex; Behcet Syndrome; Chlorambucil; Cryoglobulins; Female; Follow-Up Studies; H | 1978 |
Lymphomatoid granulomatosis after immunosuppression for pemphigus.
Topics: Aged; Autopsy; Azathioprine; Granuloma; Humans; Immunosuppressive Agents; Lung; Lymphoma; Male; Pemp | 1978 |
[Comparative study of two drug combination in non-Hodgkin's lymphoma (author's transl)].
Topics: Adolescent; Adult; Antineoplastic Agents; Cyclophosphamide; Drug Evaluation; Drug Therapy, Combinati | 1978 |
[Polychemotherapy of lymphomas. Results of a selection of 32 cases diagnosed in stage III and stage IV and not previously treated].
Topics: Antineoplastic Agents; Drug Therapy, Combination; Hodgkin Disease; Humans; Lymphoma; Mechlorethamine | 1978 |
Non-Hodgkin's lymphomas-present status of chemotherapy.
Topics: Adult; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; Humans; Lymphoma; Lymphoma, Large B | 1975 |
[Combination chemotherapy and synchronization therapy in lymphogranulomatosis and non-Hodgkin's lymphomas].
Topics: Antineoplastic Agents; Cyclophosphamide; Drug Therapy, Combination; Hodgkin Disease; Humans; Lymphom | 1976 |
Hydroxyldaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma.
Topics: Cyclophosphamide; Cytarabine; Doxorubicin; Drug Therapy, Combination; Female; Humans; Lymphoma; Lymp | 1976 |
Hydroxyldaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma.
Topics: Cyclophosphamide; Cytarabine; Doxorubicin; Drug Therapy, Combination; Female; Humans; Lymphoma; Lymp | 1976 |
Hydroxyldaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma.
Topics: Cyclophosphamide; Cytarabine; Doxorubicin; Drug Therapy, Combination; Female; Humans; Lymphoma; Lymp | 1976 |
Hydroxyldaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma.
Topics: Cyclophosphamide; Cytarabine; Doxorubicin; Drug Therapy, Combination; Female; Humans; Lymphoma; Lymp | 1976 |
Hydroxyldaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma.
Topics: Cyclophosphamide; Cytarabine; Doxorubicin; Drug Therapy, Combination; Female; Humans; Lymphoma; Lymp | 1976 |
Hydroxyldaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma.
Topics: Cyclophosphamide; Cytarabine; Doxorubicin; Drug Therapy, Combination; Female; Humans; Lymphoma; Lymp | 1976 |
Hydroxyldaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma.
Topics: Cyclophosphamide; Cytarabine; Doxorubicin; Drug Therapy, Combination; Female; Humans; Lymphoma; Lymp | 1976 |
Hydroxyldaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma.
Topics: Cyclophosphamide; Cytarabine; Doxorubicin; Drug Therapy, Combination; Female; Humans; Lymphoma; Lymp | 1976 |
Hydroxyldaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma.
Topics: Cyclophosphamide; Cytarabine; Doxorubicin; Drug Therapy, Combination; Female; Humans; Lymphoma; Lymp | 1976 |
Immunoblastic lymphadenopathy with mixed cryoglobulinemia. A detailed case study.
Topics: Complement System Proteins; Cryoglobulins; Cyclophosphamide; Diagnosis, Differential; Drug Hypersens | 1975 |
Malignant lymphoma presenting as unilateral exophtalmos and thyroid nodule (author's transl)
Topics: Axilla; Exophthalmos; Heart Neoplasms; Humans; Lymphoma; Lymphoma, Non-Hodgkin; Male; Mechlorethamin | 1975 |
Abdominal lymphoma with alpha-heavy chain disease.
Topics: Abdominal Neoplasms; Adult; Autopsy; Cyclophosphamide; Heavy Chain Disease; Humans; Immunoglobulin a | 1975 |
On a case of oesophagus involvement by non-Hodgkin's lymphoma. Remission by chemotherapy alone.
Topics: Adult; Cyclophosphamide; Diverticulum, Esophageal; Drug Therapy, Combination; Esophageal Stenosis; H | 1976 |
[Immunoblastic sarcoma with clinically primary manifestation in the testis (author's transl)].
Topics: Aged; Castration; Cyclophosphamide; Humans; Lymphoma; Male; Middle Aged; Prednisone; Testicular Neop | 1977 |
[Preliminary analysis of results of chemotherapy in patients with proliferative disease of the lymphatic system with the exclusion of Hodgkin's disease using vincristine, cyclophosphamide and prednisone].
Topics: Adolescent; Adult; Aged; Cyclophosphamide; Drug Therapy, Combination; Female; Humans; Lymphoma; Male | 1977 |
[Therapeutical evaluation of two chemotherapy regimens in 38 non-Hodgkin lymphomas (author's transl)].
Topics: Antineoplastic Agents; Cyclophosphamide; Cytarabine; Drug Therapy, Combination; Female; Humans; Lymp | 1977 |
[Combined treatment of malignant lymphoma].
Topics: Antineoplastic Agents; Drug Therapy, Combination; Humans; Lymphoma; Nitrogen Mustard Compounds; Pred | 1977 |
Avascular necrosis of the femoral head with combination therapy.
Topics: Adult; Antineoplastic Agents; Cyclophosphamide; Female; Femur Head; Femur Head Necrosis; Hodgkin Dis | 1976 |
Chemotherapy of advanced malignant lymphomas comparative evaluation of results with single agent and combination therapy.
Topics: Antineoplastic Agents; Drug Therapy, Combination; Female; Hodgkin Disease; Humans; Lymphoma; Male; N | 1976 |
[Proliferation and growth of lymphatic cell population in malignant lymphomas].
Topics: Chlorambucil; Cytogenetics; Hematopoiesis; Hodgkin Disease; Humans; Leukemia, Lymphoid; Lymphocytes; | 1976 |
Recent trends in the treatment of non-Hodgkin's lymphomas.
Topics: Child; Cyclophosphamide; Drug Therapy, Combination; Humans; Lymphoma; Prednisone; Remission, Spontan | 1976 |
Early detection of chemotherapy-related pancreatic enlargement in children using abdominal sonography: a preliminary report.
Topics: Adolescent; Asparaginase; Child; Female; Humans; Leukemia, Lymphoid; Lymphoma; Male; Pancreatitis; P | 1976 |
[Curative aspects of modern combination chemotherapy in generalized malignant lymphomas].
Topics: Agranulocytosis; Cyclophosphamide; Drug Therapy, Combination; Female; Hodgkin Disease; Humans; Life | 1976 |
Drugs five years later: cytarabine.
Topics: Acute Disease; Adult; Animals; Bone Marrow Diseases; Central Nervous System Diseases; Cyclophosphami | 1975 |
Experience in the treatment of malignant lymphomas.
Topics: Adolescent; Adult; Aged; Female; Hodgkin Disease; Humans; Lymphoma; Male; Middle Aged; Nitrogen Must | 1976 |
Combined cyclophosphamide vincristine, procarbazine, and prednisone (COPP) therapy of malignant lymphoma. Evaluation of 190 patients.
Topics: Adolescent; Adult; Aged; Child; Child, Preschool; Cyclophosphamide; Drug Therapy, Combination; Femal | 1975 |
Results of combination chemotherapy of non-Hodgkin's lymphoma.
Topics: Antineoplastic Agents; Cyclophosphamide; Drug Therapy, Combination; Humans; Lymphoma; Lymphoma, Larg | 1975 |
1,3-bis(2-chloroethyl)-1-nitrosourea(BCNU), cyclophosphamide, vincristine- and prednisone-(BCOP). A new therapeutic regimen for diffuse histiocytic lymphoma.
Topics: Carmustine; Cyclophosphamide; Cytarabine; Drug Therapy, Combination; Humans; Lymphoma; Lymphoma, Lar | 1975 |
Management of Hodgkin's and non-Hodgkin's lymphomas.
Topics: Administration, Oral; Cyclophosphamide; Drug Therapy, Combination; Hodgkin Disease; Humans; Injectio | 1975 |
Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 31-1975.
Topics: Biopsy; Cyclophosphamide; Diagnosis, Differential; Granuloma; Granulomatosis with Polyangiitis; Huma | 1975 |
[Letter: Mopp type chemotherapy applied to lymphomas. A repeated study of the immune profile of 20 patients subjected to this therapy].
Topics: Antineoplastic Agents; Drug Therapy, Combination; Humans; Immunoglobulins; Lymphocytes; Lymphoma; Mo | 1975 |
The treatment of non-Hodgkin's lymphoma.
Topics: Cyclophosphamide; Drug Therapy, Combination; Humans; Lymphoma; Prednisone; Vincristine | 1975 |
Angio-immunoblastic lymphadenopathy. Diagnosis and clinical course.
Topics: Adult; Aged; Antineoplastic Agents; Bone Marrow; Diagnosis, Differential; Female; Humans; Lymph Node | 1975 |
Osteonecrosis of the femoral head in patients with lymphoma treated with intermittent combination chemotherapy (including corticosteroids).
Topics: Adrenal Cortex Hormones; Adult; Aged; Alkylating Agents; Antineoplastic Agents; Drug Therapy, Combin | 1975 |
Non-Hodgkin's lymphoma in children.
Topics: Adolescent; Asparaginase; Bone Marrow; Brain Neoplasms; Carmustine; Child; Child, Preschool; Cycloph | 1975 |
Combination chemotherapy with vincristine, cyclophosphamide, and prednisone producing long-term remission of a transplanted canine lymphoma.
Topics: Animals; Cyclophosphamide; Dog Diseases; Dogs; Drug Therapy, Combination; Female; Lymph Nodes; Lymph | 1975 |
Effect of splenectomy on tolerance to combination chemotherapy in patients with lymphoma.
Topics: Cyclophosphamide; Drug Therapy, Combination; Hodgkin Disease; Humans; Lymphoma; Mechlorethamine; Pos | 1976 |
Non-Hodgkin's lymphoma in children. A comparative study of two modalities of therapy.
Topics: Adolescent; Antineoplastic Agents; Asparaginase; Carmustine; Child; Child, Preschool; Cyclophosphami | 1976 |
Combination chemotherapy with cyclophosphamide, vincristine, and prednisone in advanced non-Hodgkin's lymphomas.
Topics: Adult; Cyclophosphamide; Drug Therapy, Combination; Female; Humans; Lymphoma; Male; Middle Aged; Pre | 1976 |
Neurologic manifestations of hypothalamic disease.
Topics: Adult; Aged; Bromocriptine; Female; Humans; Hypothalamic Neoplasms; Lymphoma; Magnetic Resonance Ima | 1992 |
[Primary gastric lymphoma. Role of surgery].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; D | 1992 |
[Thyroid lymphoma. A medical emergency].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Emergencies; Female; | 1992 |
Management of primary cerebral lymphoma with initial chemotherapy: preliminary results and comparison with patients treated with radiotherapy alone.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Brain Neoplasms; Combined Modality | 1990 |
Gastric lymphomas: chemotherapy as a primary treatment.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomyci | 1990 |
[The COP-BLAM therapy for malignant lymphoma].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophos | 1990 |
Pneumothorax following cytotoxic chemotherapy in malignant lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Cytarabine; Daca | 1990 |
Lymphoma of the gastric stump: report of a case.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubicin; Gastrectom | 1991 |
Malignant lymphomas in HIV-seropositive patients. Frequency, features, and prognosis. Report on 31 cases.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Central Nervous System Neoplasms; | 1991 |
A reexamination of the relationship between myositis and malignancy.
Topics: Adult; Aged; Breast Neoplasms; Female; Humans; Kidney Neoplasms; Lung Neoplasms; Lymphoma; Male; Mid | 1991 |
Malignant lymphoma and coexistent tuberculous lymphadenitis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Antitubercular Agents; Cyclophosphamide; Humans; Lym | 1991 |
Treatment of end-stage chronic obstructive pulmonary disease with double lung transplantation.
Topics: Adult; Antibodies, Monoclonal; Azathioprine; Cyclosporins; Cytomegalovirus Infections; Emphysema; Fe | 1991 |
Case report: the incidental lipid embolization to the brain and kidney after lymphography in a patient with malignant lymphoma: CT findings.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Diseases; Cyclophosphamide; Doxorubicin; Embol | 1991 |
Splenic lymphoma with villous lymphocytes: natural history and response to therapy in 50 cases.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Combin | 1991 |
Active oxygen radicals produced by leukocytes of malignant lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Electron Spin Resonan | 1990 |
Orbital pseudotumor, differential diagnosis.
Topics: Aged; Diagnosis, Differential; Exophthalmos; Eye Movements; Eyelid Diseases; Fibroma; Humans; Inflam | 1990 |
Acute hepatic injury after the withdrawal of immunosuppressive chemotherapy in patients with hepatitis B.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chronic Disease; Female; Hepatitis B; Hepatit | 1990 |
Primary nasal-paranasal oropharyngeal lymphoma in the pediatric age group.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cyclophosphamid | 1990 |
Primary hepatic lymphoma in an adolescent treated with hepatic lobectomy and chemotherapy.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Combined Modality Therapy | 1990 |
[Radiation therapy for unresected gastric lymphoma].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Presch | 1990 |
Chemotherapy for large-cell lymphoma: optimism and caution.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubicin; Drug Admin | 1985 |
Rosette formation in malignant lymphoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubicin; Fema | 1985 |
"Smouldering" and symptomatic forms of central nervous system involvement in the course of non-Hodgkin's lymphoma in children.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Transformation, Neoplastic; Ch | 1985 |
[Treatment of non-Hodgkin's lymphomas with CHOP-bleo. Experience in 16 patients].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubicin; Drug Evalu | 1985 |
[Malignant lymphoma].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality Therapy; Cycloph | 1985 |
Intensive and sequential combination chemotherapy for aggressive malignant lymphomas (protocol LNH-80).
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide | 1986 |
Chemotherapy for diffuse large-cell lymphoma--rapidly responding patients have more durable remissions.
Topics: Actuarial Analysis; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamid | 1986 |
Combined modality treatment in stage I and II diffuse non-Hodgkin's lymphomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality Therapy; C | 1985 |
Combination chemotherapy only for stage II non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide | 1986 |
Tumor burden assessment and its implication for a prognostic model in advanced diffuse large-cell lymphoma.
Topics: Abdominal Neoplasms; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Do | 1986 |
Morphology and incidence of the "posttherapeutic lymphoid cell" in the bone marrow of children with acute lymphoblastic leukemia.
Topics: Adolescent; Bone Marrow; Child; Child, Preschool; Eosine Yellowish-(YS); Female; Humans; Infant; Leu | 1986 |
Acute leukemia in a patient cured of diffuse histiocytic lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Chromosome Deletion; Chromosomes, Human, | 1986 |
Hematologic malignancies: non-Hodgkin's lymphomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Dacarbazine; Doxorubici | 1986 |
Thyroid lymphomas stages IE and IIE: comparative results for radiotherapy only, combination chemotherapy only, and multimodality treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality Therapy; Cyclophosphami | 1986 |
A 10-year update of CHOP-Bleo in the treatment of diffuse large-cell lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide | 1986 |
[Contribution of anthracyclines in treatment of lymphoproliferative disorders].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Dacarbazine; Doxorubici | 1987 |
[A case of B cell malignant lymphoma with in the liver and brain metastasis in Hashimoto's disease].
Topics: Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Bleomycin; Brain Neoplasms; Cyclophos | 1987 |
The simultaneous presentation of peripheral T-cell lymphoma and hairy cell leukemia.
Topics: Antibodies, Monoclonal; Antigens, Differentiation, T-Lymphocyte; Antigens, Surface; Antineoplastic C | 1987 |
AIDS-related malignant lymphoma: results of prospective treatment trials.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antineoplastic Combined Chemotherapy Protocols; Asparagin | 1987 |
COPBLAM III: infusional combination chemotherapy for diffuse large-cell lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophos | 1988 |
Infusions, age, and drug doses: redux.
Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubici | 1988 |
Combination chemotherapy for primary small intestinal lymphoma in the Middle East.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Dexamethasone; D | 1989 |
Conservative management of primary cervical lymphoma using combination chemotherapy: a case report.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubicin; Fem | 1989 |
[Priapism with malignant lymphoma: a case report].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubicin; Huma | 1989 |
Steroid-withdrawal rosacea-like dermatitis.
Topics: Adult; Dermatitis; Humans; Lymphoma; Male; Prednisone; Rosacea | 1989 |
[A carcinoma of the right breast arising after a mastectomy in primary malignant lymphoma of the left breast].
Topics: Adenocarcinoma, Scirrhous; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combine | 1989 |
[Secondary leukemia (AML) with TcR beta rearrangement].
Topics: Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Cyclophosphamide; Female; Gene Rearra | 1989 |
[Ki-1 large cell lymphoma with secondary xanthomatous infiltration of the lesions by chemotherapy].
Topics: Aged; Aged, 80 and over; Antigens, Differentiation; Antigens, Neoplasm; Antineoplastic Agents; CD4-P | 1989 |
ProMACE-MOPP combination chemotherapy for diffuse lymphomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubicin; Etoposide; | 1985 |
[Treatment of malignant lymphoma in childhood].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Child; Child, Preschool; Comb | 1985 |
[Pagetoid lymphoma of the Ketron-Goodman type].
Topics: Adult; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; | 1989 |
[A case of cutaneous T cell lymphoma improved with local administration of tumor necrosis factor].
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Doxorub | 1989 |
Increased frequency of posttransplant lymphomas in patients treated with cyclosporin, azathioprine, and prednisone.
Topics: Azathioprine; Cyclosporins; Drug Therapy, Combination; Heart Transplantation; Humans; Immunosuppress | 1989 |
Natural killer cell activity in untreated and treated dogs with lymphoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytotoxicity, Immunologic | 1989 |
Recurrent fever in Sjøgren's syndrome.
Topics: Adult; Bone Marrow Examination; Diagnosis, Differential; Female; Fever of Unknown Origin; Humans; Ly | 1989 |
Combined modality therapy for localized aggressive lymphoma: enough or too much?
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Doxorub | 1989 |
Primary lymphoma of bone in children.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Combined Modality | 1989 |
Treatment of localized aggressive lymphomas with combination chemotherapy followed by involved-field radiation therapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Th | 1989 |
Infiltrative cardiomyopathy responsive to combination chemotherapy in a cat with lymphoma.
Topics: Animals; Cardiomyopathies; Cat Diseases; Cats; Cephalexin; Drug Therapy, Combination; Echocardiograp | 1989 |
The pathology of posttransplant lymphoproliferative disorders occurring in the setting of cyclosporine A-prednisone immunosuppression.
Topics: Adolescent; Adult; Child; Child, Preschool; Cyclosporins; Female; Genes, Immunoglobulin; Herpesvirus | 1988 |
Membrane phenotype and response to deoxycoformycin in mature T cell malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 1987 |
Side effects and emotional distress during cancer chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Cyclophosphamide; Doxor | 1989 |
Treatment and prognostic factors in lymphoma in cats: 103 cases (1977-1981).
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Cat Diseases; Cats; Cyclophos | 1989 |
Lymphoma chemotherapy as remission inducing treatment in rheumatoid arthritis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arthritis, Rheumatoid; Cyclophosphamide; Doxorubicin | 1989 |
Optic neuropathy associated with chronic lymphomatous meningitis.
Topics: Biopsy; Bone Marrow; Chronic Disease; Eye; Humans; Lymphoma; Male; Meningitis; Middle Aged; Nasal Mu | 1988 |
Effects of Mega-COMLA (cyclophosphamide, cytarabine, vincristine, and methotrexate followed by leucovorin and prednisone) plus CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) in the treatment of lymphoid neoplasms with very poor prognosi
Topics: Actuarial Analysis; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; C | 1986 |
Gastric signet-ring cell lymphoma with alpha heavy chains.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Duodenum; Gastric Juice; Humans; I | 1986 |
Diagnosis of polymyalgia rheumatica and giant cell arteritis: a note of caution.
Topics: Aged; Diagnosis, Differential; Female; Giant Cell Arteritis; Humans; Lymphoma; Male; Middle Aged; Mu | 1987 |
Mediastinal large cell lymphoma. An uncommon subset of adult lymphoma curable with combined modality therapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; | 1988 |
[Treatment of primary gastric lymphoma and factors that influence the prognosis].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophospha | 1988 |
Angiotropic large cell lymphoma presenting as interstitial lung disease.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Hemangioendot | 1988 |
[Treatment of extensive B-cell lymphoma in children: studies of the French Pediatric Oncology Society].
Topics: Actuarial Analysis; Adolescent; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Child | 1988 |
Malignant lymphoma arising in a large congenital neurofibroma of the head and neck. Report of a case.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Combined Modality Therap | 1988 |
Localized isolated angiitis of the central nervous system associated with primary intracerebral lymphoma.
Topics: Brain Neoplasms; Carotid Artery Diseases; Carotid Artery, Internal; Cerebral Arterial Diseases; Cycl | 1988 |
[Treatment of malignant lymphoma in Jichi Medical School Hospital. 3) Treatment of advanced bad-risk lymphoma with the M-CHOP regimen].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Drug Administration S | 1988 |
Intermittent high dose corticosteroid treatment in childhood cancer: behavioral and emotional consequences.
Topics: Adolescent; Appetite; Child; Child, Preschool; Emotions; Female; Humans; Leukemia, Lymphoid; Lymphom | 1986 |
Staging and therapy of orbital lymphomas.
Topics: Actuarial Analysis; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Neoplasm | 1986 |
[Pathological features and treatment of T lymphoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Humans; Leukemia; Lym | 1986 |
Difference in prognosis between T- and B-cell lymphomas: clinical study at Shikoku Cancer Center Hospital.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Combined Moda | 1986 |
Modified cyclophosphamide, vincristine, methotrexate, leucovorin, and cytarabine (COMLA) in intermediate- and high-grade lymphoma: an effective short-course regimen.
Topics: Actuarial Analysis; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; C | 1986 |
Primary chemotherapy for localized non-Hodgkin's lymphomas with diffuse histologic characteristics. Preliminary report of a prospective study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophospha | 1986 |
[A case of primary malignant lymphoma of the prostate].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Humans; Lymphoma; Male; Middle Age | 1987 |
Path model of multidimensional compliance with cancer therapy.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Allopurinol; Antineoplastic Combin | 1987 |
Compliance with oral drug therapy in patients with hematologic malignancy.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Allopurinol; Antineoplastic Agents; Appointmen | 1987 |
Sjögren's syndrome: severe upper airways obstruction due to primary malignant tracheal lymphoma developing during successful treatment of lymphocytic interstitial pneumonitis.
Topics: Aged; Airway Obstruction; Female; Humans; Lymphoma; Prednisone; Pulmonary Fibrosis; Sjogren's Syndro | 1987 |
[Clinical evaluation of cisplatin in children with malignant solid tumors. Pediatric Cisplatin Study Group].
Topics: Adrenal Gland Neoplasms; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Child; Chi | 1987 |
Combined modality therapy for adults with small noncleaved cell lymphoma (Burkitt's and non-Burkitt's types).
Topics: Abdominal Neoplasms; Actuarial Analysis; Adolescent; Adult; Aged; Antineoplastic Combined Chemothera | 1986 |
Mediastinal nonlymphoblastic lymphomas in children: a clinicopathologic study.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cyclophosphamid | 1986 |
Gastric non-Hodgkin's lymphoma after successful treatment of Hodgkin's disease.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Celiac Disease; Hodgkin Disease; Humans; Immun | 1986 |
Primary brain malignant non-Hodgkin lymphoma: report of a case treated with chemotherapy in combination with radiotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Combined Modality Therapy; Cy | 1986 |
Purpura fulminans in pneumococcal sepsis.
Topics: Acute Kidney Injury; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Fema | 1986 |
Intestinal cryptosporidiosis: a complication of cancer treatment.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Breast Neoplasms; Combin | 1986 |
Recent results of multimodal therapy of gastric lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophospha | 1986 |
[Pregnancy following chemotherapy of non-Hodgkin lymphoma].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; | 1986 |
Composite lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Humans | 1986 |
Advanced lymphoma and CHOP chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Humans; Lymphoma; Pre | 1986 |
The potential benefits of therapeutic splenectomy for patients with Hodgkin's disease and non-Hodgkin's lymphomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Tolerance; Female; Hod | 1985 |
An alternating chemotherapy and radiotherapy combination for non-Hodgkin's lymphomas of unfavourable histologies: feasibility and preliminary results.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; | 1985 |
Simultaneous presentation of relapsing Hodgkin's disease and treatment-related non-Hodgkin's lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Hodgkin Disease; Humans; | 1985 |
Progress in the management of high risk non-Hodgkin's lymphomas. 10 years of experience of the 3rd Medical Department of Hanusch Hospital, Vienna.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; | 1985 |
[Non-Hodgkin's lymphoma in children. Study of 30 patients at the Caracas University Hospital].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Combined Modali | 1985 |
Primary gastric lymphoma--the experience of a general hospital.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophospha | 1985 |
Non-Hodgkin's lymphoma of Waldeyer's ring.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Cyclophosphamide; Doxorubicin; Humans | 1985 |
Primary lymphoma of the cervix. A case report.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Humans | 1985 |
[Cytostatic polychemotherapy in the aged].
Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dac | 1985 |
[Full-dose CHOP chemotherapy--feasibility and influence upon radiotherapy].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; | 1985 |
Remarkable improvement of clinical status in a patient with multiple lymphomatous polyposis of the gastrointestinal tract after repetitive chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Drug Administr | 1985 |
Primary central nervous system lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Child, Preschool; Cran | 1985 |
Epidural spinal cord compression as the initial finding in childhood acute leukemia and non-Hodgkin lymphoma.
Topics: Acute Disease; Adolescent; Child; Child, Preschool; Daunorubicin; Dexamethasone; Female; Humans; Leu | 1985 |
[Non-Hodgkin lymphomas of the head and neck, stages I and II. Apropos 35 cases].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Combined Modality Therapy | 1985 |
High-dose adriamycin combination chemotherapy for intermediate and high-grade non-Hodgkin's lymphomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Cyclophosphamide; Cyt | 1985 |
Current status and new vistas in combination chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Combined Modality Therapy; Hodgkin Disease; H | 1985 |
[Malignant lymphoma of the skin].
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Diagnos | 1985 |
Significance of multiple types of antibodies on red blood cells of patients with positive direct antiglobulin test: a study of monospecific antiglobulin reactions in 85 patients.
Topics: Antibodies, Anti-Idiotypic; Antibody Specificity; Blood Group Antigens; Coombs Test; Humans; Leukemi | 1985 |
Non-Hodgkin's lymphomas in leukaemic phase: incidence, prognosis and therapeutic implications.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Bone Marrow | 1985 |
[Lymphocyte subpopulations in the peripheral blood during polychemotherapy of non-Hodgkin's lymphoma].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Cyclophospha | 1985 |
Effect of a luteinizing hormone releasing hormone agonist given during combination chemotherapy on posttherapy fertility in male patients with lymphoma: preliminary observations.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Drug Therapy, Combination; Fertil | 1985 |
Multifocal aggressive lymphoma of the gastrointestinal tract in a renal transplant patient treated with cyclosporin A and prednisone.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclosporins; Female; Gastrointestinal Neoplasms; Hu | 1985 |
Neoplasia in immunosuppressed renal transplant patients: a 20-year experience.
Topics: Adolescent; Adult; Aged; Antilymphocyte Serum; Azathioprine; Cadaver; Child; Child, Preschool; Cyclo | 1985 |
[Experience treating 30 cases of oromaxillofacial non-Hodgkin's lymphoma].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Combined Modality Th | 1985 |
A histologically occult lymphoma revealed by electron microscopy.
Topics: Aged; Biopsy; Chlorambucil; Demeclocycline; Diagnosis, Differential; Humans; Lymphoma; Male; Microsc | 1985 |
Primary lymphoma of bone in children: analysis of treatment results with adriamycin, prednisone, Oncovin (APO), and local radiation therapy.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Combined Modality | 1986 |
Treatment of diffuse aggressive non-Hodgkin's lymphomas with an intensive multi-drug regimen including high-dose cytosine arabinoside (F-MACHOP).
Topics: Adolescent; Adult; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide | 1985 |
[The significance of reinduction chemotherapy with adriamycin for relapsed non-Hodgkin's lymphoma of Waldeyer's ring].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; | 1985 |
[Prognostic usefulness of clinical and laboratory indicators in patients with advanced forms of non-Hodgkin lymphoma treated by the COP protocol].
Topics: Adolescent; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphami | 1985 |
Systemic lupus erythematosus six years following chemotherapy for malignant lymphoma.
Topics: Cyclophosphamide; Female; Humans; Lupus Erythematosus, Systemic; Lymphoma; Middle Aged; Prednisone; | 1985 |
De-novo brain tumours in renal-transplant recipients.
Topics: Adolescent; Adult; Azathioprine; Brain; Brain Neoplasms; Cadaver; Follow-Up Studies; Humans; Immunos | 1971 |
A two-stage therapeutic design in the spontaneous AKR lymphoma system.
Topics: Amides; Animals; Antineoplastic Agents; Azacitidine; Cyclic P-Oxides; Cyclophosphamide; Cytarabine; | 1972 |
Treatment of advanced malignant lymphomas with bleomycin.
Topics: Antibiotics, Antineoplastic; Bleomycin; Cyclophosphamide; Drug Combinations; Hodgkin Disease; Humans | 1972 |
Management of malignant lymphomas: a practical and philosophical approach.
Topics: Bleomycin; Cyclophosphamide; Hodgkin Disease; Hospitals, Special; Humans; Laparotomy; Lymphoma; Mech | 1973 |
Association of malignant melanoma and malignant lymphoma.
Topics: Biopsy; Cyclophosphamide; Lymphatic Metastasis; Lymphoma; Melanoma; Neoplasm Metastasis; Neoplasm Re | 1973 |
Treatment of non-Hodgkin's lymphoma. Standard treatment.
Topics: Antineoplastic Agents; Bleomycin; Cyclophosphamide; Drug Therapy, Combination; Humans; Immunotherapy | 1974 |
Incidence and forms of leukaemia among the Congolese Bantus.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Biopsy; Blood Protein Electrophoresis; Blood Sedimen | 1966 |
The role of immunology in the treatment of leukemias and hematosarcomas.
Topics: Animals; Antineoplastic Agents; Bone Marrow Transplantation; Burkitt Lymphoma; gamma-Globulins; Huma | 1967 |
Symptomatic control of fever in lymphoma and leukemia.
Topics: Adolescent; Adult; Aged; Aminopyrine; Analgesics; Aspirin; Female; Fever; Hodgkin Disease; Humans; I | 1969 |
An unusual dual hypersensitivity reaction induced by diphenylhydantoin.
Topics: Dermatitis, Exfoliative; Drug Hypersensitivity; Female; Humans; Leukocyte Count; Lymphoma; Middle Ag | 1973 |
Treatment of Sezary syndrome.
Topics: Chlorambucil; Cyclophosphamide; Dermatitis, Exfoliative; Humans; Keratoderma, Palmoplantar; Lymphati | 1974 |
[Rheumatoid polyarthritis and chronic lymphoid leukemia. Studies of 7 cases of association of these 2 diseases].
Topics: Adult; Age Factors; Aged; Animals; Antibodies; Arthritis, Rheumatoid; Autoimmune Diseases; Chlorambu | 1969 |
Chemotherapeutic agents in childhood malignancies.
Topics: Alkaloids; Alkylating Agents; Anti-Bacterial Agents; Antimetabolites; Asparaginase; Child; Humans; L | 1970 |
Neurology and neuropathology of immunosuppressive therapy and acquired immunological deficiency.
Topics: Adolescent; Adult; Agammaglobulinemia; Aspergillus; Azathioprine; Brain; Brain Diseases; Candida; Ce | 1971 |
Lymphography in systemic lupus erythematosus.
Topics: Adult; Antigen-Antibody Reactions; Cyclophosphamide; Diagnosis, Differential; Female; Humans; Lupus | 1971 |
Combination chemotherapy for spontaneous AKR lymphoma.
Topics: Animals; Antineoplastic Agents; Biological Assay; Carmustine; Cyclohexanes; Cyclophosphamide; Cytara | 1974 |
Chemotherapy and immunotherapy of three human lymphomas serially transplantable in the neonatal Syrian hamster.
Topics: Age Factors; Animals; Animals, Newborn; Antilymphocyte Serum; Cricetinae; Cyclophosphamide; Dactinom | 1972 |
Comparative chemotherapy of AKR lymphoma and human hematological neoplasia.
Topics: Animals; Antineoplastic Agents; Biological Assay; Carmustine; Cyclohexanes; Cyclophosphamide; Cytara | 1974 |
Infections associated with immunologic deficiency diseases.
Topics: Acute Kidney Injury; Adult; Agammaglobulinemia; Anti-Bacterial Agents; Antibody Formation; Aspergill | 1974 |
Lymphomas of the testicle.
Topics: Adult; Aged; Cyclophosphamide; Hodgkin Disease; Humans; Lymph Nodes; Lymphoma; Lymphoma, Large B-Cel | 1972 |
[Hodgkin's disease and other malignant lymphomas].
Topics: Hodgkin Disease; Humans; Lymphoma; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Prednison | 1972 |
Non-Hodgkin's lymphomas. II. Single agent chemotherapy.
Topics: Alkylating Agents; Chlorambucil; Cyclophosphamide; Humans; Lymphoma; Lymphoma, Large B-Cell, Diffuse | 1972 |
Single, combined and sequential use of uracil mustard and prednisone in the treatment of lymphoreticular tumors.
Topics: Drug Synergism; Hodgkin Disease; Humans; Lymphoma; Lymphoma, Large B-Cell, Diffuse; Prednisone; Urac | 1972 |
Management of patients with non-Hodgkin's lymphoma.
Topics: Antineoplastic Agents; Burkitt Lymphoma; Cyclophosphamide; Hodgkin Disease; Humans; Lymphography; Ly | 1973 |
Updated Hodgkin's disease. C. Advanced disease and special problems. Comment: the non-Hodgkin's lymphomas.
Topics: Burkitt Lymphoma; Cyclophosphamide; Hodgkin Disease; Humans; Leukemia; Lymphoma; Lymphoma, Large B-C | 1973 |
Alpha-chain disease in subSaharan Africa.
Topics: Adolescent; Adult; Cobalt Isotopes; Female; Heavy Chain Disease; Humans; Immunoelectrophoresis; Immu | 1973 |
Potential for prolonged disease-free survival following combination chemotherapy of non-Hodgkin's lymphoma.
Topics: Cyclophosphamide; Drug Therapy, Combination; Humans; Lymphoma; Lymphoma, Large B-Cell, Diffuse; Lymp | 1974 |
Treatment of Hodgkin's disease and other malignant lymphomas.
Topics: Alkylating Agents; Antineoplastic Agents; Carmustine; Chlorambucil; Cyclohexanes; Cyclophosphamide; | 1973 |
Blood and neoplastic diseases. Treatment of the lymphomas.
Topics: Alopecia; Bone Marrow; Cyclophosphamide; Hodgkin Disease; Humans; Lymphoma; Lymphoma, Follicular; Ne | 1974 |
Combination chemotherapy of advanced lymphoma.
Topics: Adult; Aged; Antineoplastic Agents; Cyclophosphamide; Drug Synergism; Female; Hodgkin Disease; Human | 1972 |
'Giant' orf of finger in a patient with a lymphoma.
Topics: Aged; Animals; Cyclophosphamide; Ecthyma, Contagious; Fingers; Humans; Immunosuppressive Agents; Lym | 1972 |
Combination chemotherapy for patients with malignant lymphoma.
Topics: Antineoplastic Agents; Drug Combinations; Follow-Up Studies; Humans; Lymphoma; Mechlorethamine; Pred | 1972 |
Antibody response in Hodgkin's disease and other lymphomas related to HL-A antigens, immunoglobulin levels and therapy.
Topics: Antibiotics, Antineoplastic; Antibody Formation; Complement Fixation Tests; Hemagglutination Inhibit | 1973 |
Chemotherapy of malignant lymphoma with adriamycin.
Topics: Cyclophosphamide; Cytarabine; Doxorubicin; Drug Therapy, Combination; Hematopoietic System; Hodgkin | 1973 |
Clinical and pathologic study of canine lymphoma: clinical staging, cell classification, and therapy.
Topics: Animals; Antineoplastic Agents; Bacterial Infections; Cyclophosphamide; Disease Models, Animal; Dog | 1973 |
Pseudolymphoma of the lung.
Topics: Adult; Aged; Antineoplastic Agents; Child; Female; Humans; Immunoglobulins; Immunosuppressive Agents | 1974 |
Observations on the diagnosis and treatment of sarcoidosis.
Topics: Biopsy; Diagnosis, Differential; Humans; Lymphoma; Prednisone; Sarcoidosis | 1974 |
The nitroblue tetrazolium (NBT) dye test in determining fever source in lymphoma.
Topics: Bacterial Infections; Diagnosis, Differential; Evaluation Studies as Topic; False Positive Reactions | 1974 |
Chemotherapy of the lymphomas.
Topics: Adult; Burkitt Lymphoma; Child; Chlorambucil; Cyclophosphamide; Doxorubicin; Drug Therapy, Combinati | 1974 |
[The role of vinblastine in the treatment of malignant lymphomas].
Topics: Adolescent; Adult; Aged; Cyclophosphamide; Female; Hodgkin Disease; Humans; Lymphoma; Lymphoma, Larg | 1968 |
Apparent chemotherapeutic cure of malignant lymphoma.
Topics: Adult; Antineoplastic Agents; Cyclophosphamide; Diagnosis, Differential; Histological Techniques; Hu | 1971 |
Malignant lymphomas in transplantation patients.
Topics: Adolescent; Adult; Antilymphocyte Serum; Azathioprine; Brain Neoplasms; Female; Humans; Immunosuppre | 1969 |
Rh-incompatible platelet transfusions--risks and consequences of sensitizing immunosuppressed patients.
Topics: Adolescent; Adult; Aged; Anemia, Aplastic; Antibodies; Antibody Formation; Blood Group Incompatibili | 1971 |
Non-Hodgkin's lymphomas. I. Bone marrow involvement.
Topics: Biopsy; Blood Platelets; Bone Marrow; Bone Marrow Examination; Chlorambucil; Cyclophosphamide; Hemat | 1972 |
Management of chylothorax secondary to lymphoma.
Topics: Abdominal Neoplasms; Chlorambucil; Chylothorax; Cyclophosphamide; Drainage; Humans; Lymphoma; Male; | 1972 |
Sarcoid reactions and sarcoidosis in Hodgkin's disease and other malignant lymphomata.
Topics: Adult; Aged; Autoimmune Diseases; Child; Female; Hodgkin Disease; Humans; Lymphoma; Male; Middle Age | 1972 |
Combination chemotherapy of advanced lymphomas.
Topics: Adult; Age Factors; Benzoates; Blood Cell Count; Blood Platelets; Cyclophosphamide; Drug Combination | 1972 |
[2 Cases of Löfgren's syndrome].
Topics: Adult; Erythema Nodosum; Female; Humans; Lung Neoplasms; Lymphoma; Middle Aged; Prednisone | 1972 |
Alpha heavy chain disease. A variant of Mediterranean lymphoma.
Topics: Abdominal Neoplasms; Adult; Cyclophosphamide; Ethnicity; Heavy Chain Disease; Humans; Immunoelectrop | 1971 |
Comments on treatment of leukemia in the cat.
Topics: Animals; Cat Diseases; Cats; Cyclophosphamide; Dog Diseases; Dogs; Leukemia; Lymphoma; Lymphoma, Non | 1971 |
[Hematologic therapy of malignant lymphoma].
Topics: Anemia; Blood Platelets; Blood Transfusion; Erythrocytes; Female; Hodgkin Disease; Humans; Lymphoma; | 1971 |
[Delayed hypersensitivity reaction to 2,4-dinitrochlorobenzol in cancer patients undergoing cytostatic chemotherapy].
Topics: Age Factors; Aged; Bronchial Neoplasms; Carcinoma; Cyclophosphamide; Drug Antagonism; Fractures, Bon | 1971 |
Progress in treatment for the leukemias and lymphomas.
Topics: Antineoplastic Agents; Drug Synergism; Hodgkin Disease; Humans; Leukemia, Lymphoid; Leukemia, Myeloi | 1965 |
Some problems in the management of leukaemia and lymphoma.
Topics: Antineoplastic Agents; Busulfan; Cyclophosphamide; Female; Humans; Leukemia; Leukemia, Lymphoid; Leu | 1966 |
[Guidelines in the therapy of various neoplastic diseases with cytostatic drugs].
Topics: Alkylating Agents; Antineoplastic Agents; Breast Neoplasms; Bronchial Neoplasms; Gastrointestinal Ne | 1969 |
Leukemia and lymphoma.
Topics: Antineoplastic Agents; BCG Vaccine; Burkitt Lymphoma; Busulfan; Chlorambucil; Cyclophosphamide; Cyta | 1970 |
Cytarabine.
Topics: Acute Disease; Amino Sugars; Anemia; Antibiotics, Antineoplastic; Antineoplastic Agents; Blood Cell | 1971 |
High-dose corticoid therapy in Hodgkin's disease and other lymphomas.
Topics: Adolescent; Adult; Aged; Cortisone; Diabetes Mellitus; Female; Gastrointestinal Diseases; Hodgkin Di | 1967 |
Chemotherapy of the lymphomas.
Topics: Antimetabolites; Cyclophosphamide; Female; Hodgkin Disease; Humans; Hydrazines; Lymphoma; Mechloreth | 1970 |
Serum haptoglobin level in disseminated malignant diseases in children.
Topics: Aminopterin; Child; Child, Preschool; Diagnosis, Differential; Haptoglobins; Hematologic Diseases; H | 1970 |
Hypercalcemia associated with neoplastic disease.
Topics: Breast Neoplasms; Bronchial Neoplasms; Carcinoma; Carcinoma, Squamous Cell; Dactinomycin; Electrocar | 1970 |
Current status: the management of lymphoma.
Topics: Antimetabolites; Asparaginase; Benzoates; Biopsy; Cyclophosphamide; Drug Synergism; Hodgkin Disease; | 1970 |
[Löfgren's syndrome (acute sarcoidosis)].
Topics: Acute Disease; Adult; Biopsy; Cardiomyopathies; Erythema Nodosum; Female; Humans; Hypersensitivity; | 1970 |
[Bullous malignant cutaneous reticulosis].
Topics: Aged; Blister; Humans; Lymphatic Diseases; Lymphoma; Male; Prednisone; Prognosis; Skin Neoplasms | 1970 |
Bilateral inflammatory pseudotumors of the ciliary body.
Topics: Administration, Topical; Anti-Inflammatory Agents; Atropine; Biopsy; Ciliary Body; Diagnosis, Differ | 1971 |
[Malignant reticulosis].
Topics: Aged; Drug Synergism; Humans; Hydrazines; Lymphoma; Male; Prednisone; Skin Neoplasms | 1968 |
[Combination of Löfgren's and Mikulicz' syndromes].
Topics: Adult; Erythema Nodosum; Female; Humans; Lung Neoplasms; Lymphoma; Mikulicz' Disease; Prednisone; Si | 1969 |
Corticosteroids in general medicine.
Topics: Adrenal Cortex Hormones; Arthritis, Rheumatoid; Collagen Diseases; Gastrointestinal Diseases; Hemato | 1966 |